# Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure

João Pedro Ferreira, Job Verdonschot, Timothy Collier, Ping Wang, Anne

Pizard, Christian Bär, John G. Cleland, Javier Diez, Jens Björkman,

Alessandro Boccanelli, et al.

<figure><img src="image_1.png" /></figure>

To cite this version:

João Pedro Ferreira, Job Verdonschot, Timothy Collier, Ping Wang, Anne Pizard, et al. Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. Circulation. Heart failure, 2019, 12 (5), pp.e005897. 10.1161/CIRCHEARTFAILURE.118.005897. hal-02267410

HAL Id: hal-02267410

https://hal.science/hal-02267410

Submitted on 8 Dec 2023

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_2.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_3.png" /></figure>

University
of Glasgow

Ferreira, J. P. et al. (2019) Proteomic bioprofiles and mechanistic pathways of progression to heart failure: the HOMAGE study. *Circulation*, 12(5), e005897. (doi: [10.1161/CIRCHEARTFAILURE.118.005897](https://doi.org/10.1161/CIRCHEARTFAILURE.118.005897))

This is the author's final accepted version.

There may be differences between this version and the published version.
You are advised to consult the publisher's version if you wish to cite from
it.

http://eprints.gla.ac.uk/186516/

Deposited on: 13 May 2019

Enlighten – Research publications by members of the University of Glasgow
http://eprints.gla.ac.uk
Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure: the
HOMAGE (Heart OMics in AGEing) study

João Pedro Ferreira, MD, PhD<fnref n="1" />,<fnref n="2" />* & Job Verdonschot, MD<fnref n="3" />,<fnref n="4" />*; Timothy Collier, PhD<fnref n="5" />; Ping Wang, PhD<fnref n="4" />; Anne Pizard, PhD<fnref n="1" />,<fnref n="6" />; Christian Bär, MD, PhD<fnref n="7" />; Jens Björkman, PhD<fnref n="8" />; Alessandro Boccanelli, MD<fnref n="9" />; Javed Butler, MD, PhD<fnref n="10" />; Andrew Clark, MD, PhD<fnref n="11" />; John G. Cleland, MD, PhD¹²,¹³; Christian Delles, MD, PhD¹⁴; Javier Diez, MD, PhD¹⁵,¹⁶,¹⁷,¹⁸; Nicolas Girerd, MD, PhD<fnref n="1" />; Arantxa González, MD, PhD¹⁵,¹⁶,¹⁷; Mark Hazebroek, MD, PhD<fnref n="3" />; Anne-Cécile Huby, PhD<fnref n="1" />; Wouter Jukema, MD, PhD¹⁹; Roberto Latini, MD, PhD²⁰; Joost Leenders, MD, PhD²¹; Daniel Levy, MD, PhD²²,²³; Alexandre Mebazaa, MD, PhD²⁴; Harald Mischak, MD, PhD²⁵; Florence Pinet, MD, PhD²⁶; Patrick Rossignol, MD, PhD<fnref n="1" />; Naveed Sattar, MD, PhD²⁷; Peter Sever, MD, PhD²⁸; Jan A. Staessen, MD, PhD²⁹,³⁰; Thomas Thum, MD, PhD<fnref n="7" />,³¹; Nicolas Vodovar, PhD²⁴; Zhen-Yu Zhang, MD²⁹; Stephane Heymans, MD, PhD<fnref n="3" />,³²,³³** & Faiez Zannad, MD, PhD<fnref n="1" />**

*co-first authors

**co-last authors

<footnote n="1">¹ Université de Lorraine, Inserm, Centre d'Investigations Cliniques- Plurithématique 14-33, and Inserm U1116, CHRU, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.</footnote>

<footnote n="2">² Department of Physiology and Cardiothoracic Surgery, Cardiovascular Research and Development Unit, Faculty of Medicine, University of Porto, Porto, Portugal.</footnote>

<footnote n="3">³ Department of Cardiology, Maastricht University Medical Centre, Center for Heart Failure Research, Cardiovascular Research Institute Maastricht (CARIM), University Hospital Maastricht, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands.</footnote>

<footnote n="4">⁴ Department of Clinical Genetics, Maastricht University Medical Center, 6202 AZ Maastricht, The Netherlands.</footnote>

<footnote n="5">⁵ London School of Hygiene and Tropical Medicine, London, UK.</footnote>

<footnote n="6">⁶ Inserm 1024, Institut de Biologie de l'École Normale Supérieure (IBENS), PSL University of Paris, Paris, France.</footnote>

<footnote n="7">⁷ Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany.</footnote>

<footnote n="8">⁸ TATAA Biocenter AB, Gothenburg, Sweden.</footnote>

<footnote n="9">⁹ Casa di cura Quisisana, Rome, Italy.</footnote>

<footnote n="10">¹⁰ Department of Medicine, University of Mississippi School of Medicine, Jackson, MI.</footnote>

<footnote n="10">¹⁰ Excellence Cluster REBIRTH, Hannover Medical School, Hannover, Germany.</footnote>

<footnote n="11">¹¹ Hull York Medical School, Castle Hill Hospital, Cottingham, UK.</footnote>
¹² Robertson Centre for Biostatistics and Clinical Trials, Institute of Health and Wellbeing, Glasgow, UK.

¹³ University of Glasgow, United Kingdom. National Heart and Lung Institute, Royal Brompton and Harefield Hospitals, Imperial College, London, UK.

¹⁴ Institute of Cardiovascular and Medical Sciences, University of Glasgow, Scotland, UK.

¹⁵ Program of Cardiovascular Diseases, Centre for Applied Medical Research, University of Navarra, Pamplona, Spain.

¹⁶ CIBERCV, Carlos III Institute of Health, Madrid, Spain.

¹⁷ Instituto de Investigación Sanitaria de Navarra (IdiSNA), Spain.

¹⁸ Departments of Nephrology, and Cardiology and Cardiac Surgery, University of Navarra Clinic, Pamplona, Spain.

¹⁹ Department of Cardiology, Leiden University Medical Center, Leiden, Netherlands

²⁰ IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy.

²¹ ACS Biomarker BV, Amsterdam, The Netherlands.

²² National Heart, Lung, and Blood Institute's and Boston University's Framingham Heart Study, Framingham, MA, United States.

²³ Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, Bethesda, MD, United States.

²⁴ UMRS 942; University Paris Diderot; APHP, University Hospitals Saint Louis Lariboisière, Paris, France.

²⁵ Mosaiques-diagnostics, Rotenburger Str. 20, D-30659 Hannover, Germany.

²⁶ Inserm U1167, Institut Pasteur de Lille, Université de Lille, FHU-REMOD-VHF, Lille, France.

²⁷ Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.

²⁸ International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London, London, England.

²⁹ Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.

³⁰ Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, Netherlands.

³¹ Imperial College London, National Heart and Lung Institute.

³² Department of Cardiovascular Research, University of Leuven, UZ Herestraat 49, 3000 Leuven, Belgium.

³³ Netherlands Heart Institute (ICIN), Moreelsepark 1, 3511 EP Utrecht, The Netherlands.
Word-count: 3322 words (excluding abstract and references).

Contact to:

Professor Faiez Zannad

Centre d'Investigation Clinique 1433 module Plurithématique, CHRU Nancy - Hopitaux de Brabois,

Institut Lorrain du Cœur et des Vaisseaux Louis Mathieu

4 rue du Morvan, 54500 Vandoeuvre les Nancy

Tel : 03 83 15 73 15

Fax : 03 83 15 73 24

Mail: f.zannad@chru-nancy.fr
Abstract

*Background:* Identifying the mechanistic pathways potentially associated with incident HF may provide a basis for novel preventive strategies.

*Methods and Results:* To identify proteomic biomarkers and the potential underlying mechanistic pathways that may be associated with incident HF defined as first hospitalization for HF, a nested-matched case-control design was used with cases (incident HF) and controls (without HF) selected from 3 cohorts (>20,000 individuals). Controls were matched on cohort, follow-up time, age, and sex. Two independent sample sets (a “discovery” set, with 286 cases and 591 controls and a “replication” set with 276 cases and 280 controls) were used to discover and replicate the findings. 252 circulating proteins in the plasma were studied. Adjusting for the matching variables age, sex, and follow-up time (and correcting for multiplicity of tests), 89 proteins were found to be associated with incident HF in the discovery phase, of which 38 were also associated with incident HF in the replication phase.

These 38 proteins pointed to 4 main network clusters underlying incident HF: 1) inflammation and apoptosis, indicated by the expression of the TNF-family members; 2) extracellular matrix remodelling, angiogenesis and growth, indicated by the expression of proteins associated with collagen metabolism, endothelial function and vascular homeostasis; 3) blood pressure regulation, indicated by the expression of natriuretic peptides and proteins related to the renin angiotensin aldosterone system; and 4) metabolism, associated with cholesterol and atherosclerosis.

*Conclusion:* Clusters of biomarkers associated with mechanistic pathways leading to HF were identified linking inflammation, apoptosis, vascular function, matrix remodelling, blood pressure control and metabolism. These findings provide important insight on the pathophysiological mechanisms leading to HF.

*Key-words:* incident heart failure; proteomics; ageing; prognostic; mechanistic pathways
**Introduction**

Heart failure (HF) is a major cause of morbidity and mortality worldwide and the most frequent cause of hospitalization for patients over 65 years of age¹, ², ³. The incidence and prevalence of HF are increasing due to the ageing of the population as well as rising rates of HF risk factors such as diabetes, obesity, and hypertension³⁻⁶. Identifying mechanistic pathways leading to HF may help improve preventive strategies⁷.

In the last decade, circulating biomarkers, such as N-terminal pro brain natriuretic peptide (NT-proBNP), have been studied for prediction of incident HF⁷⁻¹⁰. A recently published study¹⁰, also investigated the association of multiple proteins with incident HF for “prediction” purposes; these proteins (n=80) added little gain to the prognostic model including natriuretic peptides. However, above and beyond “prediction”, biomarkers may reflect pathophysiological processes and thus may help in assessing the underlying pathways that contribute to the progression towards HF. Investigating the pathophysiological processes may provide potential targets for future therapies. For this purpose, knowledge-based network analysis with induced network approach may help identify the links among the identified protein biomarkers, providing the basis for the identification of the underlying pathways leading to HF¹¹.

The Heart OMics in AGEing consortium (HOMAGE; NCT02556450) is an EU funded program that aims to identify and validate omics biomarkers associated with incident HF in order to potentially develop new and personalized preventive strategies. We report proteomics results, based on assays of 252 plasma proteins related to cardiovascular disease and inflammation, testing the associations of these proteins with incident HF, applying knowledge-based network analysis in order to identify mechanistic pathways underlying the progression to HF.

**Methods**

**Study Population**

The HOMAGE-consortium included 20 completed and ongoing studies conducted in eight European countries that enrolled healthy subjects, patients with HF and patients at high risk of CV disease, all of which were pooled in a common database¹². From the HOMAGE population with >20,000 patients, we identified cohorts in whom individuals had been followed-up until first hospitalisation for heart failure (HF). Patients from two suitable cohorts and one clinical trial population were identified: PREDICTOR¹³, HEALTH-ABC¹⁴, and PROSPER¹², ¹⁵. Patients with a history of HF at baseline were excluded. We then employed a nested matched case-control design were individuals who developed HF were considered to be at-risk i.e. eligible to be selected as controls up until the time they became a case¹⁶: a total of 852 incident HF cases were identified (574 in HEALTH-ABC, 234 in PROSPER, 44 in PREDICTOR); within the respective cohorts controls were selected, matched age, sex, and follow-up time (defined as time of incident HF from entry to the cohort). The final numbers after the matching procedures are provided below.
The data that support the findings of this study are available from the corresponding author upon reasonable request.

**Discovery and replication**

The HOMAGE study had two independent phases: discovery and replication. For the discovery phase, we selected 300 cases and 599 controls (1 case only had 1 match) randomly selected without replacement in a 1:2 proportion¹⁷⁻¹⁹; due to 22 missing or poor-quality samples, the final match was 286 cases to 591 controls. For replication we selected 315 cases and 315 controls randomly selected without replacement in a 1:1 proportion; due to 74 missing or poor-quality samples, the final match was 276 cases to 280 controls.

The study was conducted in accordance with the Declaration of Helsinki and approved by each site ethics committees. All participants provided written informed consent.

**Outcome**

The outcome was incident HF which was defined as first hospitalisation for HF as primary admission diagnosis (adjudicated by the investigators of the respective cohorts).

**Sample handling**

All sample shipments and sample data acquisition within the HOMAGE consortium are according to predefined standard operating procedures and material transfer agreements to maintain uniformity.

**Supplemental Figure 1** shows the sample handling and storage per cohort and the sample flow until protein measurement at the TATAA Biocenter (Gothenburg, Sweden). Aliquoting of the samples at Biobank Maastricht was performed using a multi-pipette in 1 run to reduce freeze/thaw cycles and batch effects. The entire sampling handling/protein measurement was carried out fully blind to case control status. The cases and controls were separately identified and selected by the study statistician. All patient information was then removed and a randomly sorted list of patient/sample IDs for each cohort was sent to Maastricht University Medical Center (MUMC).

**Assays and studied biomarkers**

Baseline plasma samples were analysed for protein biomarkers by the TATAA-biocenter using the Olink Proseek® Multiplex cardiovascular (CVD) II, CVD III, and inflammation panels. These panels were selected by the well-balanced inclusion of proteins with already established associations with CV disease and HF (e.g. BNP, ST2, GDF15) and others with less well-established associations (e.g. TWEAK, PON3). The assay use a proximity extension assay (PEA) technology²⁰, where 92 oligonucleotide-labelled antibody probe pairs per panel are allowed to bind to their respective targets in the sample in 96-well plate format. When binding to their correct targets, they give rise to new DNA amplicons with each ID-barcoding their respective antigens. The amplicons are subsequently quantified using a Fluidigm BioMark™ HD real-time PCR platform. The platform provides log₂-normalized protein expression (NPX) data. A detailed description of the Olink® technology is depicted in the **Supplemental Addenda 1**. For 9 proteins measured in both the inflammation panel and CVD panels, the one from CVD panels was used for further data analyses (the results for these
proteins were strongly correlated ≥0.9). In addition, 15 proteins that were below the limit of detection (LOD), were not included in the analysis. The Olink® quality control samples are considered as “flagged” if they deviate more than 0.3 NPX from the median of all samples in one of two control assays for incubation and detection. The LOD is defined by the three negative controls run on each plate and set to three standard deviations above the measured background. Patients with missing or unusable samples (22 samples in the discovery phase and 74 samples in the replication phase) were not considered for the analyses. Where the assay results were partially missing i.e. results were missing for 1 or 2 of the 3 plates (83 patients in the discovery phase and 4 patients in the replication phase) then multiple imputation using chained equations was used²¹.

The abbreviations, full names and respective Olink® multiplex panels of the studied proteins are described in the **Supplemental Table 1**.

The assays were performed “blinded” to case/control status with cases and controls randomly distributed across plates. The proteomic results were then merged with the baseline data, which included the case-control status, matching variables and the clinical risk factors.

**Statistical and bioinformatics considerations**

For the baseline clinical characteristics, continuous variables are expressed as means and respective standard deviation (SD). Categorical variables are presented as frequencies and percentages. Patient baseline characteristics were compared between cases and controls using Chi² tests for categorical variables and t-tests for continuous variables.

The main aim of this study was to test multiple proteins with regards to their association with incident HF and the respective underlying mechanistic pathways. Logistic regression models adjusting for the matching variables (age, sex, cohort, follow-up time) were used to identify protein biomarkers associated with incident HF in the discovery and replication phases²² (**Supplemental Table 2**). Only those proteins which were found to be statistically significant (after correction for “false discoveries”) in the discovery phase (n=89) were taken forward for consideration in the replication phase. In both phases we corrected for multiple testing using a false discovery rate (FDR) of 1%²³. Additional adjustment for the pre-specified clinical risk factors previously found to represent the best clinical prognostic model for incident HF in the HOMAGE population²⁴ (smoking, diabetes, history of coronary artery disease, serum creatinine, body mass index, systolic blood pressure, use of antihypertensive medication, and heart rate) was also performed, providing similar results (**Supplemental Table 3**). Since proteins were measured using NPX (Normalized Protein eXpression) values on a log₂ scale, the odds ratio for each protein estimates the increase in the odds of HF associated with a doubling in the protein concentration. After the identification of the “top” proteins, common to the derivation and replication phases, we performed a multivariable a stepwise forward model adjusted on age, sex, cohort, phase, follow-up time, smoking, diabetes, history of coronary artery disease, serum creatinine, body mass index, systolic blood pressure, use of antihypertensive medication, and heart rate forced into the model with a p-value for inclusion set at 0.05. This set of
analyses was performed using STATA version 15 software (StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LP).

We used knowledge-based network analysis with induced network approach by consensuspathDB (CPDB) online server (accessed on 29 January 2019) from Max Planck Institute for Molecular Genetics to identify the links among the protein biomarkers selected in the previous step (discovery and replication with adjustment on the matching variables), based on known knowledge of interaction networks (protein interactions, genetic interactions, biochemical interactions, and gene regulatory interactions)¹¹. The network analysis also identifies additional proteins (intermediate nodes) based on knowledge-based interactions (with exclusion of low-confidence interactions quantified by a z-score ≤20 calculated for each intermediate node). As a validation step, network analysis was repeated using ClueGO network analysis (version 2.5.3), using implemented biological GO processes²⁵. Extra known connection between BNP (brain natriuretic peptide) and angiotensin was added to the network manually due to their well described interplay on blood pressure and hydro-electrolytic regulation²⁶, ²⁷. The generated network was reorganized in Cytoscape (version 3.5) to merge genes with their expressed proteins and visualize the results. An additional overrepresentation analysis was performed using only the GO-biological processes and molecular function enriched by selected proteins against proteins on the OLINK panels, introducing an adjustment for the clustering of proteins on the network and consolidating the strength of true enrichment.

# Results

## Study population

The baseline characteristics of the studied population for both discovery (IA) and replication phases (IB) is depicted in **Table 1**. Cases and controls were well matched for age, sex, cohort and follow-up time (i.e. the matching variables) in both phases. Cases had higher BMI, creatinine, were more often hypertensive (with anti-hypertensive medications), diabetic, and had more often coronary artery disease. All these variables were included in the HOMAGE prognostic model²⁴ and were used for further adjustment in the models (please see below).

## Biomarkers associated with incident heart failure

Of the 252 proteins studied, adjusting for the matching variables age, sex, and follow-up time, 89 proteins were found to be associated with incident HF in the discovery phase, of which 38 were also associated with incident HF in the replication phase. **Table 2.** All 38 proteins were positively associated with incident HF, except for TWEAK (tumor necrosis factor ligand superfamily member 12) and PON3 (paraoxonase), where patients with higher concentrations of these proteins were less likely to develop HF. Further adjusting for the clinical risk factors (smoking, diabetes, history of coronary artery disease, serum creatinine, body mass index, systolic blood pressure, use of antihypertensive medication, and heart rate) previously determined in the well calibrated HOMAGE clinical risk model²⁴, provides similar associations to those presented in Table 2, suggesting that these
associations were independent of the patients' clinical risk (also supported by the weak correlation between the study proteins and the clinical risk factors). **Supplemental Table 3 & 4.**

The multivariable stepwise model including the matching variables and the clinical risk factors forced into the model, plus the 38 proteins independently identified in both the discovery and replication phases, retained BNP, TWEAK, NTproBNP, REN, TRAILR2, PON3, CCL16, and SLAMF1 as the biomarkers with stronger association with incident HF. **Supplemental Table 5.**

**Induced network results**

The 38 incident HF-associated protein biomarkers were linked with each other by known protein interactions, biochemical interactions, and gene regulatory interactions (Figure 1), directly or via intermediate nodes (Supplemental Table 6). Our results pointed to 4 clusters with clearly defined functions: 1) inflammatory/apoptosis of mainly TNF-family members, 2) extracellular matrix remodelling, angiogenesis and cell growth, 3) a renin-angiotensin system associated with blood pressure regulation and one minor cluster including metabolic proteins, and 4) metabolism, associated with cholesterol and atherosclerosis. The two major clusters inflammatory/apoptosis and blood pressure regulation were also detected as the main groups using the ClueGO network analysis (Supplemental Figure 2). The TNF-family members, their representative pathways and blood pressure regulation remained significantly enriched after adjustment for the preselection of proteins (Supplemental Table 7).

In addition, this analysis revealed multiple intracellular transcription factors: TP53 (tumor protein 53), HNF1B (hepatocyte nuclear factor-1-beta), HIF1A/ARNT (hypoxia inducible factor alfa/aryl hydrocarbon receptor nuclear translocator) and STAT6 (signal transducer and activator of transcription 6), which are not detected with our plasma protein panels. However, these transcription factors may supplement the biomarker profile of patients at high risk for incident HF, providing additional perspective on the interpretation of the pathophysiological processes driving HF. The role of each biomarker linked to the identified network clusters is furtherly detailed in the discussion section.

**Discussion**

In the present study we identified 38 plasma proteins associated with incident HF (in both the discovery and replication phases). The selected proteins allowed the identification of 4 main network clusters underpinning incident HF: 1) inflammation and apoptosis; 2) extracellular matrix remodelling, angiogenesis and growth; 3) blood pressure regulation, and 4) metabolism. These findings are original and provide important insight on the pathophysiological mechanisms leading to HF, potentially creating the basis for the development of new HF prevention strategies, personalized to each individual patient underlying mechanism.

A recently published study¹⁰ investigated the longitudinal association between high-throughput proteomics (also using OLINK® technology) and HF risk in two community-based
prospective cohorts of elderly individuals without HF at baseline. To some extent, the proteins
identified in that study overlapped with ours. Specifically, TRAILR2 (trail receptor 2), GDF-15
(growth differentiation factor 15), and MMP-12 (matrix metalloproteinase 12) were identified in both
studies across all discovery steps. However, the study by Stenemo *et al*. studied 80 proteins, whereas
ours analysed 252. Moreover, our study was aimed to identify the “biological signatures” leading to
HF.

Inflammation and apoptosis cluster

*Inflammation and apoptosis*, as pointed by the expression of TNF-family members, may be an
important pathway leading to HF that may be identified by the expression of circulation proteins such
as TRAILR2, IL16 (interleukin 16), IL4RA (interleukin 4 receptor alfa), CD4 (T-cell surface
glycoprotein CD4), TNFRSF10A (tumor necrosis factor receptor superfamily member 10A),
TNFRSF11A (tumor necrosis factor receptor superfamily member 11A), TNFR1 (tumor necrosis
factor receptor 1), TNFR2 (tumor necrosis factor receptor 2), TNFRSF13B (tumor necrosis factor
receptor superfamily member 13B), TNFRSF14 (tumor necrosis factor receptor superfamily member
14), CCL16 (C-C motif chemokine 16), SLAMF1 (signalling lymphocytic activation molecule family
member 1), and TWEAK. Elevated TNF signalling restrains cardiomyocyte differentiation of
resident cardiac stem cells and enhance adrenergic activation, promoting adverse cardiac remodelling
(also reflected by the elevated remodelling markers)²⁸. The TRAILR2 protein (otherwise known as
death receptor 5) is encoded by the *TNFSF10* gene and is a receptor belonging to the TNF
superfamily that preferentially induces apoptosis after binding of its ligand TRAIL²⁹, ³⁰. Increased
levels of TRAILR2 have been associated with adverse cardiovascular events in patients with
myocardial infarction, probably due to intensified apoptotic activity³¹. Interleukins, as “upstream”
biomarkers of inflammation converge on the central TNF signalling pathway, having major influence
on atherosclerosis, and consequently on the risk of cardiovascular disease³². Another TNF
superfamily member – TWEAK - activates the NF-κB (nuclear factor kappa B) and regulates several
cell functions such as proliferation, migration, differentiation, cell death, inflammation, angiogenesis,
and collagen synthesis of cardiac fibroblasts³³,³⁴, ³⁵. Low TWEAK has been associated with increased
risk of death in patients with overt HF³⁶ and patients with HF and reduced ejection fraction had lower
TWEAK levels compared to “controls”³⁴. The TWEAK-induced proliferation of cardiomyocytes and
its immunomodulatory effects may provide basis to these findings³⁶. Apart from binding to its active
receptor Fn14, TWEAK can also bind to a scavenger receptor CD163, which was shown to be
upregulated in HF, explaining the decreased levels and activity of TWEAK in HF³⁴.

The inflammation/apoptosis cluster grouped many proteins with strong and independent
association with HF: TWEAK, TRAILR2, CCL16 and SLAMF1.

Extracellular matrix remodelling, angiogenesis and growth cluster

Another major pathway identified as leading to HF was, *extracellular matrix remodelling, angiogenesis and growth* supported by the expression of ADM (adrenomedullin), IGFBP7 (insulin-
like growth factor-binding protein 7), PGF (placenta growth factor), PLC (perlecan), GAL9 (galectin 9), MMP12 (matrix metalloproteinase 12), UPAR (urokinase plasminogen activator surface receptor), SLAMF1 (signalling lymphocytic activation molecule), CEACAM8 (carcinoembryonic antigen related cell adhesion molecule 8), GDF15 (growth differentiation factor 15), FGF23 (fibroblast growth factor 23), and OPN (osteopontin). ADM is a vasodilator peptide predominantly produced by the vascular endothelium and smooth muscle that increases in response to hemodynamic stress³⁷.

IGFBP7 participates in the regulation of the availability of insulin growth factor in body fluids and tissues. IGFBP7 has been found to be associated with diastolic dysfunction and is also a strong prognosticator in HF³⁸. PGF is increased by pressure overload in the heart where it is expressed in both myocytes and other cells infiltrating the heart³⁹. PLC is constituent of the extra-cellular matrix that regulates angiogenesis and cell autophagy⁴⁰. PLC pro-angiogenic effects may be used for the treatment of ischemic diseases⁴¹. GAL9 is produced by the extracellular matrix and may be increased inpatients with ischemic stroke, its role in HF requires further study⁴². Matrix metalloproteinases degrade extracellular matrix proteins and play important roles in development and tissue repair.

MMP-12 contributes to plaque growth and destabilization and increased levels of this proteins have been associated with higher atherosclerotic disease burden⁴³. SLAMF1 is expressed in the surface of lymphocytes and is involved in the control of infectious and neoplastic processes⁴⁴. CEACAM8 is released by granulocytes and is also involved in immune regulation⁴⁵. The role of SLAMF1 and CEACAM8 in HF requires further investigation. However, they are both related to UPAR that induces cardiac fibrosis and macrophage accumulation, and is associated with worse prognosis in HF⁴⁶, ⁴⁷. GDF15 regulates inflammation and apoptosis, both key mechanisms in cardiac remodelling that are potentially associated with incident HF⁴⁸, ⁴⁹. FGF23 is released by the osteocytes and is essential for the regulation of the metabolism of phosphate, calcium and vitamin D. Importantly, FGF23 promotes myocardial fibrosis and has been associated with coronary heart disease and HF⁵⁰, ⁵¹. OPN is a member of the extracellular matrix protein family. OPN expression increases under a variety of pathophysiological conditions affecting the heart and has been associated with increased incidence of cardiovascular diseases, including HF⁵².

## Blood pressure regulation cluster

Another major pathway identified as leading to HF was associated with *blood pressure regulation*, supported by the increased expression of renin, angiotensin converting enzyme and BNP/NTproBNP. The renin-angiotensin-aldosterone (RAAS) and the natriuretic peptide systems have been thoroughly associated with cardiovascular disease, including hypertension and HF⁵³. Natriuretic peptides (BNP and NTproBNP) are produced by the cardiomyocytes, endothelial cells, T cells, and macrophages infiltrating the heart in response to cardiac overload⁵⁴. BNP/NTproBNP are recommended in the current guidelines for diagnostic and prognostic assessment in HF⁵⁵, ⁵⁶. Natriuretic peptides have been associated with incident HF⁵⁷ and a natriuretic peptide-based strategies for preventing HF have reduced the rates of both systolic and diastolic dysfunction⁵⁸. The RAAS and BNP are closely related
by inhibition on to each other by having counterbalanced regulatory functions on blood pressure²⁶.
Moreover, angiotensin can upregulate cardiac BNP gene expression²⁷. Enhanced RAAS under high
BNP may reflect a dysregulation on blood pressure leading to HF development. Natriuretic peptides
and renin were strongly and independently associated with incident HF.

Metabolism cluster

The other pathway identified as leading to HF was associated with *metabolism*, supported by the identification of PON3, FABP4 (fatty acid binding protein 4), and RARRES2 (retinoic acid receptor responder protein 2). PON3 has been associated with HDL increase and with the inhibition of LDL oxidation, thus PON3 expression might be protective in the cardiovascular setting⁵⁹. In our study PON3 was negatively associated with incident HF risk, suggesting that anti-oxidation may play a role in the mechanisms associated with HF development. In line with TWEAK, preclinical evidence supports a cardioprotective role for PON3 (which was also independently associated with incident HF in the multivariable model). FABP4 is predominantly expressed in macrophages and adipose tissue where it regulates fatty acids storage and lipolysis; FABP4 is also an important mediator of inflammation that has been associated with higher risk of cardiovascular events⁶⁰, ⁶¹. RARRES2 (or chemerin) is an adipose-derived signalling molecule that regulates adipogenesis and adipocyte metabolism, and it has also been associated with higher risk of cardiovascular events⁶², ⁶³.

Overall, the results of our proteomic biomarker assessments in patients at risk of developing
HF suggest that progression towards HF is likely to involve the interplay of several
pathophysiological mechanisms, such as “heart stress”, blood pressure regulation, apoptosis,
inflammation and metabolism-related mechanisms. A previous report identified cytokine response,
extracellular matrix organization, and inflammation as major pathways underlining HF with preserved
ejection fraction⁶⁴. The next step of this important data is to determine the activity of these processes
in different HF stages and eventually per individual. This will provide the basis for further
development strategies in preventing HF and focusing on these specific pathways at early stages of
the disease for an individual treatment approach. The intracellular transcription factors TP53, HNF1B,
HIF1A/ARNT and STAT6, which are not measured in our plasma protein panels, may complement
the biomarker profile of patients at high risk for incident HF⁶⁵, suggesting a combined multi-OMICS
approach currently being investigated within the HOMAGE consortium.

Limitations

Several limitations should be highlighted in the present study. First, this is an observational case-
control study, hence causality cannot be ascertained. The bioinformatics approach also does not allow
causality assessment, but allow for the generation of hypothesis on the underlying pathways
associated with this proteomic expression. Also, we must be aware of the biases and
oversimplification in network topology. For example, most network databases are overrepresented by
well-studied proteins and their interactions. This will lead to overrepresentation of these interactions
in the analysis as there are more interactions known for these proteins⁶⁶. Second, incident HF was
defined as first HF hospitalization, which does not exclude patients that might already have HF but
without previous hospitalizations. Also, for the avoidance of competing risk, we excluded patients
who died during follow up. Therefore, it is possible that we missed patients where death was the first
(and last) manifestation of HF. Third, we did not have access to the reported ejection fraction at the
time of hospitalization, therefore we cannot assess the potential value of these biomarkers in
distinguishing progression to HF with reduced ejection fraction from HF with preserved ejection
fraction and/or the HF cause. Fourth, clinical detail (signs, symptoms, ECG and other complementary
exams), troponin and natriuretic peptides at the time of hospitalization are not available in the dataset.
This information would help in further phenotyping these patients, and in differentiating the cases
from the controls. Fifth, the proteomics assay does not provide standard concentration units, making
comparisons with clinically applied cut-offs difficult, however the Olink® standard procedures
reassure a good correlation with the “standard” measurement methodologies. In addition, we did not
use large unbiased screens but rather selected protein biomarkers based on mechanistic hypotheses.
The 3 studied Olink® panels (CVD II, III, and Inflammation) contain circulating proteins previously
found to be associated with cardiovascular and/or inflammatory diseases. Many other “pathways” are
missing (for example, metabolism(omics), that could enrich our networks Therefore, we cannot
exclude the role of other mechanisms not targeted with our proteomics screen. Finally, prospective
validation of these biomarkers in other populations is required to improve the external validation of
these results.

Conclusions

After adjustment for the matching variables age, sex, follow-up time and correction for multiplicity of tests we identified 38 proteins in two independent sets associated with incident HF. Cluster of the selected proteins allowed the identification of 4 main networks leading to HF: 1) inflammation and apoptosis; 2) extracellular matrix remodelling, angiogenesis and growth; 3) blood pressure regulation; and 4) metabolism. These findings provide important insight on the pathophysiological mechanisms leading to HF.

Funding

The research leading to these results has received funding from the European Union Commission's Seventh Framework programme under grant agreement N° 305507 (HOMAGE). We acknowledge the support from the Netherlands Cardiovascular Research Initiative, an initiative with support of the Dutch Heart FoundationCVON2016-Early HFPEF, and CVON 2017, ShePREDICTS.

What is new?
We present a nested case:control study (with derivation and replication cohorts) to study 252 circulation proteins and their association with new-onset heart failure, to assess the mechanistic pathways that may lead to the development of heart failure.

## What are the clinical implications?

We identified four main networks that may lead to heart failure. These include inflammation and apoptosis; extracellular matrix remodelling, angiogenesis and growth; blood pressure regulation; and metabolism. These findings provide important insight on the mechanisms leading to heart failure and may help in the development of future “personalized” therapies.

## Disclosures

JF, PR and FZ are supported by the French National Research Agency Fighting Heart Failure (ANR-15-RHU-0004), by the French PIA project «Lorraine Université d'Excellence » GEENAGE (ANR-15-IDEX-04-LUE) programs, and the Contrat de Plan Etat Région Lorraine and FEDER IT2MP; HM is the co-founder and co-owner of Mosaiques Diagnostics; AM received honoraria for lectures from Roche and Abbott, consultation fees from Sanofi and Servier and research grants from Adrenomed and Sphyngotec. All other authors have no conflicts of interest to report with regards to the present study.

## Bibliography

1. Zannad F. Rising incidence of heart failure demands action. *Lancet*. 2017. Feb 10;391(10120):518-519.

2. McMurray JJ, Petrie MC, Murdoch DR and Davie AP. Clinical epidemiology of heart failure: public and private health burden. *Eur Heart J*. 1998;19 Suppl P:9-16.

3. McMurray JJ and Stewart S. Epidemiology, aetiology, and prognosis of heart failure. *Heart*. 2000;83:596-602.

4. Petrie M and McMurray J. Changes in notions about heart failure. *Lancet*. 2001;358:432-4.

5. Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, Allison M, Hemingway H, Cleland JG, McMurray JJV and Rahimi K. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. *Lancet*. 2017. Feb 10;391(10120):572-580.

6. Manzano L, Babalis D, Roughton M, Shibata M, Anker SD, Ghio S, van Veldhuisen DJ, Cohen-Solal A, Coats AJ, Poole-Wilson PP and Flather MD. Predictors of clinical outcomes in elderly patients with heart failure. *Eur J Heart Fail*. 2011;13:528-36.

7. Echouffo-Tcheugui JB, Greene SJ, Papadimitriou L, Zannad F, Yancy CW, Gheorghiade M and Butler J. Population risk prediction models for incident heart failure: a systematic review. *Circ Heart Fail*. 2015;8:438-47.

8. Wang TJ, Wollert KC, Larson MG, Coglianese E, McCabe EL, Cheng S, Ho JE, Fradley MG, Ghorbani A, Xanthakis V, Kempf T, Benjamin EJ, Levy D, Vasan RS and Januzzi JL. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. *Circulation*. 2012;126:1596-604.

9. Borne Y, Persson M, Melander O, Smith JG and Engstrom G. Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation. *Eur J Heart Fail*. 2014;16:377-83.
10. Stenemo M, Nowak C, Byberg L, Sundstrom J, Giedraitis V, Lind L, Ingelsson E, Fall T and Arnlov J. Circulating proteins as predictors of incident heart failure in the elderly. *Eur J Heart Fail.* 2017. Jan;20(1):55-62.

11. Herwig R, Hardt C, Lienhard M and Kamburov A. Analyzing and interpreting genome data at the network level with ConsensusPathDB. *Nat Protoc.* 2016;11:1889-907.

12. Jacobs L, Thijs L, Jin Y, Zannad F, Mebazaa A, Rouet P, Pinet F, Bauters C, Pieske B, Tomaschitz A, Mamas M, Diez J, McDonald K, Cleland JG, Rocca HP, Heymans S, Latini R, Masson S, Sever P, Delles C, Pocock S, Collier T, Kuznetsova T and Staessen JA. Heart 'omics' in AGEing (HOMAGE): design, research objectives and characteristics of the common database. *J Biomed Res.* 2014;28:349-59.

13. Mureddu GF, Agabiti N, Rizzello V, Forastiere F, Latini R, Cesaroni G, Masson S, Cacciatore G, Colivicchi F, Uguccioni M, Perucci CA and Boccanelli A. Prevalence of preclinical and clinical heart failure in the elderly. A population-based study in Central Italy. *Eur J Heart Fail.* 2012;14:718-29.

14. Beavers KM, Hsu FC, Houston DK, Beavers DP, Harris TB, Hue TF, Kim LJ, Koster A, Penninx BW, Simonsick EM, Strotmeyer ES, Kritchevsky SB and Nicklas BJ. The role of metabolic syndrome, adiposity, and inflammation in physical performance in the Health ABC Study. *J Gerontol A Biol Sci Med Sci.* 2013;68:617-23.

15. Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen EL, Buckley BM, Ford I, Jukema JW, Hyland M, Gaw A, Lagaay AM, Perry IJ, Macfarlane PW, Meinders AE, Sweeney BJ, Packard CJ, Westendorp RG, Twomey C and Stott DJ. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). PROSPER Study Group. PROspective Study of Pravastatin in the Elderly at Risk. *Am J Cardiol.* 1999;84:1192-7.

16. Essebag V, Genest J, Jr., Suissa S and Pilote L. The nested case-control study in cardiology. *Am Heart J.* 2003;146:581-90.

17. Wacholder S, McLaughlin JK, Silverman DT and Mandel JS. Selection of controls in case-control studies. I. Principles. *Am J Epidemiol.* 1992;135:1019-28.

18. Wacholder S, Silverman DT, McLaughlin JK and Mandel JS. Selection of controls in case-control studies. II. Types of controls. *Am J Epidemiol.* 1992;135:1029-41.

19. Wacholder S, Silverman DT, McLaughlin JK and Mandel JS. Selection of controls in case-control studies. III. Design options. *Am J Epidemiol.* 1992;135:1042-50.

20. Lundberg M, Eriksson A, Tran B, Assarsson E and Fredriksson S. Homogeneous antibody-based proximity extension assays provide sensitive and specific detection of low-abundant proteins in human blood. *Nucleic Acids Res.* 2011;39:e102.

21. Resche-Rigon M and White IR. Multiple imputation by chained equations for systematically and sporadically missing multilevel data. *Stat Methods Med Res.* 2018;27:1634-1649.

22. Pearce N. Analysis of matched case-control studies. *Bmj.* 2016;352:i969.

23. Green GH and Diggle PJ. On the operational characteristics of the Benjamini and Hochberg False Discovery Rate procedure. *Stat Appl Genet Mol Biol.* 2007;6:Article27.

24. Jacobs L, Efremov L, Ferreira JP, Thijs L, Yang WY, Zhang ZY, Latini R, Masson S, Agabiti N, Sever P, Delles C, Sattar N, Butler J, Cleland JGF, Kuznetsova T, Staessen JA and Zannad F. Risk for Incident Heart Failure: A Subject-Level Meta-Analysis From the Heart "OMics" in AGEing (HOMAGE) Study. *J Am Heart Assoc.* 2017;6.

25. Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman WH, Pages F, Trajanoski Z and Galon J. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. *Bioinformatics.* 2009;25:1091-3.

26. Richards AM. The renin-angiotensin-aldosterone system and the cardiac natriuretic peptides. *Heart.* 1996;76:36-44.

27. Majalahti T, Suo-Palosaari M, Sarman B, Hautala N, Pikkarainen S, Tokola H, Vuolteenaho O, Wang J, Paradis P, Nemer M and Ruskoaho H. Cardiac BNP gene activation by angiotensin II in vivo. *Mol Cell Endocrinol.* 2007;273:59-67.
28. Hamid T, Xu Y, Ismahil MA, Li Q, Jones SP, Bhatnagar A, Bolli R and Prabhu SD. TNF receptor signaling inhibits cardiomyogenic differentiation of cardiac stem cells and promotes a neuroadrenergic-like fate. *Am J Physiol Heart Circ Physiol.* 2016;311:H1189-h1201.

29. Ramamurthy V, Yamniuk AP, Lawrence EJ, Yong W, Schneeweis LA, Cheng L, Murdock M, Corbett MJ, Doyle ML and Sheriff S. The structure of the death receptor 4-TNF-related apoptosis-inducing ligand (DR4-TRAIL) complex. *Acta Crystallogr F Struct Biol Commun.* 2015;71:1273-81.

30. Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF, Ashkenazi A and de Vos AM. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. *Mol Cell.* 1999;4:563-71.

31. Skau E, Henriksen E, Wagner P, Hedberg P, Siegbahn A and Leppert J. GDF-15 and TRAIL-R2 are powerful predictors of long-term mortality in patients with acute myocardial infarction. *Eur J Prev Cardiol.* 2017;24:1576-1583.

32. Ridker PM and Luscher TF. Anti-inflammatory therapies for cardiovascular disease. *Eur Heart J.* 2014;35:1782-91.

33. Blanco-Colio LM. TWEAK/Fn14 Axis: A Promising Target for the Treatment of Cardiovascular Diseases. *Front Immunol.* 2014;5:3.

34. Ptaszynska-Kopczynska K, Marcinkiewicz-Siemion M, Lisowska A, Waszkiewicz E, Witkowski M, Jasiewicz M, Miklasz P, Jakim P, Galar B, Musial WJ and Kaminski KA. Alterations of soluble TWEAK and CD163 concentrations in patients with chronic heart failure. *Cytokine.* 2016;80:7-12.

35. Chen HN, Wang DJ, Ren MY, Wang QL and Sui SJ. TWEAK/Fn14 promotes the proliferation and collagen synthesis of rat cardiac fibroblasts via the NF-small ka, CyrillicB pathway. *Mol Biol Rep.* 2012;39:8231-41.

36. Richter B, Rychli K, Hohensinner PJ, Berger R, Mortl D, Neuhold S, Zorn G, Huber K, Maurer G, Wojta J, Pacher R, Hulsmann M and Niessner A. Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure. *Atherosclerosis.* 2010;213:545-8.

37. Nishikimi T and Nakagawa Y. Adrenomedullin as a Biomarker of Heart Failure. *Heart Fail Clin.* 2018;14:49-55.

38. Gandhi PU, Gaggin HK, Redfield MM, Chen HH, Stevens SR, Anstrom KJ, Semigran MJ, Liu P and Januzzi JL, Jr. Insulin-Like Growth Factor-Binding Protein-7 as a Biomarker of Diastolic Dysfunction and Functional Capacity in Heart Failure With Preserved Ejection Fraction: Results From the RELAX Trial. *JACC Heart Fail.* 2016;4:860-869.

39. Accornero F, van Berlo JH, Benard MJ, Lorenz JN, Carmeliet P and Molkentin JD. Placental growth factor regulates cardiac adaptation and hypertrophy through a paracrine mechanism. *Circ Res.* 2011;109:272-80.

40. Gubbiotti MA, Neill T and Ilozzo RV. A current view of perlecan in physiology and pathology: A mosaic of functions. *Matrix Biol.* 2017;57-58:285-298.

41. Segev A, Nili N and Strauss BH. The role of perlecan in arterial injury and angiogenesis. *Cardiovasc Res.* 2004;63:603-10.

42. He XW, Li WL, Li C, Liu P, Shen YG, Zhu M and Jin XP. Serum levels of galectin-1, galectin-3, and galectin-9 are associated with large artery atherosclerotic stroke. *Sci Rep.* 2017;7:40994.

43. Goncalves I, Bengtsson E, Colhoun HM, Shore AC, Palombo C, Natali A, Edsfeldt A, Duner P, Fredrikson GN, Bjorkbacka H, Ostling G, Aizawa K, Casanova F, Persson M, Gooding K, Strain D, Khan F, Looker HC, Adams F, Belch J, Pinnoli S, Venturi E, Kozakova M, Gan LM, Schnecke V and Nilsson J. Elevated Plasma Levels of MMP-12 Are Associated With Atherosclerotic Burden and Symptomatic Cardiovascular Disease in Subjects With Type 2 Diabetes. *Arterioscler Thromb Vasc Biol.* 2015;35:1723-31.

44. Wang N, Halibozek PJ, Yigit B, Zhao H, O'Keeffe MS, Sage P, Sharpe A and Terhorst C. Negative Regulation of Humoral Immunity Due to Interplay between the SLAMF1, SLAMF5, and SLAMF6 Receptors. *Front Immunol.* 2015;6:158.
45. Singer BB, Opp L, Heinrich A, Schreiber F, Binding-Liermann R, Berrocal-Almanza LC, Heyl KA, Muller MM, Weimann A, Zweigner J and Slevogt H. Soluble CEACAM8 interacts with CEACAM1 inhibiting TLR2-triggered immune responses. *PLoS One*. 2014;9:e94106.

46. Stempien-Otero A, Plawman A, Meznarich J, Dyamenahalli T, Otsuka G and Dichek DA. Mechanisms of cardiac fibrosis induced by urokinase plasminogen activator. *J Biol Chem*. 2006;281:15345-51.

47. Lichtenauer M, Jirak P, Wernly B, Paar V, Rohm I, Jung C, Schernthaner C, Kraus J, Motloch LJ, Yilmaz A, Hoppe UC, Christian Schulze P, Kretzschmar D and Pistulli R. A comparative analysis of novel cardiovascular biomarkers in patients with chronic heart failure. *Eur J Intern Med*. 2017;44:31-38.

48. Wollert KC, Kempf T and Wallentin L. Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease. *Clin Chem*. 2017;63:140-151.

49. Seropian IM, Toldo S, Van Tassell BW and Abbate A. Anti-inflammatory strategies for ventricular remodeling following ST-segment elevation acute myocardial infarction. *J Am Coll Cardiol*. 2014;63:1593-603.

50. Panwar B, Judd SE, Wadley VG, Jenny NS, Howard VJ, Safford MM and Gutierrez OM. Association of Fibroblast Growth Factor 23 With Risk of Incident Coronary Heart Disease in Community-Living Adults. *JAMA Cardiol*. 2018;3:318-325.

51. Hao H, Li X, Li Q, Lin H, Chen Z, Xie J, Xuan W, Liao W, Bin J, Huang X, Kitakaze M and Liao Y. FGF23 promotes myocardial fibrosis in mice through activation of beta-catenin. *Oncotarget*. 2016;7:64649-64664.

52. Singh M, Dalal S and Singh K. Osteopontin: At the cross-roads of myocyte survival and myocardial function. *Life Sci*. 2014;118:1-6.

53. Sayer G and Bhat G. The renin-angiotensin-aldosterone system and heart failure. *Cardiol Clin*. 2014;32:21-32, vii.

54. Bruggink AH, de Jonge N, van Oosterhout MF, Van Wichen DF, de Koning E, Lahpor JR, Kemperman H, Gmelig-Meyling FH and de Weger RA. Brain natriuretic peptide is produced both by cardiomyocytes and cells infiltrating the heart in patients with severe heart failure supported by a left ventricular assist device. *J Heart Lung Transplant*. 2006;25:174-80.

55. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH and van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail*. 2016. Jul 14;37(27):2129-2200.

56. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr., Colvin MM, Drazner MH, Filippatos G, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW and Westlake C. 2016 ACC/AHA/HFSA Focused Update on New Pharmacological Therapy for Heart Failure: An Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. *Circulation*. 2017 Aug 8;136(6):e137-e161.

57. de Boer RA, Nayor M, deFilippi CR, Enserro D, Bhambhani V, Kizer JR, Blaha MJ, Brouwers FP, Cushman M, Lima JAC, Bahrami H, van der Harst P, Wang TJ, Gansevoort RT, Fox CS, Gaggin HK, Kop WJ, Liu K, Vasan RS, Psaty BM, Lee DS, Hillege HL, Bartz TM, Benjamin EJ, Chan C, Allison M, Gardin JM, Januzzi JL, Jr., Shah SJ, Levy D, Herrington DM, Larson MG, van Gilst WH, Gottdiener JS, Bertoni AG and Ho JE. Association of Cardiovascular Biomarkers With Incident Heart Failure With Preserved and Reduced Ejection Fraction. *JAMA Cardiol*. 2018;3:215-224.

58. Ledwidge M, Gallagher J, Conlon C, Tallon E, O'Connell E, Dawkins I, Watson C, O'Hanlon R, Bermingham M, Patle A, Badabhagni MR, Murtagh G, Voon V, Tilson L, Barry M, McDonald L, Maurer
B and McDonald K. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. *Jama*. 2013;310:66-74.

59. Shen Y, Ding FH, Sun JT, Pu LJ, Zhang RY, Zhang Q, Chen QJ, Shen WF and Lu L. Association of elevated apoA-I glycation and reduced HDL-associated paraoxonase1, 3 activity, and their interaction with angiographic severity of coronary artery disease in patients with type 2 diabetes mellitus. *Cardiovasc Diabetol*. 2015;14:52.

60. Floresta G, Pistara V, Amata E, Dichiara M, Marrazzo A, Prezzavento O and Rescifina A. Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. A comprehensive systematic review. *Eur J Med Chem*. 2017;138:854-873.

61. Hobaus C, Herz CT, Pesau G, Wrba T, Koppensteiner R and Schernthaner GH. FABP4 and Cardiovascular Events in Peripheral Arterial Disease. *Angiology*. 2018;69:424-430.

62. Leiherer A, Muendlein A, Kinz E, Vonbank A, Rein P, Fraunberger P, Malin C, Saely CH and Drexel H. High plasma chemerin is associated with renal dysfunction and predictive for cardiovascular events - Insights from phenotype and genotype characterization. *Vascul Pharmacol*. 2016;77:60-8.

63. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, Muruganandan S and Sinal CJ. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. *J Biol Chem*. 2007;282:28175-88.

64. Tromp J, Westenbrink BD, Ouwerkerk W, van Veldhuisen DJ, Samani NJ, Ponikowski P, Metra M, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Lang CC, Ng LL, Zannad F, Zwinderman AH, Hillege HL, van der Meer P and Voors AA. Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. *J Am Coll Cardiol*. 2018;72:1081-1090.

65. Mak TW, Hauck L, Grothe D and Billia F. p53 regulates the cardiac transcriptome. *Proc Natl Acad Sci U S A*. 2017;114:2331-2336.

66. Sama IE and Huynen MA. Measuring the physical cohesiveness of proteins using physical interaction enrichment. *Bioinformatics*. 2010;26:2737-43.
Figure 1. Induced network analysis: protein interactions, biochemical interactions, and gene regulatory interactions

Legend: Please see the supplemental table 4 for the full names of the biomarkers and intermediates.
<table><caption>Table 1. Characteristics of the study population for both discovery and replication phases</caption><thead><tr><th rowspan="3">Characteristics</th><th colspan="4">Discovery</th><th colspan="4">Replication</th></tr><tr><th colspan="2">Cases</th><th colspan="2">Controls</th><th rowspan="2">p-value</th><th colspan="2">Cases</th><th colspan="2">Controls</th><th rowspan="2">p-value</th></tr><tr><th>N=286</th><th>N=591</th><th>N=286</th><th>N=591</th><th>N=276</th><th>N=280</th><th>N=276</th><th>N=280</th></tr></thead><tbody><tr><td>Age-years</td><td>74.4 (3.5)</td><td>74.4 (3.5)</td><td>0.94</td><td></td><td>75.1 (3.5)</td><td>75.2 (3.6)</td><td>0.81</td><td></td><td>0.81</td></tr><tr><td>Male sex-Nos.(%)</td><td>154 (53.8)</td><td>320 (54.1)</td><td>0.93</td><td></td><td>157 (56.9)</td><td>158 (56.4)</td><td>0.91</td><td></td><td>0.91</td></tr><tr><td>Cohort-Nos.(%)</td><td></td><td></td><td>0.74</td><td></td><td></td><td></td><td></td><td></td><td>0.57</td></tr><tr><td>HABC</td><td>215 (75.2)</td><td>433 (73.3)</td><td></td><td></td><td>109 (39.5)</td><td>99 (35.4)</td><td></td><td></td><td></td></tr><tr><td>Predictor</td><td>15 (5.2)</td><td>29 (4.9)</td><td></td><td></td><td>29 (10.5)</td><td>29 (10.4)</td><td></td><td></td><td></td></tr><tr><td>Prosper</td><td>56 (19.6)</td><td>129 (21.8)</td><td></td><td></td><td>138 (50.0)</td><td>152 (54.3)</td><td></td><td></td><td></td></tr><tr><td>Smoking Status-Nos.(%)</td><td></td><td></td><td>0.29</td><td></td><td></td><td></td><td></td><td></td><td>0.50</td></tr><tr><td>Never</td><td>139 (48.6)</td><td>309 (52.5)</td><td></td><td></td><td>157 (56.9)</td><td>169 (60.4)</td><td></td><td></td><td></td></tr><tr><td>Current</td><td>30 (10.5)</td><td>71 (12.1)</td><td></td><td></td><td>57 (20.7)</td><td>47 (16.8)</td><td></td><td></td><td></td></tr><tr><td>Past</td><td>117 (40.9)</td><td>209 (35.5)</td><td></td><td></td><td>62 (22.5)</td><td>64 (22.9)</td><td></td><td></td><td></td></tr><tr><td>Body Mass Index-kg/m²</td><td>28.1 (4.8)</td><td>27.0 (4.4)</td><td>&lt;0.001</td><td></td><td>27.6 (4.7)</td><td>26.7 (4.2)</td><td>0.02</td><td></td><td>0.02</td></tr><tr><td>Systolic blood pressure-mmHg</td><td>142.4 (23.4)</td><td>141.2 (23.0)</td><td>0.48</td><td></td><td>148.2 (22.9)</td><td>145.9 (22.7)</td><td>0.25</td><td></td><td>0.25</td></tr><tr><td>Diastolic blood pressure-mmHg</td><td>75.2 (13.7)</td><td>74.6 (12.1)</td><td>0.45</td><td></td><td>78.5 (13.7)</td><td>78.2 (12.6)</td><td>0.76</td><td></td><td>0.76</td></tr><tr><td>Heart rate-bpm</td><td>67 (11.8)</td><td>64 (11.1)</td><td>0.004</td><td></td><td>68 (11.9)</td><td>66 (10.9)</td><td>0.09</td><td></td><td>0.09</td></tr><tr><td>Serum Creatinine-µmol/l</td><td>98.8 (27.7)</td><td>93.5 (21.3)</td><td>0.002</td><td></td><td>102.8 (28.2)</td><td>95.5 (21.5)</td><td>&lt;0.001</td><td></td><td>&lt;0.001</td></tr><tr><td>Total cholesterol-mmol/l</td><td>5.33 (1.00)</td><td>5.31 (0.99)</td><td>0.88</td><td></td><td>5.34 (0.97)</td><td>5.49 (0.95)</td><td>0.08</td><td></td><td>0.08</td></tr><tr><td>HDL-cholesterol-mmol/l</td><td>1.28 (0.39)</td><td>1.34 (0.41)</td><td>0.04</td><td></td><td>1.29 (0.37)</td><td>1.36 (0.42)</td><td>0.02</td><td></td><td>0.02</td></tr><tr><td>LDL-cholesterol-mmol/l</td><td>3.32 (0.89)</td><td>3.29 (0.92)</td><td>0.64</td><td></td><td>3.41 (0.91)</td><td>3.48 (0.85)</td><td>0.35</td><td></td><td>0.35</td></tr><tr><td>Triglycerides-mmol/l</td><td>1.61 (0.83)</td><td>1.55 (0.96)</td><td>0.33</td><td></td><td>1.53 (0.77)</td><td>1.45 (0.66)</td><td>0.19</td><td></td><td>0.19</td></tr><tr><td>Blood glucose-mmol/l</td><td>5.99 (2.18)</td><td>5.60 (1.56)</td><td>0.002</td><td></td><td>5.92 (1.99)</td><td>5.49 (1.34)</td><td>0.003</td><td></td><td>0.003</td></tr><tr><td>Comorbidities-Nos.(%)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Hypertension</td><td>219 (76.8)</td><td>408 (69.2)</td><td>0.02</td><td></td><td>184 (66.9)</td><td>177 (63.4)</td><td>0.39</td><td></td><td>0.39</td></tr><tr><td>Diabetes</td><td>55 (19.2)</td><td>68 (11.5)</td><td>0.002</td><td></td><td>49 (17.8)</td><td>32 (11.4)</td><td>0.03</td><td></td><td>0.03</td></tr><tr><td>CVD</td><td>124 (44.4)</td><td>168 (28.9)</td><td>&lt;0.001</td><td></td><td>149 (54.0)</td><td>105 (37.5)</td><td>&lt;0.001</td><td></td><td>&lt;0.001</td></tr><tr><td>CAD</td><td>103 (36.5)</td><td>126 (21.6)</td><td>&lt;0.001</td><td></td><td>114 (41.3)</td><td>78 (27.9)</td><td>&lt;0.001</td><td></td><td>&lt;0.001</td></tr><tr><td>PAD</td><td>14 (5.0)</td><td>22 (3.8)</td><td>0.40</td><td></td><td>14 (5.1)</td><td>4 (1.4)</td><td>0.01</td><td></td><td>0.01</td></tr><tr><td>Cerebrovascular disease</td><td>25 (8.9)</td><td>49 (8.3)</td><td>0.76</td><td></td><td>34 (12.3)</td><td>25 (8.9)</td><td>0.19</td><td></td><td>0.19</td></tr><tr><td>Medications-Nos.(%)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Anti-hypertensives</td><td>192 (67.1)</td><td>318 (54.0)</td><td>&lt;0.001</td><td></td><td>198 (71.7)</td><td>174 (62.1)</td><td>0.02</td><td></td><td>0.02</td></tr><tr><td>ACEi</td><td>64 (22.4)</td><td>74 (12.6)</td><td>&lt;0.001</td><td></td><td>63 (22.8)</td><td>47 (16.8)</td><td>0.07</td><td></td><td>0.07</td></tr><tr><td>CCB</td><td>86 (30.1)</td><td>114 (19.4)</td><td>&lt;0.001</td><td></td><td>77 (27.9)</td><td>53 (18.9)</td><td>0.01</td><td></td><td>0.01</td></tr><tr><td>Diuretics</td><td>88 (30.8)</td><td>141 (23.9)</td><td>0.03</td><td></td><td>102 (37.0)</td><td>89 (31.8)</td><td>0.20</td><td></td><td>0.20</td></tr><tr><td>Beta-blockers</td><td>51 (17.8)</td><td>97 (16.5)</td><td>0.61</td><td></td><td>62 (22.5)</td><td>54 (19.3)</td><td>0.36</td><td></td><td>0.36</td></tr><tr><td>ARBs</td><td>13 (4.5)</td><td>14 (2.4)</td><td>0.08</td><td></td><td>17 (6.2)</td><td>13 (4.6)</td><td>0.43</td><td></td><td>0.43</td></tr><tr><td>Antiplatelet</td><td>128 (44.8)</td><td>228 (38.7)</td><td>0.09</td><td></td><td>126 (45.7)</td><td>102 (36.4)</td><td>0.03</td><td></td><td>0.03</td></tr></tbody><tfoot><tr><td colspan="10">Numbers are mean (SD) unless otherwise specified</td></tr><tr><td colspan="10">Legend: CVD, cardiovascular diseases; CAD, coronary artery diseases; PAD, peripheral arterial diseases; ACEi, angiotensin converting enzyme inhibitors; CCB, calcium channel blockers, ARBs, angiotensin receptors blockers.</td></tr></tfoot></table>
<table><caption>Table 2. Odds ratios (OR) and 95% confidence intervals (CI) for the selected proteins with regards to their association with incident heart failure after adjustment for the matching variables and correction for multiple comparisons in both discovery and replication sets</caption><thead><tr><th rowspan="2">Protein name</th><th colspan="3">Discovery</th><th colspan="3">Replication</th></tr><tr><th>OR</th><th>(95% CI)</th><th>P-value</th><th>OR</th><th>(95% CI)</th><th>P-value</th></tr></thead><tbody><tr><td>BNP</td><td>1.62</td><td>(1.42, 1.86)</td><td>&lt;0.0001</td><td>1.73</td><td>(1.50, 2.01)</td><td>&lt;0.0001</td></tr><tr><td>NTPROBNP</td><td>1.74</td><td>(1.46, 2.06)</td><td>&lt;0.0001</td><td>2.00</td><td>(1.64, 2.44)</td><td>&lt;0.0001</td></tr><tr><td>TRAILR2</td><td>3.26</td><td>(2.32, 4.60)</td><td>&lt;0.0001</td><td>3.22</td><td>(2.21, 4.69)</td><td>&lt;0.0001</td></tr><tr><td>TNFRSF13B</td><td>1.74</td><td>(1.34, 2.24)</td><td>&lt;0.0001</td><td>2.61</td><td>(1.82, 3.74)</td><td>&lt;0.0001</td></tr><tr><td>GAL9</td><td>2.96</td><td>(1.95, 4.49)</td><td>&lt;0.0001</td><td>3.14</td><td>(2.01, 4.91)</td><td>&lt;0.0001</td></tr><tr><td>FGF23</td><td>1.70</td><td>(1.40, 2.07)</td><td>&lt;0.0001</td><td>1.84</td><td>(1.44, 2.36)</td><td>&lt;0.0001</td></tr><tr><td>TNFRSF10A</td><td>2.63</td><td>(1.88, 3.69)</td><td>&lt;0.0001</td><td>2.56</td><td>(1.74, 3.77)</td><td>&lt;0.0001</td></tr><tr><td>REN</td><td>1.31</td><td>(1.11, 1.55)</td><td>0.0018</td><td>1.54</td><td>(1.29, 1.85)</td><td>&lt;0.0001</td></tr><tr><td>TNFRSF11A</td><td>2.09</td><td>(1.61, 2.72)</td><td>&lt;0.0001</td><td>1.95</td><td>(1.47, 2.59)</td><td>&lt;0.0001</td></tr><tr><td>GDF15</td><td>2.74</td><td>(2.08, 3.61)</td><td>&lt;0.0001</td><td>1.89</td><td>(1.44, 2.47)</td><td>&lt;0.0001</td></tr><tr><td>FABP4</td><td>1.82</td><td>(1.51, 2.19)</td><td>&lt;0.0001</td><td>1.57</td><td>(1.29, 1.92)</td><td>&lt;0.0001</td></tr><tr><td>SLAMF7</td><td>1.55</td><td>(1.26, 1.91)</td><td>&lt;0.0001</td><td>2.16</td><td>(1.52, 3.06)</td><td>&lt;0.0001</td></tr><tr><td>CCL16</td><td>1.47</td><td>(1.21, 1.79)</td><td>&lt;0.0001</td><td>1.72</td><td>(1.34, 2.22)</td><td>&lt;0.0001</td></tr><tr><td>TWEAK</td><td>0.51</td><td>(0.36, 0.73)</td><td>0.0003</td><td>0.53</td><td>(0.39, 0.71)</td><td>&lt;0.0001</td></tr><tr><td>KIM1</td><td>1.41</td><td>(1.19, 1.68)</td><td>&lt;0.0001</td><td>1.51</td><td>(1.23, 1.84)</td><td>&lt;0.0001</td></tr><tr><td>CD4</td><td>2.06</td><td>(1.49, 2.85)</td><td>&lt;0.0001</td><td>2.17</td><td>(1.49, 3.16)</td><td>&lt;0.0001</td></tr><tr><td>VSIG2</td><td>1.43</td><td>(1.14, 1.81)</td><td>0.0025</td><td>1.76</td><td>(1.33, 2.32)</td><td>&lt;0.0001</td></tr><tr><td>PON3</td><td>0.71</td><td>(0.58, 0.87)</td><td>0.0011</td><td>0.64</td><td>(0.51, 0.80)</td><td>&lt;0.0001</td></tr><tr><td>PLGF</td><td>2.17</td><td>(1.54, 3.06)</td><td>&lt;0.0001</td><td>1.95</td><td>(1.38, 2.75)</td><td>0.0002</td></tr><tr><td>MMP12</td><td>1.64</td><td>(1.32, 2.03)</td><td>&lt;0.0001</td><td>1.54</td><td>(1.23, 1.92)</td><td>0.0002</td></tr><tr><td>ADM</td><td>2.56</td><td>(1.82, 3.59)</td><td>&lt;0.0001</td><td>1.80</td><td>(1.32, 2.45)</td><td>0.0002</td></tr><tr><td>RARRES2</td><td>3.33</td><td>(2.02, 5.51)</td><td>&lt;0.0001</td><td>2.05</td><td>(1.38, 3.05)</td><td>0.0004</td></tr><tr><td>CEACAM8</td><td>1.51</td><td>(1.22, 1.86)</td><td>0.0001</td><td>1.49</td><td>(1.19, 1.86)</td><td>0.0005</td></tr><tr><td>SLAMF1</td><td>1.44</td><td>(1.17, 1.76)</td><td>0.0005</td><td>1.62</td><td>(1.23, 2.13)</td><td>0.0005</td></tr><tr><td>TNFR1</td><td>2.40</td><td>(1.75, 3.28)</td><td>&lt;0.0001</td><td>1.63</td><td>(1.23, 2.16)</td><td>0.0007</td></tr><tr><td>AGRP</td><td>1.82</td><td>(1.38, 2.40)</td><td>&lt;0.0001</td><td>1.90</td><td>(1.31, 2.76)</td><td>0.0007</td></tr><tr><td>TNFR2</td><td>2.11</td><td>(1.58, 2.82)</td><td>&lt;0.0001</td><td>1.55</td><td>(1.20, 2.00)</td><td>0.0008</td></tr><tr><td>IGFBP7</td><td>1.66</td><td>(1.24, 2.23)</td><td>0.0006</td><td>1.60</td><td>(1.21, 2.11)</td><td>0.0010</td></tr><tr><td>UPAR</td><td>2.70</td><td>(1.94, 3.75)</td><td>&lt;0.0001</td><td>1.67</td><td>(1.23, 2.28)</td><td>0.0011</td></tr><tr><td>PAR1</td><td>1.86</td><td>(1.33, 2.60)</td><td>0.0003</td><td>1.74</td><td>(1.24, 2.45)</td><td>0.0014</td></tr><tr><td>PLC</td><td>2.26</td><td>(1.59, 3.21)</td><td>&lt;0.0001</td><td>1.76</td><td>(1.24, 2.49)</td><td>0.0015</td></tr><tr><td>ACE2</td><td>1.60</td><td>(1.27, 2.02)</td><td>&lt;0.0001</td><td>1.52</td><td>(1.17, 1.98)</td><td>0.0016</td></tr><tr><td>IL16</td><td>1.54</td><td>(1.20, 1.97)</td><td>0.0007</td><td>1.46</td><td>(1.15, 1.86)</td><td>0.0019</td></tr><tr><td>TFF3</td><td>1.61</td><td>(1.32, 1.95)</td><td>&lt;0.0001</td><td>1.45</td><td>(1.15, 1.84)</td><td>0.0019</td></tr><tr><td>OPN</td><td>2.00</td><td>(1.52, 2.63)</td><td>&lt;0.0001</td><td>1.50</td><td>(1.16, 1.95)</td><td>0.0021</td></tr><tr><td>SPON2</td><td>2.86</td><td>(1.50, 5.48)</td><td>0.0015</td><td>2.40</td><td>(1.36, 4.25)</td><td>0.0026</td></tr><tr><td>IL4RA</td><td>1.52</td><td>(1.15, 2.02)</td><td>0.0033</td><td>1.62</td><td>(1.18, 2.22)</td><td>0.0029</td></tr><tr><td>TNFRSF14</td><td>2.09</td><td>(1.55, 2.82)</td><td>&lt;0.0001</td><td>1.52</td><td>(1.15, 2.01)</td><td>0.0034</td></tr></tbody></table>

Legend: BNP, brain natriuretic peptide; NTPROBNP, N-terminal prohormone brain natriuretic peptide; TRAILR2, TNF-related apoptosis-inducing ligand receptor 2; TNFRSF13B, tumor necrosis factor receptor superfamily member 13B; GAL9, galectin-9; FGF23, fibroblast growth factor 23; TNFRSF10A, tumor necrosis factor receptor superfamily member 10A, REN, renin; TNFRSF11A, tumor necrosis factor receptor superfamily member 11A; GDF15, growth/differentiation factor 15; FABP4, fatty acid-binding protein; SLAMF7, SLAM family member 7; CCL16, C-C motif chemokine 16; TWEAK, tumor necrosis factor (Ligand) superfamily, member 12; KIM1, kidney injury molecule 1; CD4, T-cell surface glycoprotein CD4; VSIG2, v-set and immunoglobulin domain-containing protein 2; PON3, paraoxonase; PLGF, placenta growth factor; MMP12, matrix metalloproteinase-12; ADM, adrenomedullin; RARRES2, retinoic acid receptor responder protein 2; CEACAM8, carcinoembryonic antigen-related cell adhesion molecule 8; SLAMF1, signaling lymphocytic activation molecule; tnfr1, tumor necrosis factor receptor 1; AGRP, agouti-related protein; TNFR2, tumor necrosis factor receptor 2; IGFBP7, insulin-like growth factor-binding protein 7; UPAR, urokinase plasminogen activator surface receptor; PAR1, proteinase-activated receptor 1; PLC, perlecan; ACE2, angiotensin-converting enzyme 2; IL16, pro-interleukin-16; TFF3, trefoil factor 3; OPN, osteopontin; SPON2, spondin-2; IL4RA, interleukin-4 receptor subunit alpha; TNFRSF14, tumor necrosis factor receptor superfamily member 14.
<figure><img src="image_4.png" /></figure>

Link color

Biochemical reaction

Protein interaction

Gene regulatory interaction

Node color

Protein

Protein/Gene

Complex

Node label color

Black: seed

Magenta: intermediate
Supplemental Material
<table><caption>Supplemental Table 1. Protein names and respective Olink® panel sorted in alphabetical order</caption><thead><tr><td>Protein full name</td><td>Entry name</td><td>Olink® Panel*</td><td>Uniprot ID**</td></tr></thead><tbody><tr><td>Angiotensin-converting enzyme 2</td><td>ACE2</td><td>CVD II</td><td>Q9BYF1</td></tr><tr><td>Adenosine Deaminase</td><td>ADA</td><td>INF</td><td>P00813</td></tr><tr><td>Adisintegrin and metalloproteinase with thrombospondin motifs 13</td><td>ADAMTS13</td><td>CVD II</td><td>Q76LX8</td></tr><tr><td>ADM</td><td>ADM</td><td>CVD II</td><td>P35318</td></tr><tr><td>Agouti-related protein</td><td>AGRP</td><td>CVD II</td><td>O00253</td></tr><tr><td>CD166 antigen</td><td>ALCAM</td><td>CVD III</td><td>Q13740</td></tr><tr><td>Protein AMBP</td><td>AMBP</td><td>CVD II</td><td>P02760</td></tr><tr><td>Angiopoietin-1</td><td>ANG1</td><td>CVD II</td><td>Q15389</td></tr><tr><td>Aminopeptidase N</td><td>APN</td><td>CVD III</td><td>P15144</td></tr><tr><td>Axin-1</td><td>AXIN1</td><td>INF</td><td>O15169</td></tr><tr><td>Tyrosine-protein kinase receptor UFO</td><td>AXL</td><td>CVD III</td><td>P30530</td></tr><tr><td>Azurocidin</td><td>AZU1</td><td>CVD III</td><td>P20160</td></tr><tr><td>Brain-derived neurotrophic factor</td><td>BDNF</td><td>INF</td><td>P23560</td></tr><tr><td>Beta-nerve growth factor</td><td>BETANGF</td><td>INF</td><td>P01138</td></tr><tr><td>Bleomycin hydrolase</td><td>BLMHYDROLASE</td><td>CVD III</td><td>Q13867</td></tr><tr><td>Bone morphogenetic protein 6</td><td>BMP6</td><td>CVD II</td><td>P22004</td></tr><tr><td>Natriuretic peptides B</td><td>BNP</td><td>CVD II</td><td>P16860</td></tr><tr><td>Eukaryotic translation initiation factor 4E-binding protein 1</td><td>BP1_4E</td><td>INF</td><td>Q13541</td></tr><tr><td>Carbonic anhydrase 5A, mitochondrial</td><td>CA5A</td><td>CVD II</td><td>P35218</td></tr><tr><td>Caspase-3</td><td>CASP3</td><td>CVD III</td><td>P42574</td></tr><tr><td>Caspase 8</td><td>CASP8</td><td>INF</td><td>Q14790</td></tr><tr><td>Eotaxin-1</td><td>CCL11</td><td>INF</td><td>P51671</td></tr><tr><td>C-C motif chemokine 15</td><td>CCL15</td><td>CVD III</td><td>Q16663</td></tr><tr><td>C-C motif chemokine 16</td><td>CCL16</td><td>CVD III</td><td>O15467</td></tr><tr><td>C-C motif chemokine 17</td><td>CCL17</td><td>CVD II</td><td>Q92583</td></tr><tr><td>C-C motif chemokine 19</td><td>CCL19</td><td>INF</td><td>Q99731</td></tr><tr><td>C-C motif chemokine 20</td><td>CCL20</td><td>INF</td><td>P78556</td></tr><tr><td>C-C motif chemokine 22</td><td>CCL22</td><td>CVD III</td><td>O00626</td></tr><tr><td>C-C motif chemokine 23</td><td>CCL23</td><td>INF</td><td>P55773</td></tr><tr><td>C-C motif chemokine 24</td><td>CCL24</td><td>CVD III</td><td>O00175</td></tr><tr><td>C-C motif chemokine 25</td><td>CCL25</td><td>INF</td><td>O15444</td></tr><tr><td>C-C motif chemokine 28</td><td>CCL28</td><td>INF</td><td>Q9NRJ3</td></tr><tr><td>C-C motif chemokine 3</td><td>CCL3</td><td>CVD II</td><td>P10147</td></tr><tr><td>C-C motif chemokine 4</td><td>CCL4</td><td>INF</td><td>P13236</td></tr><tr><td>Scavenger receptor cysteine-rich type 1 protein M130</td><td>CD163</td><td>CVD III</td><td>Q86VB7</td></tr><tr><td>Natural killer cell receptor 2B4</td><td>CD244</td><td>INF</td><td>Q9BZW8</td></tr><tr><td>T-cell surface glycoprotein CD4</td><td>CD4</td><td>CVD II</td><td>P01730</td></tr><tr><td>CD40L receptor</td><td>CD40</td><td>INF</td><td>P25942</td></tr><tr><td>CD40 ligand</td><td>CD40L</td><td>CVD II</td><td>P29965</td></tr><tr><td>T-cell surface glycoprotein CD5</td><td>CD5</td><td>INF</td><td>P06127</td></tr><tr><td>T cell surface glycoprotein CD6</td><td>CD6</td><td>INF</td><td>P30203</td></tr><tr><td>SLAM family member 5</td><td>CD84</td><td>CVD II</td><td>Q9UIB8</td></tr><tr><td>Complement component C1q receptor</td><td>CD93</td><td>CVD III</td><td>Q9NPY3</td></tr><tr><td>CUB domain-containing protein 1</td><td>CDCP1</td><td>INF</td><td>Q9H5V8</td></tr><tr><td>Cadherin-5</td><td>CDH5</td><td>CVD III</td><td>P33151</td></tr><tr><td>Carcinoembryonic antigen-related cell adhesion molecule 8</td><td>CEACAM8</td><td>CVD II</td><td>P31997</td></tr></tbody></table>
<table>
  <tr>
    <td>Chitinase-3-like protein 1</td>
    <td>CHI3L1</td>
    <td>CVD III</td>
    <td>P36222</td>
  </tr>
  <tr>
    <td>Chitotriosidase-1</td>
    <td>CHIT1</td>
    <td>CVD III</td>
    <td>Q13231</td>
  </tr>
  <tr>
    <td>Contactin-1</td>
    <td>CNTN1</td>
    <td>CVD III</td>
    <td>Q12860</td>
  </tr>
  <tr>
    <td>Collagen alpha-1(I) chain</td>
    <td>COL1A1</td>
    <td>CVD III</td>
    <td>P02452</td>
  </tr>
  <tr>
    <td>Carboxypeptidase A1</td>
    <td>CPA1</td>
    <td>CVD III</td>
    <td>P15085</td>
  </tr>
  <tr>
    <td>Carboxypeptidase B</td>
    <td>CPB1</td>
    <td>CVD III</td>
    <td>P15086</td>
  </tr>
  <tr>
    <td>Macrophage colony-stimulating factor 1</td>
    <td>CSF1</td>
    <td>INF</td>
    <td>P09603</td>
  </tr>
  <tr>
    <td>Cystatin D</td>
    <td>CST5</td>
    <td>INF</td>
    <td>P28325</td>
  </tr>
  <tr>
    <td>Cystatin-B</td>
    <td>CSTB</td>
    <td>CVD III</td>
    <td>P04080</td>
  </tr>
  <tr>
    <td>Chymotrypsin C</td>
    <td>CTRC</td>
    <td>CVD II</td>
    <td>Q99895</td>
  </tr>
  <tr>
    <td>Cathepsin D</td>
    <td>CTSD</td>
    <td>CVD III</td>
    <td>P07339</td>
  </tr>
  <tr>
    <td>Cathepsin L1</td>
    <td>CTSL1</td>
    <td>CVD II</td>
    <td>P07711</td>
  </tr>
  <tr>
    <td>Cathepsin Z</td>
    <td>CTSZ</td>
    <td>CVD III</td>
    <td>Q9UBR2</td>
  </tr>
  <tr>
    <td>Fractalkine</td>
    <td>CX3CL1</td>
    <td>INF</td>
    <td>P78423</td>
  </tr>
  <tr>
    <td>C-X-C motif chemokine 1 (CVD2)</td>
    <td>CXCL1</td>
    <td>CVD II</td>
    <td>P09341</td>
  </tr>
  <tr>
    <td>C-X-C motif chemokine 10</td>
    <td>CXCL10</td>
    <td>INF</td>
    <td>P02778</td>
  </tr>
  <tr>
    <td>C-X-C motif chemokine 11</td>
    <td>CXCL11</td>
    <td>INF</td>
    <td>O14625</td>
  </tr>
  <tr>
    <td>C-X-C motif chemokine 16</td>
    <td>CXCL16</td>
    <td>CVD III</td>
    <td>Q9H2A7</td>
  </tr>
  <tr>
    <td>C-X-C motif chemokine 5</td>
    <td>CXCL5</td>
    <td>INF</td>
    <td>P42830</td>
  </tr>
  <tr>
    <td>C-X-C motif chemokine 6</td>
    <td>CXCL6</td>
    <td>INF</td>
    <td>P80162</td>
  </tr>
  <tr>
    <td>C-X-C motif chemokine 9</td>
    <td>CXCL9</td>
    <td>INF</td>
    <td>Q07325</td>
  </tr>
  <tr>
    <td>Decorin</td>
    <td>DCN</td>
    <td>CVD II</td>
    <td>P07585</td>
  </tr>
  <tr>
    <td>2,4-dienoyl-CoA reductase, mitochondrial</td>
    <td>DECR1</td>
    <td>CVD II</td>
    <td>Q16698</td>
  </tr>
  <tr>
    <td>Dickkopf-related protein 1</td>
    <td>DKK1</td>
    <td>CVD II</td>
    <td>O94907</td>
  </tr>
  <tr>
    <td>Azurocidin</td>
    <td>DLK1</td>
    <td>CVD III</td>
    <td>P80370</td>
  </tr>
  <tr>
    <td>Delta and Notch-like epidermal growth factor-related receptor</td>
    <td>DNER</td>
    <td>INF</td>
    <td>Q8NFT8</td>
  </tr>
  <tr>
    <td>Epidermal growth factor receptor</td>
    <td>EGFR</td>
    <td>CVD III</td>
    <td>P00533</td>
  </tr>
  <tr>
    <td>Protein S100-A12</td>
    <td>ENRAGE</td>
    <td>INF</td>
    <td>P80511</td>
  </tr>
  <tr>
    <td>Epithelial cell adhesion molecule</td>
    <td>EPCAM</td>
    <td>CVD III</td>
    <td>P16422</td>
  </tr>
  <tr>
    <td>Ephrin type-B receptor 4</td>
    <td>EPHB4</td>
    <td>CVD III</td>
    <td>P54760</td>
  </tr>
  <tr>
    <td>Fatty acid-binding protein, intestinal</td>
    <td>FABP2</td>
    <td>CVD II</td>
    <td>P12104</td>
  </tr>
  <tr>
    <td>Fatty acid-binding protein, adipocyte</td>
    <td>FABP4</td>
    <td>CVD III</td>
    <td>P15090</td>
  </tr>
  <tr>
    <td>Tumor necrosis factor receptor superfamily member 6</td>
    <td>FAS</td>
    <td>CVD III</td>
    <td>P25445</td>
  </tr>
  <tr>
    <td>Fibroblast growth factor 19</td>
    <td>FGF19</td>
    <td>INF</td>
    <td>O95750</td>
  </tr>
  <tr>
    <td>Fibroblast growth factor 21 (CVD2)</td>
    <td>FGF21</td>
    <td>CVD II</td>
    <td>Q9NSA1</td>
  </tr>
  <tr>
    <td>Fibroblast growth factor 23 (CVD2)</td>
    <td>FGF23</td>
    <td>CVD II</td>
    <td>Q9GZV9</td>
  </tr>
  <tr>
    <td>Fibroblast growth factor 5</td>
    <td>FGF5</td>
    <td>INF</td>
    <td>P12034</td>
  </tr>
  <tr>
    <td>Fms-related tyrosine kinase 3 ligand</td>
    <td>FLT3L</td>
    <td>INF</td>
    <td>P49771</td>
  </tr>
  <tr>
    <td>Follistatin</td>
    <td>FS</td>
    <td>CVD II</td>
    <td>P19883</td>
  </tr>
  <tr>
    <td>Galectin-3</td>
    <td>GAL3</td>
    <td>CVD III</td>
    <td>P17931</td>
  </tr>
  <tr>
    <td>Galectin-4</td>
    <td>GAL4</td>
    <td>CVD III</td>
    <td>P56470</td>
  </tr>
  <tr>
    <td>Galectin-9</td>
    <td>GAL9</td>
    <td>CVD II</td>
    <td>O00182</td>
  </tr>
  <tr>
    <td>Growth/differentiation factor 15</td>
    <td>GDF15</td>
    <td>CVD III</td>
    <td>Q99988</td>
  </tr>
  <tr>
    <td>Growth/differentiation factor 2</td>
    <td>GDF2</td>
    <td>CVD II</td>
    <td>Q9UK05</td>
  </tr>
  <tr>
    <td>Growth hormone</td>
    <td>GH</td>
    <td>CVD II</td>
    <td>P01241</td>
  </tr>
  <tr>
    <td>Gastric intrinsic factor</td>
    <td>GIF</td>
    <td>CVD II</td>
    <td>P27352</td>
  </tr>
  <tr>
    <td>Lactoylglutathione lyase</td>
    <td>GLO1</td>
    <td>CVD II</td>
    <td>Q04760</td>
  </tr>
  <tr>
    <td>Granulins</td>
    <td>GRN</td>
    <td>CVD III</td>
    <td>P28799</td>
  </tr>
  <tr>
    <td>Gastrotropin</td>
    <td>GT</td>
    <td>CVD II</td>
    <td>P51161</td>
  </tr>
  <tr>
    <td>Hydroxyacid oxidase 1</td>
    <td>HAOX1</td>
    <td>CVD II</td>
    <td>Q9UJM8</td>
  </tr>
  <tr>
    <td>Proheparin-binding EGF-like growth factor</td>
    <td>HBEGF</td>
    <td>CVD II</td>
    <td>Q99075</td>
  </tr>
</table>
<table>
  <tr>
    <td>Glial cell line-derived neurotrophic factor</td>
    <td>HGDNF</td>
    <td>INF</td>
    <td>P39905</td>
  </tr>
  <tr>
    <td>Hepatocyte growth factor</td>
    <td>HGF</td>
    <td>INF</td>
    <td>P14210</td>
  </tr>
  <tr>
    <td>Heme oxygenase 1</td>
    <td>HO1</td>
    <td>CVD II</td>
    <td>P09601</td>
  </tr>
  <tr>
    <td>Osteoclast-associated immunoglobulin-like receptor</td>
    <td>HOSCAR</td>
    <td>CVD II</td>
    <td>Q8IYS5</td>
  </tr>
  <tr>
    <td>Heat shock 27 kDa protein</td>
    <td>HSP27</td>
    <td>CVD II</td>
    <td>P04792</td>
  </tr>
  <tr>
    <td>Intercellular adhesion molecule 2</td>
    <td>ICAM2</td>
    <td>CVD III</td>
    <td>P13598</td>
  </tr>
  <tr>
    <td>Alpha-L-iduronidase</td>
    <td>IDUA</td>
    <td>CVD II</td>
    <td>P35475</td>
  </tr>
  <tr>
    <td>Insulin-like growth factor-binding protein 1</td>
    <td>IGFBP1</td>
    <td>CVD III</td>
    <td>P08833</td>
  </tr>
  <tr>
    <td>Insulin-like Growth Factor-Binding Protein 2</td>
    <td>IGFBP2</td>
    <td>CVD III</td>
    <td>P18065</td>
  </tr>
  <tr>
    <td>Insulin-like growth factor-binding protein 7</td>
    <td>IGFBP7</td>
    <td>CVD III</td>
    <td>Q16270</td>
  </tr>
  <tr>
    <td>Low affinity immunoglobulin gamma Fc region receptor II-b</td>
    <td>IGGFCRECEP TORIIB</td>
    <td>CVD II</td>
    <td>P31994</td>
  </tr>
  <tr>
    <td>Interleukin-10</td>
    <td>IL10</td>
    <td>INF</td>
    <td>P22301</td>
  </tr>
  <tr>
    <td>Interleukin-10 receptor subunit alpha</td>
    <td>IL10RA</td>
    <td>INF</td>
    <td>Q13651</td>
  </tr>
  <tr>
    <td>Interleukin-10 receptor subunit beta</td>
    <td>IL10RB</td>
    <td>INF</td>
    <td>Q08334</td>
  </tr>
  <tr>
    <td>Interleukin-12 subunit beta</td>
    <td>IL12B</td>
    <td>INF</td>
    <td>P29460</td>
  </tr>
  <tr>
    <td>Interleukin-13</td>
    <td>IL13</td>
    <td>INF</td>
    <td>P35225</td>
  </tr>
  <tr>
    <td>Interleukin-15 receptor subunit alpha</td>
    <td>IL15RA</td>
    <td>INF</td>
    <td>Q13261</td>
  </tr>
  <tr>
    <td>Pro-interleukin-16</td>
    <td>IL16</td>
    <td>CVD II</td>
    <td>Q14005</td>
  </tr>
  <tr>
    <td>Interleukin-17A</td>
    <td>IL17A</td>
    <td>INF</td>
    <td>Q16552</td>
  </tr>
  <tr>
    <td>Interleukin-17C</td>
    <td>IL17C</td>
    <td>INF</td>
    <td>Q9P0M4</td>
  </tr>
  <tr>
    <td>Interleukin-17D</td>
    <td>IL17D</td>
    <td>CVD II</td>
    <td>Q8TAD2</td>
  </tr>
  <tr>
    <td>Interleukin-17 receptor A</td>
    <td>IL17RA</td>
    <td>CVD III</td>
    <td>Q96F46</td>
  </tr>
  <tr>
    <td>Interleukin-18 (CVD2)</td>
    <td>IL18</td>
    <td>CVD II</td>
    <td>Q14116</td>
  </tr>
  <tr>
    <td>Interleukin-18-binding protein</td>
    <td>IL18BP</td>
    <td>CVD III</td>
    <td>Q95998</td>
  </tr>
  <tr>
    <td>Interleukin-18 receptor 1</td>
    <td>IL18R1</td>
    <td>INF</td>
    <td>Q13478</td>
  </tr>
  <tr>
    <td>Interleukin-1 receptor antagonist protein</td>
    <td>IL1RA</td>
    <td>CVD II</td>
    <td>P18510</td>
  </tr>
  <tr>
    <td>Interleukin-1 receptor-like 2</td>
    <td>IL1RL2</td>
    <td>CVD II</td>
    <td>Q9HB29</td>
  </tr>
  <tr>
    <td>Interleukin-1 receptor type 1</td>
    <td>IL1RT1</td>
    <td>CVD III</td>
    <td>P14778</td>
  </tr>
  <tr>
    <td>Interleukin-1 receptor type 2</td>
    <td>IL1RT2</td>
    <td>CVD III</td>
    <td>P27930</td>
  </tr>
  <tr>
    <td>Interleukin-20 receptor subunit alpha</td>
    <td>IL20RA</td>
    <td>INF</td>
    <td>Q9UHF4</td>
  </tr>
  <tr>
    <td>Interleukin-27</td>
    <td>IL27</td>
    <td>CVD II</td>
    <td>Q8NEV9</td>
  </tr>
  <tr>
    <td>Interleukin-2 receptor subunit alpha</td>
    <td>IL2RA</td>
    <td>CVD III</td>
    <td>P01589</td>
  </tr>
  <tr>
    <td>Interleukin-4 receptor subunit alpha</td>
    <td>IL4RA</td>
    <td>CVD II</td>
    <td>P24394</td>
  </tr>
  <tr>
    <td>Interleukin-6 (CVD2)</td>
    <td>IL6</td>
    <td>CVD II</td>
    <td>P05231</td>
  </tr>
  <tr>
    <td>Interleukin-6 receptor subunit alpha</td>
    <td>IL6RA</td>
    <td>CVD III</td>
    <td>P08887</td>
  </tr>
  <tr>
    <td>Interleukin-7</td>
    <td>IL7</td>
    <td>INF</td>
    <td>P13232</td>
  </tr>
  <tr>
    <td>Interleukin-8</td>
    <td>IL8</td>
    <td>INF</td>
    <td>P10145</td>
  </tr>
  <tr>
    <td>Melusin</td>
    <td>ITGB1BP2</td>
    <td>CVD II</td>
    <td>Q9UKP3</td>
  </tr>
  <tr>
    <td>Integrin beta-2</td>
    <td>ITGB2</td>
    <td>CVD III</td>
    <td>P05107</td>
  </tr>
  <tr>
    <td>Junctional adhesion molecule A</td>
    <td>JAMA</td>
    <td>CVD III</td>
    <td>Q9Y624</td>
  </tr>
  <tr>
    <td>Kidney injury molecule 1</td>
    <td>KIM1</td>
    <td>CVD II</td>
    <td>Q96D42</td>
  </tr>
  <tr>
    <td>Kallikrein-6</td>
    <td>KLK6</td>
    <td>CVD III</td>
    <td>Q92876</td>
  </tr>
  <tr>
    <td>Latency-associated peptide transforming growth factor beta 1</td>
    <td>LAPTGFBETA 1</td>
    <td>INF</td>
    <td>P01137</td>
  </tr>
  <tr>
    <td>Low-density lipoprotein receptor</td>
    <td>LDLRECEPTOR</td>
    <td>CVD III</td>
    <td>P01130</td>
  </tr>
  <tr>
    <td>Leptin</td>
    <td>LEP</td>
    <td>CVD II</td>
    <td>P41159</td>
  </tr>
  <tr>
    <td>Leukemia inhibitory factor receptor</td>
    <td>LIFR</td>
    <td>INF</td>
    <td>P42702</td>
  </tr>
  <tr>
    <td>Lectin-like oxidized LDL receptor 1</td>
    <td>LOX1</td>
    <td>CVD II</td>
    <td>P78380</td>
  </tr>
  <tr>
    <td>Lipoprotein lipase</td>
    <td>LPL</td>
    <td>CVD II</td>
    <td>P06858</td>
  </tr>
  <tr>
    <td>Lymphotoxin-beta receptor</td>
    <td>LTBR</td>
    <td>CVD III</td>
    <td>P36941</td>
  </tr>
  <tr>
    <td>Macrophage receptor MARCO</td>
    <td>MARCO</td>
    <td>CVD II</td>
    <td>Q9UEW3</td>
  </tr>
</table>
<table><tr><td>Myoglobin</td><td>MB</td><td>CVD III</td><td>P02144</td></tr><tr><td>Monocyte chemotactic protein 1</td><td>MCP1_CVD3</td><td>CVD III</td><td>P13500</td></tr><tr><td>Monocyte chemotactic protein 2</td><td>MCP2</td><td>INF</td><td>P80075</td></tr><tr><td>Monocyte chemotactic protein 3</td><td>MCP3</td><td>INF</td><td>P80098</td></tr><tr><td>Monocyte chemotactic protein 4</td><td>MCP4</td><td>INF</td><td>Q99616</td></tr><tr><td>Matrix extracellular phosphoglycoprotein</td><td>MEPE</td><td>CVD III</td><td>Q9NQ76</td></tr><tr><td>Tyrosine-protein kinase Mer</td><td>MERTK</td><td>CVD II</td><td>Q12866</td></tr><tr><td>Matrix metalloproteinase-1</td><td>MMP1</td><td>INF</td><td>P03956</td></tr><tr><td>Matrix metalloproteinase-10</td><td>MMP10</td><td>INF</td><td>P09238</td></tr><tr><td>Matrix metalloproteinase-12</td><td>MMP12</td><td>CVD II</td><td>P39900</td></tr><tr><td>Matrix metalloproteinase-2</td><td>MMP2</td><td>CVD III</td><td>P08253</td></tr><tr><td>Matrix metalloproteinase-3</td><td>MMP3</td><td>CVD III</td><td>P08254</td></tr><tr><td>Matrix metalloproteinase-7</td><td>MMP7</td><td>CVD II</td><td>P09237</td></tr><tr><td>Matrix metalloproteinase-9</td><td>MMP9</td><td>CVD III</td><td>P14780</td></tr><tr><td>Myeloperoxidase</td><td>MPO</td><td>CVD III</td><td>P05164</td></tr><tr><td>NF-kappa-B essential modulator</td><td>NEMO</td><td>CVD II</td><td>Q9Y6K9</td></tr><tr><td>Neurogenic locus notch homolog protein 3</td><td>NOTCH3</td><td>CVD III</td><td>Q9UM47</td></tr><tr><td>Neurotrophin-3</td><td>NT3</td><td>INF</td><td>P20783</td></tr><tr><td>N-terminal prohormone brain natriuretic peptide</td><td>NTPROBNP</td><td>CVDII</td><td>P16860</td></tr><tr><td>Osteoprotegerin</td><td>QPG_CVD3</td><td>CVD III</td><td>O00300</td></tr><tr><td>Osteopontin</td><td>OPN</td><td>CVD III</td><td>P10451</td></tr><tr><td>Oncostatin-M</td><td>OSM</td><td>INF</td><td>P13725</td></tr><tr><td>Plasminogen activator inhibitor 1</td><td>PAI</td><td>CVD III</td><td>P05121</td></tr><tr><td>Pappalysin-1</td><td>PAPPA</td><td>CVD II</td><td>Q13219</td></tr><tr><td>Proteinase-activated receptor 1</td><td>PAR1</td><td>CVD II</td><td>P25116</td></tr><tr><td>Poly [ADP-ribose] polymerase 1</td><td>PARP1</td><td>CVD II</td><td>P09874</td></tr><tr><td>Proprotein convertase subtilisin/kexin type 9</td><td>PCSK9</td><td>CVD III</td><td>Q8NBP7</td></tr><tr><td>Platelet-derived growth factor subunit A</td><td>PDGFSUBUNI TA</td><td>CVD III</td><td>P04085</td></tr><tr><td>Platelet-derived growth factor subunit B</td><td>PDGFSUBUNI TB</td><td>CVD II</td><td>P01127</td></tr><tr><td>Programmed cell death 1 ligand 1</td><td>PDL1</td><td>INF</td><td>Q9NZQ7</td></tr><tr><td>Programmed cell death 1 ligand 2</td><td>PDL2</td><td>CVD II</td><td>Q9BQ51</td></tr><tr><td>Platelet endothelial cell adhesion molecule</td><td>PECAM1</td><td>CVD III</td><td>P16284</td></tr><tr><td>Peptidoglycan recognition protein 1</td><td>PGLYRP1</td><td>CVD III</td><td>O75594</td></tr><tr><td>Elafin</td><td>PI3</td><td>CVD III</td><td>P19957</td></tr><tr><td>Polymeric immunoglobulin receptor</td><td>PIGR</td><td>CVD II</td><td>P01833</td></tr><tr><td>Perlecan</td><td>PLC</td><td>CVD III</td><td>P98160</td></tr><tr><td>Placenta growth factor</td><td>PLGF</td><td>CVD II</td><td>P49763</td></tr><tr><td>Paraoxonase (PON 3)</td><td>PON3</td><td>CVD III</td><td>Q15166</td></tr><tr><td>Prolargin</td><td>PRELP</td><td>CVD II</td><td>P51888</td></tr><tr><td>Brother of CDO</td><td>PROTEINBOC</td><td>CVD II</td><td>Q9BWV1</td></tr><tr><td>Serine protease 27</td><td>PRSS27</td><td>CVD II</td><td>Q9BQR3</td></tr><tr><td>Prostasin</td><td>PRSS8</td><td>CVD II</td><td>Q16651</td></tr><tr><td>Myeloblastin</td><td>PRTN3</td><td>CVD III</td><td>P24158</td></tr><tr><td>P-selectin glycoprotein ligand 1</td><td>PSGL1</td><td>CVD II</td><td>Q14242</td></tr><tr><td>Pulmonary surfactant-associated protein D</td><td>PSPD</td><td>CVD III</td><td>P35247</td></tr><tr><td>Pentraxin-related protein PTX3</td><td>PTX3</td><td>CVD II</td><td>P26022</td></tr><tr><td>Receptor for advanced glycosylation end products</td><td>RAGE</td><td>CVD II</td><td>Q15109</td></tr><tr><td>Retinoic acid receptor responder protein 2</td><td>RARRES2</td><td>CVD III</td><td>Q99969</td></tr><tr><td>Renin</td><td>REN</td><td>CVD II</td><td>P00797</td></tr><tr><td>Resistin</td><td>RETN</td><td>CVD III</td><td>Q9HD89</td></tr><tr><td>Stem cell factor (CVD2)</td><td>SCF</td><td>CVD II</td><td>P21583</td></tr></table>
<table>
  <tr>
    <td>Secretoglobin family 3A member 2</td>
    <td>SCGB3A2</td>
    <td>CVD III</td>
    <td>Q96PL1</td>
  </tr>
  <tr>
    <td>E-selectin</td>
    <td>SELE</td>
    <td>CVD III</td>
    <td>P16581</td>
  </tr>
  <tr>
    <td>P-selectin</td>
    <td>SELP</td>
    <td>CVD III</td>
    <td>P16109</td>
  </tr>
  <tr>
    <td>Serpin A12</td>
    <td>SERPINA12</td>
    <td>CVD II</td>
    <td>Q8IW75</td>
  </tr>
  <tr>
    <td>Tyrosine-protein phosphatase non-receptor type substrate 1</td>
    <td>SHPS1</td>
    <td>CVD III</td>
    <td>P78324</td>
  </tr>
  <tr>
    <td>SIR2-like protein 2</td>
    <td>SIRT2</td>
    <td>INF</td>
    <td>Q8IXJ6</td>
  </tr>
  <tr>
    <td>Signaling lymphocytic activation molecule</td>
    <td>SLAMF1</td>
    <td>INF</td>
    <td>Q13291</td>
  </tr>
  <tr>
    <td>SLAM family member 7</td>
    <td>SLAMF7</td>
    <td>CVD II</td>
    <td>Q9NQ25</td>
  </tr>
  <tr>
    <td>Superoxide dismutase [Mn], mitochondrial</td>
    <td>SOD2</td>
    <td>CVD II</td>
    <td>P04179</td>
  </tr>
  <tr>
    <td>Sortilin</td>
    <td>SORT1</td>
    <td>CVD II</td>
    <td>Q99523</td>
  </tr>
  <tr>
    <td>Spondin-1</td>
    <td>SPON1</td>
    <td>CVD III</td>
    <td>Q9HCB6</td>
  </tr>
  <tr>
    <td>Spondin-2</td>
    <td>SPON2</td>
    <td>CVD II</td>
    <td>Q9BUD6</td>
  </tr>
  <tr>
    <td>Proto-oncogene tyrosine-protein kinase Src</td>
    <td>SRC</td>
    <td>CVD II</td>
    <td>P12931</td>
  </tr>
  <tr>
    <td>Sulfotransferase 1A1</td>
    <td>ST1A1</td>
    <td>INF</td>
    <td>P50225</td>
  </tr>
  <tr>
    <td>ST2 protein</td>
    <td>ST2</td>
    <td>CVD III</td>
    <td>Q01638</td>
  </tr>
  <tr>
    <td>STAM-binding protein</td>
    <td>STAMPB</td>
    <td>INF</td>
    <td>O95630</td>
  </tr>
  <tr>
    <td>Serine/threonine-protein kinase 4</td>
    <td>STK4</td>
    <td>CVD II</td>
    <td>Q13043</td>
  </tr>
  <tr>
    <td>Tissue factor</td>
    <td>TF</td>
    <td>CVD II</td>
    <td>P13726</td>
  </tr>
  <tr>
    <td>Trefoil factor 3</td>
    <td>TFF3</td>
    <td>CVD III</td>
    <td>Q07654</td>
  </tr>
  <tr>
    <td>Tissue factor pathway inhibitor</td>
    <td>TFPI</td>
    <td>CVD III</td>
    <td>P10646</td>
  </tr>
  <tr>
    <td>Transforming growth factor alpha</td>
    <td>TGFALPHA</td>
    <td>INF</td>
    <td>P01135</td>
  </tr>
  <tr>
    <td>Protein-glutamine gamma-glutamyltransferase 2</td>
    <td>TGM2</td>
    <td>CVD II</td>
    <td>P21980</td>
  </tr>
  <tr>
    <td>Thrombospondin-2</td>
    <td>THBS2</td>
    <td>CVD II</td>
    <td>P35442</td>
  </tr>
  <tr>
    <td>Thrombopoietin</td>
    <td>THPO</td>
    <td>CVD II</td>
    <td>P40225</td>
  </tr>
  <tr>
    <td>Angiopoietin-1 receptor</td>
    <td>TIE2</td>
    <td>CVD II</td>
    <td>Q02763</td>
  </tr>
  <tr>
    <td>Metalloproteinase inhibitor 4</td>
    <td>TIMP4</td>
    <td>CVD III</td>
    <td>Q99727</td>
  </tr>
  <tr>
    <td>Trem-like transcript 2 protein</td>
    <td>TLT2</td>
    <td>CVD III</td>
    <td>Q5T2D2</td>
  </tr>
  <tr>
    <td>Thrombomodulin</td>
    <td>TM</td>
    <td>CVD II</td>
    <td>P07204</td>
  </tr>
  <tr>
    <td>Tumor necrosis factor</td>
    <td>TNF</td>
    <td>INF</td>
    <td>P01375</td>
  </tr>
  <tr>
    <td>TNF-beta</td>
    <td>TNFB</td>
    <td>INF</td>
    <td>P01374</td>
  </tr>
  <tr>
    <td>Tumor necrosis factor receptor 1</td>
    <td>TNFR1</td>
    <td>CVD III</td>
    <td>P19438</td>
  </tr>
  <tr>
    <td>Tumor necrosis factor receptor 2</td>
    <td>TNFR2</td>
    <td>CVD III</td>
    <td>P20333</td>
  </tr>
  <tr>
    <td>Tumor necrosis factor receptor superfamily member 10A</td>
    <td>TNFRSF10A</td>
    <td>CVD II</td>
    <td>O00220</td>
  </tr>
  <tr>
    <td>Tumor necrosis factor receptor superfamily member 10C</td>
    <td>TNFRSF10C</td>
    <td>CVD III</td>
    <td>O14798</td>
  </tr>
  <tr>
    <td>Tumor necrosis factor receptor superfamily member 11A</td>
    <td>TNFRSF11A</td>
    <td>CVD II</td>
    <td>Q9Y6Q6</td>
  </tr>
  <tr>
    <td>Tumor necrosis factor receptor superfamily member 13B</td>
    <td>TNFRSF13B</td>
    <td>CVD II</td>
    <td>O14836</td>
  </tr>
  <tr>
    <td>Tumor necrosis factor receptor superfamily member 14</td>
    <td>TNFRSF14</td>
    <td>CVD III</td>
    <td>Q92956</td>
  </tr>
  <tr>
    <td>Tumor necrosis factor receptor superfamily member 9</td>
    <td>TNFRSF9</td>
    <td>INF</td>
    <td>Q07011</td>
  </tr>
  <tr>
    <td>Tumor necrosis factor ligand superfamily member 13B</td>
    <td>TNFSF13B</td>
    <td>CVD III</td>
    <td>Q9Y275</td>
  </tr>
  <tr>
    <td>Tumor necrosis factor ligand superfamily member 14</td>
    <td>TNFSF14</td>
    <td>INF</td>
    <td>O43557</td>
  </tr>
  <tr>
    <td>Tissue-type plasminogen activator</td>
    <td>TPA</td>
    <td>CVD III</td>
    <td>P00750</td>
  </tr>
  <tr>
    <td>Transferrin receptor protein 1</td>
    <td>TR</td>
    <td>CVD III</td>
    <td>P02786</td>
  </tr>
  <tr>
    <td>TNF-related apoptosis-inducing ligand</td>
    <td>TRAIL</td>
    <td>INF</td>
    <td>P50591</td>
  </tr>
  <tr>
    <td>TNF-related apoptosis-inducing ligand receptor 2</td>
    <td>TRAILR2</td>
    <td>CVD II</td>
    <td>O14763</td>
  </tr>
  <tr>
    <td>TNF-related activation-induced cytokine</td>
    <td>TRANCE</td>
    <td>INF</td>
    <td>O14788</td>
  </tr>
  <tr>
    <td>Tartrate-resistant acid phosphatase type 5</td>
    <td>TRAP</td>
    <td>CVD III</td>
    <td>P13686</td>
  </tr>
  <tr>
    <td>Tumor necrosis factor (Ligand) superfamily, member 12</td>
    <td>TWEAK</td>
    <td>INF</td>
    <td>O43508</td>
  </tr>
  <tr>
    <td>Urokinase-type plasminogen activator</td>
    <td>UPA_CVD3</td>
    <td>CVD III</td>
    <td>P00749</td>
  </tr>
  <tr>
    <td>Urokinase plasminogen activator surface receptor</td>
    <td>UPAR</td>
    <td>CVD III</td>
    <td>Q03405</td>
  </tr>
  <tr>
    <td>Vascular endothelial growth factor A</td>
    <td>VEGFA</td>
    <td>INF</td>
    <td>P15692</td>
  </tr>
  <tr>
    <td>Vascular endothelial growth factor D</td>
    <td>VEGFD</td>
    <td>CVD II</td>
    <td>O43915</td>
  </tr>
</table>
<table><tr><td>V-set and immunoglobulin domain-containing protein 2</td><td>VSIG2</td><td>CVD II</td><td>Q96IQ7</td></tr><tr><td>von Willebrand factor</td><td>VWF</td><td>CVD III</td><td>P04275</td></tr><tr><td>Lymphotactin</td><td>XCL1</td><td>CVD II</td><td>P47992</td></tr></table>

Legend: *CVII: cardiovascular II; CVIII: cardiovascular III; INF: inflammation panels; **UniProt ID from UniProt Knowledgebase
<table><caption>Supplemental Table 2. Study proteins order by p-value (from lowest to highest in the discovery set) in both discovery and replication phases</caption><thead><tr><th rowspan="3">Protein name</th><th colspan="8">Discovery (phase 1a)</th><th colspan="8">Replication (phase 1b)</th></tr><tr><th colspan="4">Adjusted for matching variables</th><th colspan="4">Adjusted for matching variables and risk factors</th><th colspan="4">Adjusted for matching variables</th><th colspan="4">Adjusted for matching variables and risk factors</th></tr><tr><th>OR</th><th>(95% CI)</th><th>P-value</th><th>Z</th><th>OR</th><th>(95% CI)</th><th>P-value</th><th>Z</th><th>OR</th><th>(95% CI)</th><th>P-value</th><th>Z</th><th>OR</th><th>(95% CI)</th><th>P-value</th><th>Z</th></tr></thead><tbody><tr><td>NTPROBNP</td><td>1.74</td><td>(1.46, 2.06)</td><td>&lt;0.0001</td><td>6.3</td><td>1.79</td><td>(1.49, 2.14)</td><td>&lt;0.0001</td><td>6.3</td><td>2</td><td>(1.64, 2.44)</td><td>&lt;0.0001</td><td>6.9</td><td>2.06</td><td>(1.66, 2.54)</td><td>&lt;0.0001</td><td>6.6</td></tr><tr><td>BNP</td><td>1.62</td><td>(1.42, 1.86)</td><td>&lt;0.0001</td><td>7</td><td>1.59</td><td>(1.37, 1.84)</td><td>&lt;0.0001</td><td>6.3</td><td>1.73</td><td>(1.50, 2.01)</td><td>&lt;0.0001</td><td>7.3</td><td>1.77</td><td>(1.51, 2.07)</td><td>&lt;0.0001</td><td>7.1</td></tr><tr><td>GDF15</td><td>2.74</td><td>(2.08, 3.61)</td><td>&lt;0.0001</td><td>7.2</td><td>2.34</td><td>(1.72, 3.19)</td><td>&lt;0.0001</td><td>5.4</td><td>1.89</td><td>(1.44, 2.47)</td><td>&lt;0.0001</td><td>4.6</td><td>1.55</td><td>(1.15, 2.09)</td><td>0.0036</td><td>2.9</td></tr><tr><td>TRAILR2</td><td>3.26</td><td>(2.32, 4.60)</td><td>&lt;0.0001</td><td>6.8</td><td>2.7</td><td>(1.86, 3.92)</td><td>&lt;0.0001</td><td>5.2</td><td>3.22</td><td>(2.21, 4.69)</td><td>&lt;0.0001</td><td>6.1</td><td>2.65</td><td>(1.72, 4.07)</td><td>&lt;0.0001</td><td>4.4</td></tr><tr><td>CSTB</td><td>2.1</td><td>(1.67, 2.66)</td><td>&lt;0.0001</td><td>6.2</td><td>1.84</td><td>(1.43, 2.37)</td><td>&lt;0.0001</td><td>4.8</td><td>1.3</td><td>(1.07, 1.60)</td><td>0.0101</td><td>2.6</td><td>1.16</td><td>(0.93, 1.44)</td><td>0.1808</td><td>1.3</td></tr><tr><td>UPAR</td><td>2.7</td><td>(1.94, 3.75)</td><td>&lt;0.0001</td><td>5.9</td><td>2.27</td><td>(1.61, 3.21)</td><td>&lt;0.0001</td><td>4.6</td><td>1.67</td><td>(1.23, 2.28)</td><td>0.0011</td><td>3.3</td><td>1.38</td><td>(1.00, 1.92)</td><td>0.0519</td><td>1.9</td></tr><tr><td>VEGFA</td><td>2.65</td><td>(1.91, 3.67)</td><td>&lt;0.0001</td><td>5.9</td><td>2.27</td><td>(1.59, 3.22)</td><td>&lt;0.0001</td><td>4.5</td><td>1.52</td><td>(1.09, 2.11)</td><td>0.0129</td><td>2.5</td><td>1.27</td><td>(0.89, 1.80)</td><td>0.1837</td><td>1.3</td></tr><tr><td>HGF</td><td>2.49</td><td>(1.78, 3.48)</td><td>&lt;0.0001</td><td>5.3</td><td>2.12</td><td>(1.50, 3.01)</td><td>&lt;0.0001</td><td>4.2</td><td>1.5</td><td>(1.11, 2.02)</td><td>0.0077</td><td>2.7</td><td>1.29</td><td>(0.94, 1.77)</td><td>0.119</td><td>1.6</td></tr><tr><td>CXCL9</td><td>1.56</td><td>(1.30, 1.87)</td><td>&lt;0.0001</td><td>4.7</td><td>1.52</td><td>(1.25, 1.84)</td><td>&lt;0.0001</td><td>4.2</td><td>1.09</td><td>(0.89, 1.34)</td><td>0.3813</td><td>0.9</td><td>1.03</td><td>(0.83, 1.28)</td><td>0.7895</td><td>0.3</td></tr><tr><td>IL6</td><td>1.51</td><td>(1.29, 1.78)</td><td>&lt;0.0001</td><td>5.1</td><td>1.42</td><td>(1.20, 1.68)</td><td>&lt;0.0001</td><td>4.1</td><td>1.21</td><td>(1.03, 1.43)</td><td>0.021</td><td>2.3</td><td>1.09</td><td>(0.92, 1.30)</td><td>0.3325</td><td>1</td></tr><tr><td>OPN</td><td>2</td><td>(1.52, 2.63)</td><td>&lt;0.0001</td><td>5</td><td>1.81</td><td>(1.36, 2.41)</td><td>&lt;0.0001</td><td>4.1</td><td>1.5</td><td>(1.16, 1.95)</td><td>0.0021</td><td>3.1</td><td>1.36</td><td>(1.03, 1.79)</td><td>0.0298</td><td>2.2</td></tr><tr><td>ADM</td><td>2.56</td><td>(1.82, 3.59)</td><td>&lt;0.0001</td><td>5.4</td><td>2.12</td><td>(1.48, 3.05)</td><td>&lt;0.0001</td><td>4.1</td><td>1.8</td><td>(1.32, 2.45)</td><td>0.0002</td><td>3.7</td><td>1.41</td><td>(1.02, 1.96)</td><td>0.0389</td><td>2.1</td></tr><tr><td>CD40</td><td>2.26</td><td>(1.68, 3.04)</td><td>&lt;0.0001</td><td>5.4</td><td>1.93</td><td>(1.41, 2.66)</td><td>&lt;0.0001</td><td>4.1</td><td>1.27</td><td>(0.94, 1.72)</td><td>0.1228</td><td>1.5</td><td>1.05</td><td>(0.76, 1.46)</td><td>0.7743</td><td>0.3</td></tr><tr><td>MCP3</td><td>1.7</td><td>(1.35, 2.15)</td><td>&lt;0.0001</td><td>4.5</td><td>1.61</td><td>(1.27, 2.05)</td><td>&lt;0.0001</td><td>3.9</td><td>1.18</td><td>(0.89, 1.55)</td><td>0.2444</td><td>1.2</td><td>1.08</td><td>(0.81, 1.44)</td><td>0.6164</td><td>0.5</td></tr><tr><td>TFF3</td><td>1.61</td><td>(1.32, 1.95)</td><td>&lt;0.0001</td><td>4.8</td><td>1.52</td><td>(1.23, 1.87)</td><td>0.0001</td><td>3.9</td><td>1.45</td><td>(1.15, 1.84)</td><td>0.0019</td><td>3.1</td><td>1.25</td><td>(0.96, 1.62)</td><td>0.0924</td><td>1.7</td></tr><tr><td>FABP4</td><td>1.82</td><td>(1.51, 2.19)</td><td>&lt;0.0001</td><td>6.2</td><td>1.57</td><td>(1.25, 1.97)</td><td>0.0001</td><td>3.9</td><td>1.57</td><td>(1.29, 1.92)</td><td>&lt;0.0001</td><td>4.5</td><td>1.28</td><td>(1.01, 1.61)</td><td>0.0383</td><td>2.1</td></tr><tr><td>OPG_CVD3</td><td>2.31</td><td>(1.63, 3.27)</td><td>&lt;0.0001</td><td>4.7</td><td>2.05</td><td>(1.42, 2.95)</td><td>0.0001</td><td>3.9</td><td>1.45</td><td>(1.02, 2.06)</td><td>0.0385</td><td>2.1</td><td>1.25</td><td>(0.86, 1.82)</td><td>0.2381</td><td>1.2</td></tr><tr><td>CXCL11</td><td>1.34</td><td>(1.17, 1.55)</td><td>&lt;0.0001</td><td>4.1</td><td>1.33</td><td>(1.15, 1.54)</td><td>0.0001</td><td>3.8</td><td>1.11</td><td>(0.96, 1.29)</td><td>0.1425</td><td>1.5</td><td>1.13</td><td>(0.96, 1.32)</td><td>0.1375</td><td>1.5</td></tr><tr><td>TNFRSF10A</td><td>2.63</td><td>(1.88, 3.69)</td><td>&lt;0.0001</td><td>5.6</td><td>2.01</td><td>(1.40, 2.88)</td><td>0.0002</td><td>3.8</td><td>2.56</td><td>(1.74, 3.77)</td><td>&lt;0.0001</td><td>4.8</td><td>1.98</td><td>(1.31, 3.01)</td><td>0.0013</td><td>3.2</td></tr><tr><td>TNFR1</td><td>2.4</td><td>(1.75, 3.28)</td><td>&lt;0.0001</td><td>5.5</td><td>1.98</td><td>(1.38, 2.84)</td><td>0.0002</td><td>3.7</td><td>1.63</td><td>(1.23, 2.16)</td><td>0.0007</td><td>3.4</td><td>1.26</td><td>(0.92, 1.73)</td><td>0.1488</td><td>1.4</td></tr><tr><td>SPON1</td><td>2.25</td><td>(1.55, 3.26)</td><td>&lt;0.0001</td><td>4.3</td><td>2.05</td><td>(1.40, 2.98)</td><td>0.0002</td><td>3.7</td><td>1.76</td><td>(1.16, 2.67)</td><td>0.0083</td><td>2.6</td><td>1.42</td><td>(0.91, 2.21)</td><td>0.1225</td><td>1.5</td></tr><tr><td>GAL9</td><td>2.96</td><td>(1.95, 4.49)</td><td>&lt;0.0001</td><td>5.1</td><td>2.3</td><td>(1.48, 3.58)</td><td>0.0002</td><td>3.7</td><td>3.14</td><td>(2.01, 4.91)</td><td>&lt;0.0001</td><td>5</td><td>2.59</td><td>(1.61, 4.19)</td><td>&lt;0.0001</td><td>3.9</td></tr><tr><td>FGF23</td><td>1.7</td><td>(1.40, 2.07)</td><td>&lt;0.0001</td><td>5.3</td><td>1.48</td><td>(1.20, 1.81)</td><td>0.0002</td><td>3.7</td><td>1.84</td><td>(1.44, 2.36)</td><td>&lt;0.0001</td><td>4.8</td><td>1.69</td><td>(1.30, 2.20)</td><td>&lt;0.0001</td><td>3.9</td></tr><tr><td>TNFRSF11A</td><td>2.09</td><td>(1.61, 2.72)</td><td>&lt;0.0001</td><td>5.6</td><td>1.72</td><td>(1.28, 2.31)</td><td>0.0003</td><td>3.6</td><td>1.95</td><td>(1.47, 2.59)</td><td>&lt;0.0001</td><td>4.6</td><td>1.53</td><td>(1.12, 2.11)</td><td>0.0085</td><td>2.6</td></tr><tr><td>IL2RA</td><td>1.74</td><td>(1.33, 2.28)</td><td>&lt;0.0001</td><td>4.1</td><td>1.66</td><td>(1.25, 2.22)</td><td>0.0005</td><td>3.5</td><td>1.42</td><td>(1.09, 1.84)</td><td>0.0092</td><td>2.6</td><td>1.26</td><td>(0.94, 1.67)</td><td>0.1163</td><td>1.6</td></tr><tr><td>TNFR2</td><td>2.11</td><td>(1.58, 2.82)</td><td>&lt;0.0001</td><td>5.1</td><td>1.75</td><td>(1.27, 2.42)</td><td>0.0007</td><td>3.4</td><td>1.55</td><td>(1.20, 2.00)</td><td>0.0008</td><td>3.3</td><td>1.29</td><td>(0.98, 1.71)</td><td>0.0743</td><td>1.8</td></tr><tr><td>RETN</td><td>1.82</td><td>(1.42, 2.33)</td><td>&lt;0.0001</td><td>4.7</td><td>1.58</td><td>(1.21, 2.06)</td><td>0.0008</td><td>3.3</td><td>1.37</td><td>(1.05, 1.77)</td><td>0.0182</td><td>2.4</td><td>1.22</td><td>(0.92, 1.62)</td><td>0.1584</td><td>1.4</td></tr><tr><td>TNFRSF13B</td><td>1.74</td><td>(1.34, 2.24)</td><td>&lt;0.0001</td><td>4.2</td><td>1.58</td><td>(1.21, 2.06)</td><td>0.0008</td><td>3.3</td><td>2.61</td><td>(1.82, 3.74)</td><td>&lt;0.0001</td><td>5.2</td><td>2.33</td><td>(1.58, 3.44)</td><td>&lt;0.0001</td><td>4.3</td></tr><tr><td>AGRP</td><td>1.82</td><td>(1.38, 2.40)</td><td>&lt;0.0001</td><td>4.2</td><td>1.64</td><td>(1.23, 2.20)</td><td>0.0009</td><td>3.3</td><td>1.9</td><td>(1.31, 2.76)</td><td>0.0007</td><td>3.4</td><td>1.62</td><td>(1.08, 2.44)</td><td>0.0193</td><td>2.3</td></tr><tr><td>TNFRSF14</td><td>2.09</td><td>(1.55, 2.82)</td><td>&lt;0.0001</td><td>4.9</td><td>1.76</td><td>(1.26, 2.46)</td><td>0.0009</td><td>3.3</td><td>1.52</td><td>(1.15, 2.01)</td><td>0.0034</td><td>2.9</td><td>1.26</td><td>(0.93, 1.71)</td><td>0.1394</td><td>1.5</td></tr><tr><td>GAL4</td><td>1.89</td><td>(1.47, 2.42)</td><td>&lt;0.0001</td><td>5</td><td>1.57</td><td>(1.19, 2.05)</td><td>0.0012</td><td>3.2</td><td>1.44</td><td>(1.10, 1.87)</td><td>0.0071</td><td>2.7</td><td>1.18</td><td>(0.89, 1.57)</td><td>0.2553</td><td>1.1</td></tr><tr><td>RARRES2</td><td>3.33</td><td>(2.02, 5.51)</td><td>&lt;0.0001</td><td>4.7</td><td>2.45</td><td>(1.42, 4.23)</td><td>0.0014</td><td>3.2</td><td>2.05</td><td>(1.38, 3.05)</td><td>0.0004</td><td>3.5</td><td>1.67</td><td>(1.09, 2.56)</td><td>0.0183</td><td>2.4</td></tr><tr><td>ACE2</td><td>1.6</td><td>(1.27, 2.02)</td><td>&lt;0.0001</td><td>4</td><td>1.48</td><td>(1.16, 1.89)</td><td>0.0014</td><td>3.2</td><td>1.52</td><td>(1.17, 1.98)</td><td>0.0016</td><td>3.2</td><td>1.4</td><td>(1.06, 1.84)</td><td>0.0173</td><td>2.4</td></tr><tr><td>PLGF</td><td>2.17</td><td>(1.54, 3.06)</td><td>&lt;0.0001</td><td>4.4</td><td>1.86</td><td>(1.27, 2.72)</td><td>0.0014</td><td>3.2</td><td>1.95</td><td>(1.38, 2.75)</td><td>0.0002</td><td>3.8</td><td>1.61</td><td>(1.11, 2.34)</td><td>0.0131</td><td>2.5</td></tr><tr><td>PGLYRP1</td><td>1.68</td><td>(1.31, 2.15)</td><td>&lt;0.0001</td><td>4.1</td><td>1.53</td><td>(1.17, 1.98)</td><td>0.0016</td><td>3.2</td><td>1.36</td><td>(1.06, 1.74)</td><td>0.0151</td><td>2.4</td><td>1.2</td><td>(0.92, 1.56)</td><td>0.1893</td><td>1.3</td></tr><tr><td>TGFALPHA</td><td>1.9</td><td>(1.40, 2.59)</td><td>&lt;0.0001</td><td>4.1</td><td>1.66</td><td>(1.21, 2.28)</td><td>0.0016</td><td>3.2</td><td>1.38</td><td>(1.07, 1.78)</td><td>0.0122</td><td>2.5</td><td>1.23</td><td>(0.94, 1.61)</td><td>0.1345</td><td>1.5</td></tr><tr><td>MMP12</td><td>1.64</td><td>(1.32, 2.03)</td><td>&lt;0.0001</td><td>4.6</td><td>1.42</td><td>(1.13, 1.79)</td><td>0.0023</td><td>3</td><td>1.54</td><td>(1.23, 1.92)</td><td>0.0002</td><td>3.8</td><td>1.33</td><td>(1.04, 1.70)</td><td>0.0236</td><td>2.3</td></tr><tr><td>TIMP4</td><td>1.72</td><td>(1.32, 2.23)</td><td>&lt;0.0001</td><td>4</td><td>1.54</td><td>(1.17, 2.04)</td><td>0.0024</td><td>3</td><td>1.2</td><td>(0.93, 1.53)</td><td>0.1568</td><td>1.4</td><td>1.08</td><td>(0.83, 1.41)</td><td>0.5465</td><td>0.6</td></tr><tr><td>SLAMF7</td><td>1.55</td><td>(1.26, 1.91)</td><td>&lt;0.0001</td><td>4.1</td><td>1.41</td><td>(1.13, 1.76)</td><td>0.0024</td><td>3</td><td>2.16</td><td>(1.52, 3.06)</td><td>&lt;0.0001</td><td>4.3</td><td>2</td><td>(1.38, 2.91)</td><td>0.0003</td><td>3.7</td></tr><tr><td>TNFRSF9</td><td>1.54</td><td>(1.25, 1.90)</td><td>&lt;0.0001</td><td>4</td><td>1.41</td><td>(1.13, 1.76)</td><td>0.0025</td><td>3</td><td>1.33</td><td>(1.03, 1.72)</td><td>0.0318</td><td>2.1</td><td>1.15</td><td>(0.86, 1.53)</td><td>0.3411</td><td>1</td></tr><tr><td>IL1RA</td><td>1.54</td><td>(1.27, 1.86)</td><td>&lt;0.0001</td><td>4.4</td><td>1.37</td><td>(1.11, 1.69)</td><td>0.003</td><td>3</td><td>1.25</td><td>(1.07, 1.46)</td><td>0.0048</td><td>2.8</td><td>1.17</td><td>(0.99, 1.39)</td><td>0.059</td><td>1.9</td></tr><tr><td>CCL16</td><td>1.47</td><td>(1.21, 1.79)</td><td>&lt;0.0001</td><td>3.9</td><td>1.37</td><td>(1.11, 1.68)</td><td>0.003</td><td>3</td><td>1.72</td><td>(1.34, 2.22)</td><td>&lt;0.0001</td><td>4.2</td><td>1.55</td><td>(1.18, 2.02)</td><td>0.0015</td><td>3.2</td></tr><tr><td>CD4</td><td>2.06</td><td>(1.49, 2.85)</td><td>&lt;0.0001</td><td>4.3</td><td>1.67</td><td>(1.18, 2.35)</td><td>0.0035</td><td>2.9</td><td>2.17</td><td>(1.49, 3.16)</td><td>&lt;0.0001</td><td>4</td><td>1.86</td><td>(1.25, 2.77)</td><td>0.0021</td><td>3.1</td></tr></tbody></table>
<table>
  <tr>
    <td>LTBR</td>
    <td>1.93</td>
    <td>(1.40, 2.68)</td>
    <td>&lt;0.0001</td>
    <td>4</td>
    <td>1.7</td>
    <td>(1.18, 2.45)</td>
    <td>0.004</td>
    <td>2.9</td>
    <td>1.42</td>
    <td>(1.06, 1.90)</td>
    <td>0.0203</td>
    <td>2.3</td>
    <td>1.22</td>
    <td>(0.88, 1.68)</td>
    <td>0.2287</td>
    <td>1.2</td>
  </tr>
  <tr>
    <td>IL15RA</td>
    <td>2.12</td>
    <td>(1.47, 3.05)</td>
    <td>&lt;0.0001</td>
    <td>4</td>
    <td>1.74</td>
    <td>(1.18, 2.56)</td>
    <td>0.0053</td>
    <td>2.8</td>
    <td>1.75</td>
    <td>(1.07, 2.85)</td>
    <td>0.0258</td>
    <td>2.2</td>
    <td>1.46</td>
    <td>(0.86, 2.49)</td>
    <td>0.1579</td>
    <td>1.4</td>
  </tr>
  <tr>
    <td>KIM1</td>
    <td>1.41</td>
    <td>(1.19, 1.68)</td>
    <td>&lt;0.0001</td>
    <td>4</td>
    <td>1.29</td>
    <td>(1.07, 1.55)</td>
    <td>0.0065</td>
    <td>2.7</td>
    <td>1.51</td>
    <td>(1.23, 1.84)</td>
    <td>&lt;0.0001</td>
    <td>4</td>
    <td>1.31</td>
    <td>(1.05, 1.62)</td>
    <td>0.0159</td>
    <td>2.4</td>
  </tr>
  <tr>
    <td>PLC</td>
    <td>2.26</td>
    <td>(1.59, 3.21)</td>
    <td>&lt;0.0001</td>
    <td>4.5</td>
    <td>1.77</td>
    <td>(1.17, 2.68)</td>
    <td>0.0071</td>
    <td>2.7</td>
    <td>1.76</td>
    <td>(1.24, 2.49)</td>
    <td>0.0015</td>
    <td>3.2</td>
    <td>1.43</td>
    <td>(0.97, 2.11)</td>
    <td>0.0686</td>
    <td>1.8</td>
  </tr>
  <tr>
    <td>CEACAM8</td>
    <td>1.51</td>
    <td>(1.22, 1.86)</td>
    <td>0.0001</td>
    <td>3.8</td>
    <td>1.47</td>
    <td>(1.18, 1.83)</td>
    <td>0.0006</td>
    <td>3.4</td>
    <td>1.49</td>
    <td>(1.19, 1.86)</td>
    <td>0.0005</td>
    <td>3.5</td>
    <td>1.36</td>
    <td>(1.08, 1.73)</td>
    <td>0.0098</td>
    <td>2.6</td>
  </tr>
  <tr>
    <td>ICAM2</td>
    <td>1.91</td>
    <td>(1.37, 2.66)</td>
    <td>0.0001</td>
    <td>3.8</td>
    <td>1.73</td>
    <td>(1.22, 2.44)</td>
    <td>0.0019</td>
    <td>3.1</td>
    <td>1.16</td>
    <td>(0.86, 1.57)</td>
    <td>0.3262</td>
    <td>1</td>
    <td>1.06</td>
    <td>(0.77, 1.45)</td>
    <td>0.7229</td>
    <td>0.4</td>
  </tr>
  <tr>
    <td>EPHB4</td>
    <td>1.96</td>
    <td>(1.40, 2.76)</td>
    <td>0.0001</td>
    <td>3.9</td>
    <td>1.62</td>
    <td>(1.11, 2.37)</td>
    <td>0.0121</td>
    <td>2.5</td>
    <td>1.38</td>
    <td>(1.00, 1.91)</td>
    <td>0.0499</td>
    <td>2</td>
    <td>1.19</td>
    <td>(0.84, 1.69)</td>
    <td>0.3334</td>
    <td>1</td>
  </tr>
  <tr>
    <td>HSP27</td>
    <td>2.13</td>
    <td>(1.42, 3.22)</td>
    <td>0.0003</td>
    <td>3.6</td>
    <td>2.03</td>
    <td>(1.32, 3.14)</td>
    <td>0.0013</td>
    <td>3.2</td>
    <td>1.32</td>
    <td>(1.02, 1.71)</td>
    <td>0.0357</td>
    <td>2.1</td>
    <td>1.27</td>
    <td>(0.97, 1.68)</td>
    <td>0.0826</td>
    <td>1.7</td>
  </tr>
  <tr>
    <td>LAPTGFBETA1</td>
    <td>1.68</td>
    <td>(1.27, 2.22)</td>
    <td>0.0003</td>
    <td>3.6</td>
    <td>1.58</td>
    <td>(1.18, 2.12)</td>
    <td>0.0021</td>
    <td>3.1</td>
    <td>1.15</td>
    <td>(0.88, 1.49)</td>
    <td>0.3102</td>
    <td>1</td>
    <td>1.11</td>
    <td>(0.84, 1.47)</td>
    <td>0.4747</td>
    <td>0.7</td>
  </tr>
  <tr>
    <td>PAR1</td>
    <td>1.86</td>
    <td>(1.33, 2.60)</td>
    <td>0.0003</td>
    <td>3.6</td>
    <td>1.64</td>
    <td>(1.16, 2.31)</td>
    <td>0.0048</td>
    <td>2.8</td>
    <td>1.74</td>
    <td>(1.24, 2.45)</td>
    <td>0.0014</td>
    <td>3.2</td>
    <td>1.53</td>
    <td>(1.07, 2.19)</td>
    <td>0.0186</td>
    <td>2.4</td>
  </tr>
  <tr>
    <td>TWEAK</td>
    <td>0.51</td>
    <td>(0.36, 0.73)</td>
    <td>0.0003</td>
    <td>3.6</td>
    <td>0.58</td>
    <td>(0.39, 0.85)</td>
    <td>0.0052</td>
    <td>2.8</td>
    <td>0.53</td>
    <td>(0.39, 0.71)</td>
    <td>&lt;0.0001</td>
    <td>4.1</td>
    <td>0.58</td>
    <td>(0.42, 0.80)</td>
    <td>0.0008</td>
    <td>3.4</td>
  </tr>
  <tr>
    <td>CXCL16</td>
    <td>1.95</td>
    <td>(1.36, 2.79)</td>
    <td>0.0003</td>
    <td>3.6</td>
    <td>1.66</td>
    <td>(1.13, 2.46)</td>
    <td>0.0101</td>
    <td>2.6</td>
    <td>1.29</td>
    <td>(0.93, 1.81)</td>
    <td>0.1317</td>
    <td>1.5</td>
    <td>1.12</td>
    <td>(0.78, 1.60)</td>
    <td>0.5478</td>
    <td>0.6</td>
  </tr>
  <tr>
    <td>JAMA</td>
    <td>1.43</td>
    <td>(1.18, 1.73)</td>
    <td>0.0003</td>
    <td>3.6</td>
    <td>1.29</td>
    <td>(1.06, 1.58)</td>
    <td>0.0122</td>
    <td>2.5</td>
    <td>1.11</td>
    <td>(0.94, 1.32)</td>
    <td>0.2257</td>
    <td>1.2</td>
    <td>1.07</td>
    <td>(0.90, 1.28)</td>
    <td>0.4462</td>
    <td>0.8</td>
  </tr>
  <tr>
    <td>IL18BP</td>
    <td>1.71</td>
    <td>(1.28, 2.29)</td>
    <td>0.0003</td>
    <td>3.6</td>
    <td>1.5</td>
    <td>(1.09, 2.07)</td>
    <td>0.013</td>
    <td>2.5</td>
    <td>1.39</td>
    <td>(1.06, 1.83)</td>
    <td>0.0192</td>
    <td>2.3</td>
    <td>1.18</td>
    <td>(0.87, 1.59)</td>
    <td>0.2842</td>
    <td>1.1</td>
  </tr>
  <tr>
    <td>CCL15</td>
    <td>1.51</td>
    <td>(1.21, 1.88)</td>
    <td>0.0003</td>
    <td>3.6</td>
    <td>1.29</td>
    <td>(1.00, 1.65)</td>
    <td>0.0463</td>
    <td>2</td>
    <td>1.39</td>
    <td>(1.08, 1.79)</td>
    <td>0.0117</td>
    <td>2.5</td>
    <td>1.18</td>
    <td>(0.89, 1.57)</td>
    <td>0.238</td>
    <td>1.2</td>
  </tr>
  <tr>
    <td>CHI3L1</td>
    <td>1.33</td>
    <td>(1.14, 1.56)</td>
    <td>0.0004</td>
    <td>3.5</td>
    <td>1.25</td>
    <td>(1.06, 1.47)</td>
    <td>0.0086</td>
    <td>2.6</td>
    <td>1.2</td>
    <td>(1.01, 1.42)</td>
    <td>0.0352</td>
    <td>2.1</td>
    <td>1.08</td>
    <td>(0.90, 1.29)</td>
    <td>0.4317</td>
    <td>0.8</td>
  </tr>
  <tr>
    <td>CSF1</td>
    <td>2.27</td>
    <td>(1.43, 3.61)</td>
    <td>0.0005</td>
    <td>3.5</td>
    <td>1.91</td>
    <td>(1.18, 3.09)</td>
    <td>0.0088</td>
    <td>2.6</td>
    <td>1.37</td>
    <td>(0.78, 2.42)</td>
    <td>0.2774</td>
    <td>1.1</td>
    <td>1.05</td>
    <td>(0.57, 1.93)</td>
    <td>0.8707</td>
    <td>0.2</td>
  </tr>
  <tr>
    <td>PDL1</td>
    <td>1.64</td>
    <td>(1.24, 2.16)</td>
    <td>0.0005</td>
    <td>3.5</td>
    <td>1.47</td>
    <td>(1.09, 1.98)</td>
    <td>0.0107</td>
    <td>2.6</td>
    <td>1.3</td>
    <td>(0.93, 1.81)</td>
    <td>0.1215</td>
    <td>1.5</td>
    <td>0.96</td>
    <td>(0.67, 1.39)</td>
    <td>0.8473</td>
    <td>0.2</td>
  </tr>
  <tr>
    <td>PDL2</td>
    <td>1.96</td>
    <td>(1.34, 2.87)</td>
    <td>0.0005</td>
    <td>3.5</td>
    <td>1.68</td>
    <td>(1.13, 2.50)</td>
    <td>0.011</td>
    <td>2.5</td>
    <td>1.77</td>
    <td>(1.18, 2.65)</td>
    <td>0.006</td>
    <td>2.7</td>
    <td>1.62</td>
    <td>(1.05, 2.50)</td>
    <td>0.0287</td>
    <td>2.2</td>
  </tr>
  <tr>
    <td>FAS</td>
    <td>1.78</td>
    <td>(1.29, 2.46)</td>
    <td>0.0005</td>
    <td>3.5</td>
    <td>1.49</td>
    <td>(1.06, 2.09)</td>
    <td>0.0223</td>
    <td>2.3</td>
    <td>1.52</td>
    <td>(1.10, 2.11)</td>
    <td>0.012</td>
    <td>2.5</td>
    <td>1.29</td>
    <td>(0.90, 1.84)</td>
    <td>0.1601</td>
    <td>1.4</td>
  </tr>
  <tr>
    <td>GRN</td>
    <td>2.09</td>
    <td>(1.38, 3.16)</td>
    <td>0.0005</td>
    <td>3.5</td>
    <td>1.66</td>
    <td>(1.07, 2.57)</td>
    <td>0.0239</td>
    <td>2.3</td>
    <td>1.41</td>
    <td>(0.96, 2.08)</td>
    <td>0.0811</td>
    <td>1.7</td>
    <td>1.16</td>
    <td>(0.76, 1.75)</td>
    <td>0.4918</td>
    <td>0.7</td>
  </tr>
  <tr>
    <td>SLAMF1</td>
    <td>1.44</td>
    <td>(1.17, 1.76)</td>
    <td>0.0005</td>
    <td>3.5</td>
    <td>1.27</td>
    <td>(1.02, 1.58)</td>
    <td>0.0293</td>
    <td>2.2</td>
    <td>1.62</td>
    <td>(1.23, 2.13)</td>
    <td>0.0005</td>
    <td>3.5</td>
    <td>1.42</td>
    <td>(1.06, 1.89)</td>
    <td>0.0175</td>
    <td>2.4</td>
  </tr>
  <tr>
    <td>CTSZ</td>
    <td>1.74</td>
    <td>(1.27, 2.39)</td>
    <td>0.0005</td>
    <td>3.5</td>
    <td>1.44</td>
    <td>(1.03, 2.02)</td>
    <td>0.0321</td>
    <td>2.1</td>
    <td>1.32</td>
    <td>(0.97, 1.78)</td>
    <td>0.0748</td>
    <td>1.8</td>
    <td>1.09</td>
    <td>(0.79, 1.52)</td>
    <td>0.5884</td>
    <td>0.5</td>
  </tr>
  <tr>
    <td>IGFBP7</td>
    <td>1.66</td>
    <td>(1.24, 2.23)</td>
    <td>0.0006</td>
    <td>3.4</td>
    <td>1.42</td>
    <td>(1.04, 1.94)</td>
    <td>0.0259</td>
    <td>2.2</td>
    <td>1.6</td>
    <td>(1.21, 2.11)</td>
    <td>0.001</td>
    <td>3.3</td>
    <td>1.42</td>
    <td>(1.05, 1.91)</td>
    <td>0.021</td>
    <td>2.3</td>
  </tr>
  <tr>
    <td>IL16</td>
    <td>1.54</td>
    <td>(1.20, 1.97)</td>
    <td>0.0007</td>
    <td>3.4</td>
    <td>1.38</td>
    <td>(1.06, 1.79)</td>
    <td>0.016</td>
    <td>2.4</td>
    <td>1.46</td>
    <td>(1.15, 1.86)</td>
    <td>0.0019</td>
    <td>3.1</td>
    <td>1.34</td>
    <td>(1.04, 1.72)</td>
    <td>0.0232</td>
    <td>2.3</td>
  </tr>
  <tr>
    <td>CCL25</td>
    <td>1.51</td>
    <td>(1.18, 1.94)</td>
    <td>0.0009</td>
    <td>3.3</td>
    <td>1.35</td>
    <td>(1.04, 1.75)</td>
    <td>0.0234</td>
    <td>2.3</td>
    <td>0.96</td>
    <td>(0.72, 1.29)</td>
    <td>0.8091</td>
    <td>0.2</td>
    <td>0.85</td>
    <td>(0.62, 1.17)</td>
    <td>0.3243</td>
    <td>1</td>
  </tr>
  <tr>
    <td>IL12B</td>
    <td>1.4</td>
    <td>(1.14, 1.72)</td>
    <td>0.0011</td>
    <td>3.3</td>
    <td>1.3</td>
    <td>(1.05, 1.62)</td>
    <td>0.0173</td>
    <td>2.4</td>
    <td>1.25</td>
    <td>(1.00, 1.56)</td>
    <td>0.0476</td>
    <td>2</td>
    <td>1.12</td>
    <td>(0.88, 1.43)</td>
    <td>0.3453</td>
    <td>0.9</td>
  </tr>
  <tr>
    <td>PON3</td>
    <td>0.71</td>
    <td>(0.58, 0.87)</td>
    <td>0.0011</td>
    <td>3.3</td>
    <td>0.83</td>
    <td>(0.66, 1.04)</td>
    <td>0.0977</td>
    <td>1.7</td>
    <td>0.64</td>
    <td>(0.51, 0.80)</td>
    <td>&lt;0.0001</td>
    <td>3.9</td>
    <td>0.72</td>
    <td>(0.56, 0.91)</td>
    <td>0.0064</td>
    <td>2.7</td>
  </tr>
  <tr>
    <td>IGFBP1</td>
    <td>1.26</td>
    <td>(1.09, 1.45)</td>
    <td>0.0013</td>
    <td>3.2</td>
    <td>1.41</td>
    <td>(1.19, 1.66)</td>
    <td>&lt;0.0001</td>
    <td>4.1</td>
    <td>1.08</td>
    <td>(0.92, 1.26)</td>
    <td>0.3564</td>
    <td>0.9</td>
    <td>1.14</td>
    <td>(0.95, 1.37)</td>
    <td>0.153</td>
    <td>1.4</td>
  </tr>
  <tr>
    <td>CCL23</td>
    <td>1.6</td>
    <td>(1.20, 2.14)</td>
    <td>0.0014</td>
    <td>3.2</td>
    <td>1.74</td>
    <td>(1.28, 2.37)</td>
    <td>0.0005</td>
    <td>3.5</td>
    <td>1.08</td>
    <td>(0.79, 1.47)</td>
    <td>0.6256</td>
    <td>0.5</td>
    <td>0.98</td>
    <td>(0.70, 1.37)</td>
    <td>0.9144</td>
    <td>0.1</td>
  </tr>
  <tr>
    <td>DECR1</td>
    <td>1.19</td>
    <td>(1.07, 1.33)</td>
    <td>0.0014</td>
    <td>3.2</td>
    <td>1.17</td>
    <td>(1.04, 1.31)</td>
    <td>0.0085</td>
    <td>2.6</td>
    <td>1.03</td>
    <td>(0.93, 1.15)</td>
    <td>0.5695</td>
    <td>0.6</td>
    <td>1.02</td>
    <td>(0.91, 1.15)</td>
    <td>0.7041</td>
    <td>0.4</td>
  </tr>
  <tr>
    <td>SPON2</td>
    <td>2.86</td>
    <td>(1.50, 5.48)</td>
    <td>0.0015</td>
    <td>3.2</td>
    <td>2.66</td>
    <td>(1.36, 5.21)</td>
    <td>0.0044</td>
    <td>2.8</td>
    <td>2.4</td>
    <td>(1.36, 4.25)</td>
    <td>0.0026</td>
    <td>3</td>
    <td>2.1</td>
    <td>(1.16, 3.79)</td>
    <td>0.0137</td>
    <td>2.5</td>
  </tr>
  <tr>
    <td>TM</td>
    <td>1.9</td>
    <td>(1.27, 2.82)</td>
    <td>0.0016</td>
    <td>3.2</td>
    <td>1.63</td>
    <td>(1.07, 2.48)</td>
    <td>0.0233</td>
    <td>2.3</td>
    <td>1.5</td>
    <td>(1.03, 2.19)</td>
    <td>0.0354</td>
    <td>2.1</td>
    <td>1.24</td>
    <td>(0.85, 1.82)</td>
    <td>0.2637</td>
    <td>1.1</td>
  </tr>
  <tr>
    <td>REN</td>
    <td>1.31</td>
    <td>(1.11, 1.55)</td>
    <td>0.0018</td>
    <td>3.1</td>
    <td>1.18</td>
    <td>(0.98, 1.41)</td>
    <td>0.0772</td>
    <td>1.8</td>
    <td>1.54</td>
    <td>(1.29, 1.85)</td>
    <td>&lt;0.0001</td>
    <td>4.7</td>
    <td>1.38</td>
    <td>(1.13, 1.68)</td>
    <td>0.0014</td>
    <td>3.2</td>
  </tr>
  <tr>
    <td>MMP3</td>
    <td>1.4</td>
    <td>(1.13, 1.74)</td>
    <td>0.0021</td>
    <td>3.1</td>
    <td>1.37</td>
    <td>(1.09, 1.73)</td>
    <td>0.0062</td>
    <td>2.7</td>
    <td>1.17</td>
    <td>(0.94, 1.45)</td>
    <td>0.1521</td>
    <td>1.4</td>
    <td>1.05</td>
    <td>(0.83, 1.33)</td>
    <td>0.673</td>
    <td>0.4</td>
  </tr>
  <tr>
    <td>CASP8</td>
    <td>1.26</td>
    <td>(1.09, 1.47)</td>
    <td>0.0021</td>
    <td>3.1</td>
    <td>1.22</td>
    <td>(1.04, 1.43)</td>
    <td>0.0126</td>
    <td>2.5</td>
    <td>1.19</td>
    <td>(1.03, 1.37)</td>
    <td>0.0148</td>
    <td>2.4</td>
    <td>1.18</td>
    <td>(1.02, 1.37)</td>
    <td>0.0286</td>
    <td>2.2</td>
  </tr>
  <tr>
    <td>TLT2</td>
    <td>1.49</td>
    <td>(1.16, 1.93)</td>
    <td>0.0021</td>
    <td>3.1</td>
    <td>1.39</td>
    <td>(1.06, 1.82)</td>
    <td>0.0169</td>
    <td>2.4</td>
    <td>1.06</td>
    <td>(0.80, 1.40)</td>
    <td>0.6846</td>
    <td>0.4</td>
    <td>0.98</td>
    <td>(0.73, 1.32)</td>
    <td>0.9002</td>
    <td>0.1</td>
  </tr>
  <tr>
    <td>MMP2</td>
    <td>1.64</td>
    <td>(1.19, 2.24)</td>
    <td>0.0023</td>
    <td>3</td>
    <td>1.55</td>
    <td>(1.11, 2.16)</td>
    <td>0.0096</td>
    <td>2.6</td>
    <td>1.38</td>
    <td>(1.01, 1.88)</td>
    <td>0.0452</td>
    <td>2</td>
    <td>1.38</td>
    <td>(0.99, 1.91)</td>
    <td>0.0553</td>
    <td>1.9</td>
  </tr>
  <tr>
    <td>IL10RB</td>
    <td>1.77</td>
    <td>(1.22, 2.56)</td>
    <td>0.0024</td>
    <td>3</td>
    <td>1.56</td>
    <td>(1.06, 2.30)</td>
    <td>0.0247</td>
    <td>2.2</td>
    <td>1.27</td>
    <td>(0.83, 1.92)</td>
    <td>0.2708</td>
    <td>1.1</td>
    <td>0.92</td>
    <td>(0.58, 1.46)</td>
    <td>0.7309</td>
    <td>0.3</td>
  </tr>
  <tr>
    <td>GAL3</td>
    <td>1.52</td>
    <td>(1.16, 2.00)</td>
    <td>0.0025</td>
    <td>3</td>
    <td>1.44</td>
    <td>(1.08, 1.92)</td>
    <td>0.012</td>
    <td>2.5</td>
    <td>1.17</td>
    <td>(0.89, 1.54)</td>
    <td>0.2714</td>
    <td>1.1</td>
    <td>1.02</td>
    <td>(0.76, 1.37)</td>
    <td>0.887</td>
    <td>0.1</td>
  </tr>
  <tr>
    <td>CD163</td>
    <td>1.46</td>
    <td>(1.14, 1.87)</td>
    <td>0.0025</td>
    <td>3</td>
    <td>1.35</td>
    <td>(1.05, 1.75)</td>
    <td>0.0198</td>
    <td>2.3</td>
    <td>1.07</td>
    <td>(0.84, 1.35)</td>
    <td>0.581</td>
    <td>0.6</td>
    <td>0.99</td>
    <td>(0.77, 1.27)</td>
    <td>0.9236</td>
    <td>0.1</td>
  </tr>
  <tr>
    <td>VSIG2</td>
    <td>1.43</td>
    <td>(1.14, 1.81)</td>
    <td>0.0025</td>
    <td>3</td>
    <td>1.24</td>
    <td>(0.96, 1.59)</td>
    <td>0.0967</td>
    <td>1.7</td>
    <td>1.76</td>
    <td>(1.33, 2.32)</td>
    <td>&lt;0.0001</td>
    <td>4</td>
    <td>1.46</td>
    <td>(1.06, 2.01)</td>
    <td>0.02</td>
    <td>2.3</td>
  </tr>
  <tr>
    <td>TR</td>
    <td>1.37</td>
    <td>(1.12, 1.69)</td>
    <td>0.0028</td>
    <td>3</td>
    <td>1.29</td>
    <td>(1.04, 1.61)</td>
    <td>0.0202</td>
    <td>2.3</td>
    <td>1.24</td>
    <td>(0.99, 1.55)</td>
    <td>0.0663</td>
    <td>1.8</td>
    <td>1.12</td>
    <td>(0.88, 1.43)</td>
    <td>0.3645</td>
    <td>0.9</td>
  </tr>
  <tr>
    <td>CCL20</td>
    <td>1.21</td>
    <td>(1.07, 1.38)</td>
    <td>0.003</td>
    <td>3</td>
    <td>1.17</td>
    <td>(1.02, 1.33)</td>
    <td>0.0223</td>
    <td>2.3</td>
    <td>1.06</td>
    <td>(0.94, 1.21)</td>
    <td>0.3405</td>
    <td>1</td>
    <td>1.03</td>
    <td>(0.90, 1.18)</td>
    <td>0.6877</td>
    <td>0.4</td>
  </tr>
  <tr>
    <td>NEMO</td>
    <td>1.19</td>
    <td>(1.06, 1.34)</td>
    <td>0.0032</td>
    <td>2.9</td>
    <td>1.16</td>
    <td>(1.02, 1.31)</td>
    <td>0.0224</td>
    <td>2.3</td>
    <td>1.07</td>
    <td>(0.93, 1.23)</td>
    <td>0.3387</td>
    <td>1</td>
    <td>1.04</td>
    <td>(0.90, 1.21)</td>
    <td>0.5799</td>
    <td>0.6</td>
  </tr>
  <tr>
    <td>IL4RA*</td>
    <td>1.52</td>
    <td>(1.15, 2.02)</td>
    <td>0.0033</td>
    <td>2.9</td>
    <td>1.42</td>
    <td>(1.06, 1.90)</td>
    <td>0.0171</td>
    <td>2.4</td>
    <td>1.62</td>
    <td>(1.18, 2.22)</td>
    <td>0.0029</td>
    <td>3</td>
    <td>1.45</td>
    <td>(1.03, 2.03)</td>
    <td>0.0309</td>
    <td>2.2</td>
  </tr>
  <tr>
    <td>MERTK</td>
    <td>1.66</td>
    <td>(1.18, 2.33)</td>
    <td>0.0038</td>
    <td>2.9</td>
    <td>1.6</td>
    <td>(1.12, 2.28)</td>
    <td>0.0101</td>
    <td>2.6</td>
    <td>1.38</td>
    <td>(0.96, 1.99)</td>
    <td>0.0863</td>
    <td>1.7</td>
    <td>1.29</td>
    <td>(0.87, 1.91)</td>
    <td>0.2016</td>
    <td>1.3</td>
  </tr>
  <tr>
    <td>IL17C</td>
    <td>1.41</td>
    <td>(1.12, 1.77)</td>
    <td>0.0038</td>
    <td>2.9</td>
    <td>1.29</td>
    <td>(1.01, 1.65)</td>
    <td>0.0398</td>
    <td>2.1</td>
    <td>1.07</td>
    <td>(0.80, 1.44)</td>
    <td>0.6416</td>
    <td>0.5</td>
    <td>1.02</td>
    <td>(0.75, 1.39)</td>
    <td>0.8845</td>
    <td>0.1</td>
  </tr>
</table>
<table>
  <tr>
    <td>CCCL10</td>
    <td>1.28</td>
    <td>(1.08, 1.52)</td>
    <td>0.0042</td>
    <td>2.9</td>
    <td>1.26</td>
    <td>(1.05, 1.51)</td>
    <td>0.0116</td>
    <td>2.5</td>
    <td>1.05</td>
    <td>(0.88, 1.25)</td>
    <td>0.5963</td>
    <td>0.5</td>
    <td>1.08</td>
    <td>(0.89, 1.29)</td>
    <td>0.437</td>
    <td>0.8</td>
  </tr>
  <tr>
    <td>ENRAGE</td>
    <td>1.26</td>
    <td>(1.08, 1.47)</td>
    <td>0.0042</td>
    <td>2.9</td>
    <td>1.23</td>
    <td>(1.04, 1.46)</td>
    <td>0.0137</td>
    <td>2.5</td>
    <td>1.54</td>
    <td>(1.25, 1.90)</td>
    <td>&lt;0.0001</td>
    <td>4</td>
    <td>1.44</td>
    <td>(1.15, 1.81)</td>
    <td>0.0016</td>
    <td>3.2</td>
  </tr>
  <tr>
    <td>BETANGF</td>
    <td>1.66</td>
    <td>(1.16, 2.36)</td>
    <td>0.005</td>
    <td>2.8</td>
    <td>1.38</td>
    <td>(0.95, 2.00)</td>
    <td>0.0917</td>
    <td>1.7</td>
    <td>1.15</td>
    <td>(0.77, 1.72)</td>
    <td>0.4889</td>
    <td>0.7</td>
    <td>1.06</td>
    <td>(0.70, 1.62)</td>
    <td>0.7691</td>
    <td>0.3</td>
  </tr>
  <tr>
    <td>LOX1</td>
    <td>1.39</td>
    <td>(1.10, 1.76)</td>
    <td>0.0054</td>
    <td>2.8</td>
    <td>1.36</td>
    <td>(1.07, 1.74)</td>
    <td>0.0129</td>
    <td>2.5</td>
    <td>1.49</td>
    <td>(1.19, 1.86)</td>
    <td>0.0005</td>
    <td>3.5</td>
    <td>1.46</td>
    <td>(1.15, 1.86)</td>
    <td>0.0018</td>
    <td>3.1</td>
  </tr>
  <tr>
    <td>MMP10</td>
    <td>1.34</td>
    <td>(1.09, 1.66)</td>
    <td>0.0055</td>
    <td>2.8</td>
    <td>1.25</td>
    <td>(1.00, 1.55)</td>
    <td>0.0463</td>
    <td>2</td>
    <td>0.88</td>
    <td>(0.68, 1.14)</td>
    <td>0.3391</td>
    <td>1</td>
    <td>0.76</td>
    <td>(0.57, 1.00)</td>
    <td>0.0518</td>
    <td>1.9</td>
  </tr>
  <tr>
    <td>PECAM1</td>
    <td>1.51</td>
    <td>(1.13, 2.01)</td>
    <td>0.0058</td>
    <td>2.8</td>
    <td>1.41</td>
    <td>(1.04, 1.91)</td>
    <td>0.0267</td>
    <td>2.2</td>
    <td>1.05</td>
    <td>(0.81, 1.35)</td>
    <td>0.7106</td>
    <td>0.4</td>
    <td>1.06</td>
    <td>(0.81, 1.38)</td>
    <td>0.6884</td>
    <td>0.4</td>
  </tr>
  <tr>
    <td>IL10</td>
    <td>1.35</td>
    <td>(1.09, 1.67)</td>
    <td>0.0062</td>
    <td>2.7</td>
    <td>1.31</td>
    <td>(1.05, 1.63)</td>
    <td>0.0161</td>
    <td>2.4</td>
    <td>1.03</td>
    <td>(0.84, 1.27)</td>
    <td>0.7601</td>
    <td>0.3</td>
    <td>0.96</td>
    <td>(0.78, 1.20)</td>
    <td>0.742</td>
    <td>0.3</td>
  </tr>
  <tr>
    <td>LIFR</td>
    <td>1.68</td>
    <td>(1.16, 2.45)</td>
    <td>0.0067</td>
    <td>2.7</td>
    <td>1.44</td>
    <td>(0.97, 2.14)</td>
    <td>0.0679</td>
    <td>1.8</td>
    <td>1.15</td>
    <td>(0.75, 1.76)</td>
    <td>0.5178</td>
    <td>0.6</td>
    <td>0.94</td>
    <td>(0.60, 1.49)</td>
    <td>0.7975</td>
    <td>0.3</td>
  </tr>
  <tr>
    <td>HOSCAR</td>
    <td>2.11</td>
    <td>(1.23, 3.64)</td>
    <td>0.0069</td>
    <td>2.7</td>
    <td>1.93</td>
    <td>(1.09, 3.39)</td>
    <td>0.023</td>
    <td>2.3</td>
    <td>1.93</td>
    <td>(1.12, 3.32)</td>
    <td>0.0175</td>
    <td>2.4</td>
    <td>1.68</td>
    <td>(0.95, 2.97)</td>
    <td>0.0764</td>
    <td>1.8</td>
  </tr>
  <tr>
    <td>IGFBP2</td>
    <td>1.35</td>
    <td>(1.08, 1.68)</td>
    <td>0.0072</td>
    <td>2.7</td>
    <td>1.55</td>
    <td>(1.21, 1.99)</td>
    <td>0.0005</td>
    <td>3.5</td>
    <td>1.25</td>
    <td>(0.99, 1.58)</td>
    <td>0.0628</td>
    <td>1.9</td>
    <td>1.35</td>
    <td>(1.03, 1.77)</td>
    <td>0.0298</td>
    <td>2.2</td>
  </tr>
  <tr>
    <td>CDCP1</td>
    <td>1.34</td>
    <td>(1.08, 1.66)</td>
    <td>0.0074</td>
    <td>2.7</td>
    <td>1.26</td>
    <td>(1.01, 1.59)</td>
    <td>0.0431</td>
    <td>2</td>
    <td>0.98</td>
    <td>(0.76, 1.26)</td>
    <td>0.8736</td>
    <td>0.2</td>
    <td>0.85</td>
    <td>(0.65, 1.11)</td>
    <td>0.2395</td>
    <td>1.2</td>
  </tr>
  <tr>
    <td>MCP2</td>
    <td>1.36</td>
    <td>(1.09, 1.70)</td>
    <td>0.0075</td>
    <td>2.7</td>
    <td>1.35</td>
    <td>(1.07, 1.71)</td>
    <td>0.0127</td>
    <td>2.5</td>
    <td>1.13</td>
    <td>(0.91, 1.41)</td>
    <td>0.2737</td>
    <td>1.1</td>
    <td>1.11</td>
    <td>(0.88, 1.41)</td>
    <td>0.3724</td>
    <td>0.9</td>
  </tr>
  <tr>
    <td>CC3CL1</td>
    <td>1.48</td>
    <td>(1.11, 1.97)</td>
    <td>0.0075</td>
    <td>2.7</td>
    <td>1.3</td>
    <td>(0.96, 1.77)</td>
    <td>0.0926</td>
    <td>1.7</td>
    <td>1.18</td>
    <td>(0.87, 1.60)</td>
    <td>0.2787</td>
    <td>1.1</td>
    <td>1.01</td>
    <td>(0.72, 1.41)</td>
    <td>0.9603</td>
    <td>0</td>
  </tr>
  <tr>
    <td>PRTN3</td>
    <td>1.35</td>
    <td>(1.08, 1.68)</td>
    <td>0.0081</td>
    <td>2.6</td>
    <td>1.3</td>
    <td>(1.04, 1.64)</td>
    <td>0.0238</td>
    <td>2.3</td>
    <td>1.26</td>
    <td>(0.99, 1.59)</td>
    <td>0.0557</td>
    <td>1.9</td>
    <td>1.18</td>
    <td>(0.92, 1.51)</td>
    <td>0.1911</td>
    <td>1.3</td>
  </tr>
  <tr>
    <td>AXIN1</td>
    <td>1.16</td>
    <td>(1.04, 1.29)</td>
    <td>0.0085</td>
    <td>2.6</td>
    <td>1.13</td>
    <td>(1.01, 1.26)</td>
    <td>0.0403</td>
    <td>2.1</td>
    <td>0.96</td>
    <td>(0.84, 1.10)</td>
    <td>0.5615</td>
    <td>0.6</td>
    <td>0.94</td>
    <td>(0.81, 1.09)</td>
    <td>0.4114</td>
    <td>0.8</td>
  </tr>
  <tr>
    <td>MPO</td>
    <td>1.43</td>
    <td>(1.09, 1.86)</td>
    <td>0.009</td>
    <td>2.6</td>
    <td>1.36</td>
    <td>(1.03, 1.79)</td>
    <td>0.0323</td>
    <td>2.1</td>
    <td>1.17</td>
    <td>(0.90, 1.51)</td>
    <td>0.2337</td>
    <td>1.2</td>
    <td>1.09</td>
    <td>(0.83, 1.43)</td>
    <td>0.524</td>
    <td>0.6</td>
  </tr>
  <tr>
    <td>GT</td>
    <td>1.27</td>
    <td>(1.06, 1.53)</td>
    <td>0.0101</td>
    <td>2.6</td>
    <td>1.19</td>
    <td>(0.97, 1.44)</td>
    <td>0.088</td>
    <td>1.7</td>
    <td>1.3</td>
    <td>(1.02, 1.67)</td>
    <td>0.037</td>
    <td>2.1</td>
    <td>1.26</td>
    <td>(0.96, 1.65)</td>
    <td>0.092</td>
    <td>1.7</td>
  </tr>
  <tr>
    <td>SORT1</td>
    <td>1.93</td>
    <td>(1.17, 3.18)</td>
    <td>0.0103</td>
    <td>2.6</td>
    <td>1.99</td>
    <td>(1.17, 3.38)</td>
    <td>0.0107</td>
    <td>2.6</td>
    <td>1.68</td>
    <td>(1.08, 2.62)</td>
    <td>0.0218</td>
    <td>2.3</td>
    <td>1.8</td>
    <td>(1.12, 2.89)</td>
    <td>0.0149</td>
    <td>2.4</td>
  </tr>
  <tr>
    <td>ST1A1</td>
    <td>1.16</td>
    <td>(1.04, 1.31)</td>
    <td>0.0103</td>
    <td>2.6</td>
    <td>1.13</td>
    <td>(1.00, 1.27)</td>
    <td>0.0593</td>
    <td>1.9</td>
    <td>1.02</td>
    <td>(0.91, 1.15)</td>
    <td>0.7111</td>
    <td>0.4</td>
    <td>1.01</td>
    <td>(0.89, 1.15)</td>
    <td>0.8863</td>
    <td>0.1</td>
  </tr>
  <tr>
    <td>CCL11</td>
    <td>1.45</td>
    <td>(1.09, 1.93)</td>
    <td>0.0104</td>
    <td>2.6</td>
    <td>1.41</td>
    <td>(1.05, 1.91)</td>
    <td>0.0242</td>
    <td>2.3</td>
    <td>1.46</td>
    <td>(1.06, 1.99)</td>
    <td>0.019</td>
    <td>2.3</td>
    <td>1.36</td>
    <td>(0.97, 1.91)</td>
    <td>0.0734</td>
    <td>1.8</td>
  </tr>
  <tr>
    <td>CST5</td>
    <td>1.35</td>
    <td>(1.07, 1.70)</td>
    <td>0.0113</td>
    <td>2.5</td>
    <td>1.19</td>
    <td>(0.92, 1.54)</td>
    <td>0.1858</td>
    <td>1.3</td>
    <td>1.01</td>
    <td>(0.76, 1.35)</td>
    <td>0.9334</td>
    <td>0.1</td>
    <td>0.85</td>
    <td>(0.62, 1.18)</td>
    <td>0.3325</td>
    <td>1</td>
  </tr>
  <tr>
    <td>SELP</td>
    <td>1.33</td>
    <td>(1.07, 1.67)</td>
    <td>0.0121</td>
    <td>2.5</td>
    <td>1.26</td>
    <td>(1.00, 1.60)</td>
    <td>0.0529</td>
    <td>1.9</td>
    <td>1.12</td>
    <td>(0.91, 1.37)</td>
    <td>0.3031</td>
    <td>1</td>
    <td>1.11</td>
    <td>(0.89, 1.39)</td>
    <td>0.3584</td>
    <td>0.9</td>
  </tr>
  <tr>
    <td>BP1_4E</td>
    <td>1.17</td>
    <td>(1.04, 1.33)</td>
    <td>0.0121</td>
    <td>2.5</td>
    <td>1.14</td>
    <td>(1.00, 1.30)</td>
    <td>0.0541</td>
    <td>1.9</td>
    <td>1.17</td>
    <td>(1.02, 1.34)</td>
    <td>0.0254</td>
    <td>2.2</td>
    <td>1.12</td>
    <td>(0.97, 1.29)</td>
    <td>0.135</td>
    <td>1.5</td>
  </tr>
  <tr>
    <td>SIRT2</td>
    <td>1.13</td>
    <td>(1.03, 1.24)</td>
    <td>0.0131</td>
    <td>2.5</td>
    <td>1.11</td>
    <td>(1.00, 1.22)</td>
    <td>0.049</td>
    <td>2</td>
    <td>1.05</td>
    <td>(0.94, 1.17)</td>
    <td>0.3818</td>
    <td>0.9</td>
    <td>1.03</td>
    <td>(0.92, 1.15)</td>
    <td>0.6376</td>
    <td>0.5</td>
  </tr>
  <tr>
    <td>ST2</td>
    <td>1.37</td>
    <td>(1.07, 1.75)</td>
    <td>0.0131</td>
    <td>2.5</td>
    <td>1.25</td>
    <td>(0.97, 1.62)</td>
    <td>0.0861</td>
    <td>1.7</td>
    <td>1.42</td>
    <td>(1.09, 1.83)</td>
    <td>0.0083</td>
    <td>2.6</td>
    <td>1.33</td>
    <td>(1.01, 1.76)</td>
    <td>0.0395</td>
    <td>2.1</td>
  </tr>
  <tr>
    <td>CASP3</td>
    <td>1.15</td>
    <td>(1.03, 1.28)</td>
    <td>0.0133</td>
    <td>2.5</td>
    <td>1.12</td>
    <td>(1.00, 1.26)</td>
    <td>0.0486</td>
    <td>2</td>
    <td>1.04</td>
    <td>(0.93, 1.17)</td>
    <td>0.4996</td>
    <td>0.7</td>
    <td>1.02</td>
    <td>(0.90, 1.16)</td>
    <td>0.7465</td>
    <td>0.3</td>
  </tr>
  <tr>
    <td>PRSS8</td>
    <td>1.62</td>
    <td>(1.11, 2.38)</td>
    <td>0.0133</td>
    <td>2.5</td>
    <td>1.39</td>
    <td>(0.93, 2.07)</td>
    <td>0.1063</td>
    <td>1.6</td>
    <td>1.3</td>
    <td>(1.04, 1.63)</td>
    <td>0.0193</td>
    <td>2.3</td>
    <td>1.21</td>
    <td>(0.96, 1.53)</td>
    <td>0.1148</td>
    <td>1.6</td>
  </tr>
  <tr>
    <td>VWF</td>
    <td>1.18</td>
    <td>(1.04, 1.35)</td>
    <td>0.0135</td>
    <td>2.5</td>
    <td>1.15</td>
    <td>(1.00, 1.32)</td>
    <td>0.0539</td>
    <td>1.9</td>
    <td>1.18</td>
    <td>(1.03, 1.36)</td>
    <td>0.0153</td>
    <td>2.4</td>
    <td>1.17</td>
    <td>(1.01, 1.35)</td>
    <td>0.0347</td>
    <td>2.1</td>
  </tr>
  <tr>
    <td>FGF21</td>
    <td>1.15</td>
    <td>(1.03, 1.28)</td>
    <td>0.0139</td>
    <td>2.5</td>
    <td>1.08</td>
    <td>(0.96, 1.21)</td>
    <td>0.2096</td>
    <td>1.3</td>
    <td>1.15</td>
    <td>(1.03, 1.30)</td>
    <td>0.0161</td>
    <td>2.4</td>
    <td>1.07</td>
    <td>(0.95, 1.22)</td>
    <td>0.272</td>
    <td>1.1</td>
  </tr>
  <tr>
    <td>TGM2</td>
    <td>1.26</td>
    <td>(1.05, 1.51)</td>
    <td>0.0144</td>
    <td>2.4</td>
    <td>1.22</td>
    <td>(1.01, 1.48)</td>
    <td>0.0383</td>
    <td>2.1</td>
    <td>1.43</td>
    <td>(1.18, 1.73)</td>
    <td>0.0003</td>
    <td>3.6</td>
    <td>1.55</td>
    <td>(1.25, 1.91)</td>
    <td>&lt;0.0001</td>
    <td>4</td>
  </tr>
  <tr>
    <td>IL1RT1</td>
    <td>1.58</td>
    <td>(1.09, 2.28)</td>
    <td>0.0145</td>
    <td>2.4</td>
    <td>1.39</td>
    <td>(0.94, 2.06)</td>
    <td>0.0991</td>
    <td>1.6</td>
    <td>1.18</td>
    <td>(0.86, 1.62)</td>
    <td>0.3017</td>
    <td>1</td>
    <td>1.07</td>
    <td>(0.76, 1.49)</td>
    <td>0.704</td>
    <td>0.4</td>
  </tr>
  <tr>
    <td>CD244</td>
    <td>1.48</td>
    <td>(1.08, 2.04)</td>
    <td>0.0154</td>
    <td>2.4</td>
    <td>1.36</td>
    <td>(0.97, 1.90)</td>
    <td>0.0737</td>
    <td>1.8</td>
    <td>0.79</td>
    <td>(0.55, 1.12)</td>
    <td>0.1841</td>
    <td>1.3</td>
    <td>0.7</td>
    <td>(0.48, 1.02)</td>
    <td>0.0603</td>
    <td>1.9</td>
  </tr>
  <tr>
    <td>MCP1_CVD3</td>
    <td>1.27</td>
    <td>(1.05, 1.55)</td>
    <td>0.0162</td>
    <td>2.4</td>
    <td>1.23</td>
    <td>(1.02, 1.49)</td>
    <td>0.0308</td>
    <td>2.2</td>
    <td>1.14</td>
    <td>(0.91, 1.43)</td>
    <td>0.265</td>
    <td>1.1</td>
    <td>1.09</td>
    <td>(0.86, 1.38)</td>
    <td>0.4702</td>
    <td>0.7</td>
  </tr>
  <tr>
    <td>CD93</td>
    <td>1.6</td>
    <td>(1.09, 2.35)</td>
    <td>0.0163</td>
    <td>2.4</td>
    <td>1.38</td>
    <td>(0.91, 2.09)</td>
    <td>0.1272</td>
    <td>1.5</td>
    <td>1.62</td>
    <td>(1.12, 2.35)</td>
    <td>0.0107</td>
    <td>2.6</td>
    <td>1.44</td>
    <td>(0.96, 2.15)</td>
    <td>0.0793</td>
    <td>1.8</td>
  </tr>
  <tr>
    <td>PCSK9</td>
    <td>1.43</td>
    <td>(1.07, 1.93)</td>
    <td>0.0171</td>
    <td>2.4</td>
    <td>1.32</td>
    <td>(0.97, 1.79)</td>
    <td>0.0791</td>
    <td>1.8</td>
    <td>1</td>
    <td>(0.74, 1.36)</td>
    <td>0.982</td>
    <td>0</td>
    <td>0.91</td>
    <td>(0.66, 1.25)</td>
    <td>0.5486</td>
    <td>0.6</td>
  </tr>
  <tr>
    <td>PI3</td>
    <td>1.27</td>
    <td>(1.04, 1.54)</td>
    <td>0.0174</td>
    <td>2.4</td>
    <td>1.08</td>
    <td>(0.87, 1.35)</td>
    <td>0.4985</td>
    <td>0.7</td>
    <td>1.21</td>
    <td>(1.01, 1.45)</td>
    <td>0.0384</td>
    <td>2.1</td>
    <td>1.09</td>
    <td>(0.90, 1.32)</td>
    <td>0.3972</td>
    <td>0.8</td>
  </tr>
  <tr>
    <td>IL6RA</td>
    <td>1.5</td>
    <td>(1.07, 2.10)</td>
    <td>0.0192</td>
    <td>2.3</td>
    <td>1.58</td>
    <td>(1.10, 2.25)</td>
    <td>0.0126</td>
    <td>2.5</td>
    <td>1.21</td>
    <td>(0.89, 1.63)</td>
    <td>0.228</td>
    <td>1.2</td>
    <td>1.17</td>
    <td>(0.85, 1.61)</td>
    <td>0.3472</td>
    <td>0.9</td>
  </tr>
  <tr>
    <td>VEGFD</td>
    <td>1.52</td>
    <td>(1.07, 2.17)</td>
    <td>0.0205</td>
    <td>2.3</td>
    <td>1.75</td>
    <td>(1.19, 2.58)</td>
    <td>0.0045</td>
    <td>2.8</td>
    <td>1.81</td>
    <td>(1.29, 2.54)</td>
    <td>0.0007</td>
    <td>3.4</td>
    <td>1.98</td>
    <td>(1.36, 2.89)</td>
    <td>0.0004</td>
    <td>3.6</td>
  </tr>
  <tr>
    <td>TNFSF14</td>
    <td>1.28</td>
    <td>(1.04, 1.57)</td>
    <td>0.0212</td>
    <td>2.3</td>
    <td>1.22</td>
    <td>(0.98, 1.52)</td>
    <td>0.0795</td>
    <td>1.8</td>
    <td>1.14</td>
    <td>(0.94, 1.38)</td>
    <td>0.1775</td>
    <td>1.3</td>
    <td>1.17</td>
    <td>(0.96, 1.44)</td>
    <td>0.1236</td>
    <td>1.5</td>
  </tr>
  <tr>
    <td>ITGB1BP2</td>
    <td>1.11</td>
    <td>(1.02, 1.21)</td>
    <td>0.0213</td>
    <td>2.3</td>
    <td>1.09</td>
    <td>(0.99, 1.19)</td>
    <td>0.0842</td>
    <td>1.7</td>
    <td>1.03</td>
    <td>(0.93, 1.14)</td>
    <td>0.5949</td>
    <td>0.5</td>
    <td>1.01</td>
    <td>(0.90, 1.12)</td>
    <td>0.9105</td>
    <td>0.1</td>
  </tr>
  <tr>
    <td>FABP2</td>
    <td>1.27</td>
    <td>(1.03, 1.56)</td>
    <td>0.0223</td>
    <td>2.3</td>
    <td>1.2</td>
    <td>(0.97, 1.50)</td>
    <td>0.0998</td>
    <td>1.6</td>
    <td>1.32</td>
    <td>(1.06, 1.63)</td>
    <td>0.0119</td>
    <td>2.5</td>
    <td>1.19</td>
    <td>(0.95, 1.49)</td>
    <td>0.1356</td>
    <td>1.5</td>
  </tr>
  <tr>
    <td>BLMH</td>
    <td>1.44</td>
    <td>(1.05, 1.96)</td>
    <td>0.0224</td>
    <td>2.3</td>
    <td>1.5</td>
    <td>(1.08, 2.09)</td>
    <td>0.0154</td>
    <td>2.4</td>
    <td>0.79</td>
    <td>(0.58, 1.07)</td>
    <td>0.1287</td>
    <td>1.5</td>
    <td>0.83</td>
    <td>(0.60, 1.15)</td>
    <td>0.2558</td>
    <td>1.1</td>
  </tr>
  <tr>
    <td>SRC</td>
    <td>1.19</td>
    <td>(1.02, 1.38)</td>
    <td>0.0231</td>
    <td>2.3</td>
    <td>1.15</td>
    <td>(0.99, 1.35)</td>
    <td>0.0733</td>
    <td>1.8</td>
    <td>1.07</td>
    <td>(0.92, 1.26)</td>
    <td>0.3867</td>
    <td>0.9</td>
    <td>1.03</td>
    <td>(0.87, 1.21)</td>
    <td>0.7691</td>
    <td>0.3</td>
  </tr>
  <tr>
    <td>IL8</td>
    <td>1.2</td>
    <td>(1.03, 1.40)</td>
    <td>0.0232</td>
    <td>2.3</td>
    <td>1.18</td>
    <td>(1.00, 1.39)</td>
    <td>0.0508</td>
    <td>2</td>
    <td>1.13</td>
    <td>(0.94, 1.36)</td>
    <td>0.2025</td>
    <td>1.3</td>
    <td>1.1</td>
    <td>(0.90, 1.33)</td>
    <td>0.3563</td>
    <td>0.9</td>
  </tr>
  <tr>
    <td>SELE</td>
    <td>1.37</td>
    <td>(1.04, 1.79)</td>
    <td>0.0239</td>
    <td>2.3</td>
    <td>1.13</td>
    <td>(0.85, 1.51)</td>
    <td>0.409</td>
    <td>0.8</td>
    <td>1.31</td>
    <td>(0.99, 1.75)</td>
    <td>0.0624</td>
    <td>1.9</td>
    <td>1.18</td>
    <td>(0.87, 1.60)</td>
    <td>0.2917</td>
    <td>1.1</td>
  </tr>
  <tr>
    <td>LEP</td>
    <td>1.17</td>
    <td>(1.02, 1.35)</td>
    <td>0.0246</td>
    <td>2.2</td>
    <td>1.01</td>
    <td>(0.84, 1.21)</td>
    <td>0.9082</td>
    <td>0.1</td>
    <td>1.22</td>
    <td>(1.04, 1.43)</td>
    <td>0.0148</td>
    <td>2.4</td>
    <td>1.03</td>
    <td>(0.83, 1.28)</td>
    <td>0.7984</td>
    <td>0.3</td>
  </tr>
  <tr>
    <td>PSPD</td>
    <td>1.22</td>
    <td>(1.02, 1.46)</td>
    <td>0.0262</td>
    <td>2.2</td>
    <td>1.27</td>
    <td>(1.05, 1.54)</td>
    <td>0.0122</td>
    <td>2.5</td>
    <td>1.29</td>
    <td>(1.03, 1.61)</td>
    <td>0.0236</td>
    <td>2.3</td>
    <td>1.32</td>
    <td>(1.05, 1.67)</td>
    <td>0.0194</td>
    <td>2.3</td>
  </tr>
  <tr>
    <td>IL18R1</td>
    <td>1.42</td>
    <td>(1.04, 1.94)</td>
    <td>0.0266</td>
    <td>2.2</td>
    <td>1.2</td>
    <td>(0.86, 1.66)</td>
    <td>0.2856</td>
    <td>1.1</td>
    <td>1.2</td>
    <td>(0.84, 1.72)</td>
    <td>0.3199</td>
    <td>1</td>
    <td>0.96</td>
    <td>(0.65, 1.41)</td>
    <td>0.8428</td>
    <td>0.2</td>
  </tr>
</table>
<table>
  <tr>
    <td>SOD2</td>
    <td>2.01</td>
    <td>(1.08, 3.73)</td>
    <td>0.0274</td>
    <td>2.2</td>
    <td>2.3</td>
    <td>(1.20, 4.42)</td>
    <td>0.0122</td>
    <td>2.5</td>
    <td>1.46</td>
    <td>(0.87, 2.45)</td>
    <td>0.1539</td>
    <td>1.4</td>
    <td>1.53</td>
    <td>(0.88, 2.66)</td>
    <td>0.1353</td>
    <td>1.5</td>
  </tr>
  <tr>
    <td>NT3</td>
    <td>1.37</td>
    <td>(1.04, 1.82)</td>
    <td>0.0274</td>
    <td>2.2</td>
    <td>1.29</td>
    <td>(0.96, 1.74)</td>
    <td>0.0929</td>
    <td>1.7</td>
    <td>0.95</td>
    <td>(0.74, 1.23)</td>
    <td>0.7178</td>
    <td>0.4</td>
    <td>1</td>
    <td>(0.76, 1.30)</td>
    <td>0.986</td>
    <td>0</td>
  </tr>
  <tr>
    <td>BMP6</td>
    <td>1.23</td>
    <td>(1.02, 1.47)</td>
    <td>0.0278</td>
    <td>2.2</td>
    <td>1.17</td>
    <td>(0.97, 1.42)</td>
    <td>0.1076</td>
    <td>1.6</td>
    <td>1.09</td>
    <td>(0.91, 1.31)</td>
    <td>0.3624</td>
    <td>0.9</td>
    <td>1.08</td>
    <td>(0.88, 1.31)</td>
    <td>0.4708</td>
    <td>0.7</td>
  </tr>
  <tr>
    <td>APN</td>
    <td>1.53</td>
    <td>(1.05, 2.23)</td>
    <td>0.0279</td>
    <td>2.2</td>
    <td>1.37</td>
    <td>(0.92, 2.04)</td>
    <td>0.1161</td>
    <td>1.6</td>
    <td>0.96</td>
    <td>(0.68, 1.34)</td>
    <td>0.7958</td>
    <td>0.3</td>
    <td>0.92</td>
    <td>(0.64, 1.32)</td>
    <td>0.6636</td>
    <td>0.4</td>
  </tr>
  <tr>
    <td>STK4</td>
    <td>1.13</td>
    <td>(1.01, 1.26)</td>
    <td>0.0285</td>
    <td>2.2</td>
    <td>1.1</td>
    <td>(0.98, 1.24)</td>
    <td>0.0908</td>
    <td>1.7</td>
    <td>1.06</td>
    <td>(0.94, 1.20)</td>
    <td>0.3107</td>
    <td>1</td>
    <td>1.04</td>
    <td>(0.92, 1.18)</td>
    <td>0.5008</td>
    <td>0.7</td>
  </tr>
  <tr>
    <td>AMBP</td>
    <td>1.98</td>
    <td>(1.07, 3.64)</td>
    <td>0.0285</td>
    <td>2.2</td>
    <td>1.63</td>
    <td>(0.85, 3.12)</td>
    <td>0.1424</td>
    <td>1.5</td>
    <td>2.48</td>
    <td>(1.35, 4.55)</td>
    <td>0.0034</td>
    <td>2.9</td>
    <td>1.86</td>
    <td>(0.97, 3.53)</td>
    <td>0.06</td>
    <td>1.9</td>
  </tr>
  <tr>
    <td>IL27</td>
    <td>1.46</td>
    <td>(1.04, 2.05)</td>
    <td>0.0303</td>
    <td>2.2</td>
    <td>1.57</td>
    <td>(1.10, 2.26)</td>
    <td>0.014</td>
    <td>2.5</td>
    <td>1.83</td>
    <td>(1.22, 2.74)</td>
    <td>0.0036</td>
    <td>2.9</td>
    <td>1.77</td>
    <td>(1.15, 2.72)</td>
    <td>0.0095</td>
    <td>2.6</td>
  </tr>
  <tr>
    <td>CTS11</td>
    <td>1.49</td>
    <td>(1.04, 2.13)</td>
    <td>0.0314</td>
    <td>2.2</td>
    <td>1.51</td>
    <td>(1.03, 2.20)</td>
    <td>0.0331</td>
    <td>2.1</td>
    <td>1.31</td>
    <td>(0.95, 1.79)</td>
    <td>0.0972</td>
    <td>1.7</td>
    <td>1.26</td>
    <td>(0.90, 1.76)</td>
    <td>0.1822</td>
    <td>1.3</td>
  </tr>
  <tr>
    <td>TNFSF13B</td>
    <td>1.45</td>
    <td>(1.03, 2.05)</td>
    <td>0.0322</td>
    <td>2.1</td>
    <td>1.35</td>
    <td>(0.94, 1.94)</td>
    <td>0.1018</td>
    <td>1.6</td>
    <td>1.04</td>
    <td>(0.76, 1.42)</td>
    <td>0.819</td>
    <td>0.2</td>
    <td>1.04</td>
    <td>(0.75, 1.44)</td>
    <td>0.8279</td>
    <td>0.2</td>
  </tr>
  <tr>
    <td>MMP1</td>
    <td>1.13</td>
    <td>(1.01, 1.28)</td>
    <td>0.0346</td>
    <td>2.1</td>
    <td>1.1</td>
    <td>(0.97, 1.24)</td>
    <td>0.1339</td>
    <td>1.5</td>
    <td>1.1</td>
    <td>(0.96, 1.25)</td>
    <td>0.158</td>
    <td>1.4</td>
    <td>1.06</td>
    <td>(0.92, 1.22)</td>
    <td>0.398</td>
    <td>0.8</td>
  </tr>
  <tr>
    <td>SHPS1</td>
    <td>1.38</td>
    <td>(1.02, 1.86)</td>
    <td>0.0347</td>
    <td>2.1</td>
    <td>1.14</td>
    <td>(0.83, 1.58)</td>
    <td>0.4173</td>
    <td>0.8</td>
    <td>1.19</td>
    <td>(0.91, 1.54)</td>
    <td>0.1971</td>
    <td>1.3</td>
    <td>1.07</td>
    <td>(0.81, 1.42)</td>
    <td>0.6111</td>
    <td>0.5</td>
  </tr>
  <tr>
    <td>MMP7</td>
    <td>1.18</td>
    <td>(1.01, 1.39)</td>
    <td>0.0352</td>
    <td>2.1</td>
    <td>1.12</td>
    <td>(0.95, 1.32)</td>
    <td>0.1941</td>
    <td>1.3</td>
    <td>1.1</td>
    <td>(0.96, 1.25)</td>
    <td>0.1669</td>
    <td>1.4</td>
    <td>1.1</td>
    <td>(0.96, 1.26)</td>
    <td>0.1809</td>
    <td>1.3</td>
  </tr>
  <tr>
    <td>IL18</td>
    <td>1.21</td>
    <td>(1.01, 1.45)</td>
    <td>0.0366</td>
    <td>2.1</td>
    <td>1.16</td>
    <td>(0.97, 1.41)</td>
    <td>0.1113</td>
    <td>1.6</td>
    <td>1.27</td>
    <td>(1.07, 1.51)</td>
    <td>0.0074</td>
    <td>2.7</td>
    <td>1.24</td>
    <td>(1.03, 1.49)</td>
    <td>0.0239</td>
    <td>2.3</td>
  </tr>
  <tr>
    <td>STAMPB</td>
    <td>1.14</td>
    <td>(1.01, 1.29)</td>
    <td>0.0367</td>
    <td>2.1</td>
    <td>1.11</td>
    <td>(0.97, 1.26)</td>
    <td>0.1225</td>
    <td>1.5</td>
    <td>1.03</td>
    <td>(0.89, 1.20)</td>
    <td>0.6566</td>
    <td>0.4</td>
    <td>1</td>
    <td>(0.86, 1.18)</td>
    <td>0.9529</td>
    <td>0.1</td>
  </tr>
  <tr>
    <td>TF</td>
    <td>1.44</td>
    <td>(1.02, 2.03)</td>
    <td>0.0385</td>
    <td>2.1</td>
    <td>1.24</td>
    <td>(0.86, 1.78)</td>
    <td>0.2487</td>
    <td>1.2</td>
    <td>1.55</td>
    <td>(1.05, 2.31)</td>
    <td>0.0285</td>
    <td>2.2</td>
    <td>1.35</td>
    <td>(0.89, 2.05)</td>
    <td>0.159</td>
    <td>1.4</td>
  </tr>
  <tr>
    <td>ITGB2</td>
    <td>1.38</td>
    <td>(1.02, 1.87)</td>
    <td>0.0387</td>
    <td>2.1</td>
    <td>1.31</td>
    <td>(0.95, 1.81)</td>
    <td>0.0988</td>
    <td>1.7</td>
    <td>1.02</td>
    <td>(0.79, 1.31)</td>
    <td>0.8783</td>
    <td>0.2</td>
    <td>1.01</td>
    <td>(0.77, 1.33)</td>
    <td>0.9216</td>
    <td>0.1</td>
  </tr>
  <tr>
    <td>OSM</td>
    <td>1.19</td>
    <td>(1.01, 1.41)</td>
    <td>0.0395</td>
    <td>2.1</td>
    <td>1.18</td>
    <td>(0.99, 1.41)</td>
    <td>0.0644</td>
    <td>1.8</td>
    <td>1.19</td>
    <td>(1.01, 1.40)</td>
    <td>0.0334</td>
    <td>2.1</td>
    <td>1.14</td>
    <td>(0.96, 1.36)</td>
    <td>0.1331</td>
    <td>1.5</td>
  </tr>
  <tr>
    <td>XCL1</td>
    <td>1.26</td>
    <td>(1.01, 1.57)</td>
    <td>0.0403</td>
    <td>2.1</td>
    <td>1.18</td>
    <td>(0.94, 1.49)</td>
    <td>0.1584</td>
    <td>1.4</td>
    <td>1.33</td>
    <td>(1.04, 1.70)</td>
    <td>0.0235</td>
    <td>2.3</td>
    <td>1.26</td>
    <td>(0.97, 1.64)</td>
    <td>0.0808</td>
    <td>1.7</td>
  </tr>
  <tr>
    <td>CCL19</td>
    <td>1.16</td>
    <td>(1.01, 1.34)</td>
    <td>0.0403</td>
    <td>2.1</td>
    <td>1.08</td>
    <td>(0.93, 1.26)</td>
    <td>0.3193</td>
    <td>1</td>
    <td>1.23</td>
    <td>(1.04, 1.47)</td>
    <td>0.0164</td>
    <td>2.4</td>
    <td>1.21</td>
    <td>(1.01, 1.45)</td>
    <td>0.0414</td>
    <td>2</td>
  </tr>
  <tr>
    <td>DKK1</td>
    <td>1.27</td>
    <td>(1.01, 1.61)</td>
    <td>0.0443</td>
    <td>2</td>
    <td>1.27</td>
    <td>(0.99, 1.63)</td>
    <td>0.0579</td>
    <td>1.9</td>
    <td>1.19</td>
    <td>(0.97, 1.46)</td>
    <td>0.0952</td>
    <td>1.7</td>
    <td>1.21</td>
    <td>(0.97, 1.51)</td>
    <td>0.091</td>
    <td>1.7</td>
  </tr>
  <tr>
    <td>ALCAM</td>
    <td>1.42</td>
    <td>(1.00, 2.02)</td>
    <td>0.0486</td>
    <td>2</td>
    <td>1.33</td>
    <td>(0.92, 1.92)</td>
    <td>0.126</td>
    <td>1.5</td>
    <td>1.1</td>
    <td>(0.79, 1.52)</td>
    <td>0.5788</td>
    <td>0.6</td>
    <td>1.03</td>
    <td>(0.73, 1.46)</td>
    <td>0.8773</td>
    <td>0.2</td>
  </tr>
  <tr>
    <td>PTX3</td>
    <td>1.25</td>
    <td>(0.99, 1.58)</td>
    <td>0.0597</td>
    <td>1.9</td>
    <td>1.24</td>
    <td>(0.97, 1.59)</td>
    <td>0.0816</td>
    <td>1.7</td>
    <td>1.31</td>
    <td>(0.97, 1.78)</td>
    <td>0.0778</td>
    <td>1.8</td>
    <td>1.43</td>
    <td>(1.03, 1.97)</td>
    <td>0.0302</td>
    <td>2.2</td>
  </tr>
  <tr>
    <td>IL17D</td>
    <td>1.38</td>
    <td>(0.99, 1.94)</td>
    <td>0.06</td>
    <td>1.9</td>
    <td>1.37</td>
    <td>(0.96, 1.95)</td>
    <td>0.0816</td>
    <td>1.7</td>
    <td>1.22</td>
    <td>(0.79, 1.89)</td>
    <td>0.3631</td>
    <td>0.9</td>
    <td>1.28</td>
    <td>(0.80, 2.03)</td>
    <td>0.3057</td>
    <td>1</td>
  </tr>
  <tr>
    <td>HGDNF</td>
    <td>1.3</td>
    <td>(0.98, 1.72)</td>
    <td>0.0687</td>
    <td>1.8</td>
    <td>1.05</td>
    <td>(0.78, 1.43)</td>
    <td>0.7318</td>
    <td>0.3</td>
    <td>1.17</td>
    <td>(0.80, 1.72)</td>
    <td>0.4178</td>
    <td>0.8</td>
    <td>1.02</td>
    <td>(0.68, 1.54)</td>
    <td>0.9082</td>
    <td>0.1</td>
  </tr>
  <tr>
    <td>CXCL6</td>
    <td>1.17</td>
    <td>(0.99, 1.38)</td>
    <td>0.069</td>
    <td>1.8</td>
    <td>1.18</td>
    <td>(0.99, 1.40)</td>
    <td>0.0677</td>
    <td>1.8</td>
    <td>0.99</td>
    <td>(0.84, 1.18)</td>
    <td>0.9326</td>
    <td>0.1</td>
    <td>1.01</td>
    <td>(0.84, 1.21)</td>
    <td>0.9013</td>
    <td>0.1</td>
  </tr>
  <tr>
    <td>FGF19</td>
    <td>1.15</td>
    <td>(0.99, 1.35)</td>
    <td>0.0722</td>
    <td>1.8</td>
    <td>1.14</td>
    <td>(0.97, 1.35)</td>
    <td>0.1164</td>
    <td>1.6</td>
    <td>0.93</td>
    <td>(0.78, 1.10)</td>
    <td>0.387</td>
    <td>0.9</td>
    <td>0.89</td>
    <td>(0.74, 1.08)</td>
    <td>0.2396</td>
    <td>1.2</td>
  </tr>
  <tr>
    <td>IL17A</td>
    <td>1.25</td>
    <td>(0.98, 1.61)</td>
    <td>0.0779</td>
    <td>1.8</td>
    <td>1.18</td>
    <td>(0.91, 1.53)</td>
    <td>0.2225</td>
    <td>1.2</td>
    <td>0.93</td>
    <td>(0.67, 1.30)</td>
    <td>0.6714</td>
    <td>0.4</td>
    <td>0.94</td>
    <td>(0.67, 1.33)</td>
    <td>0.7287</td>
    <td>0.3</td>
  </tr>
  <tr>
    <td>IGGFRECEPTORIIB</td>
    <td>1.23</td>
    <td>(0.98, 1.54)</td>
    <td>0.0784</td>
    <td>1.8</td>
    <td>1.25</td>
    <td>(0.98, 1.58)</td>
    <td>0.0672</td>
    <td>1.8</td>
    <td>1.18</td>
    <td>(0.86, 1.60)</td>
    <td>0.3064</td>
    <td>1</td>
    <td>1.13</td>
    <td>(0.81, 1.57)</td>
    <td>0.466</td>
    <td>0.7</td>
  </tr>
  <tr>
    <td>PARP1</td>
    <td>1.13</td>
    <td>(0.99, 1.29)</td>
    <td>0.0805</td>
    <td>1.7</td>
    <td>1.1</td>
    <td>(0.95, 1.27)</td>
    <td>0.2035</td>
    <td>1.3</td>
    <td>1.16</td>
    <td>(1.00, 1.36)</td>
    <td>0.0535</td>
    <td>1.9</td>
    <td>1.19</td>
    <td>(1.00, 1.40)</td>
    <td>0.0435</td>
    <td>2</td>
  </tr>
  <tr>
    <td>IDUA</td>
    <td>1.26</td>
    <td>(0.97, 1.64)</td>
    <td>0.0834</td>
    <td>1.7</td>
    <td>1.25</td>
    <td>(0.95, 1.64)</td>
    <td>0.1091</td>
    <td>1.6</td>
    <td>1.03</td>
    <td>(0.82, 1.30)</td>
    <td>0.7905</td>
    <td>0.3</td>
    <td>0.94</td>
    <td>(0.74, 1.21)</td>
    <td>0.6409</td>
    <td>0.5</td>
  </tr>
  <tr>
    <td>PDGFSUBUNITB</td>
    <td>1.12</td>
    <td>(0.98, 1.27)</td>
    <td>0.0855</td>
    <td>1.7</td>
    <td>1.13</td>
    <td>(0.99, 1.29)</td>
    <td>0.0757</td>
    <td>1.8</td>
    <td>1.09</td>
    <td>(0.94, 1.27)</td>
    <td>0.2374</td>
    <td>1.2</td>
    <td>1.09</td>
    <td>(0.93, 1.28)</td>
    <td>0.2947</td>
    <td>1</td>
  </tr>
  <tr>
    <td>CD40L</td>
    <td>1.1</td>
    <td>(0.99, 1.23)</td>
    <td>0.0899</td>
    <td>1.7</td>
    <td>1.09</td>
    <td>(0.97, 1.23)</td>
    <td>0.1281</td>
    <td>1.5</td>
    <td>1.07</td>
    <td>(0.96, 1.20)</td>
    <td>0.2244</td>
    <td>1.2</td>
    <td>1.09</td>
    <td>(0.97, 1.23)</td>
    <td>0.1406</td>
    <td>1.5</td>
  </tr>
  <tr>
    <td>TNFRSF10C</td>
    <td>1.26</td>
    <td>(0.96, 1.64)</td>
    <td>0.0925</td>
    <td>1.7</td>
    <td>1.09</td>
    <td>(0.83, 1.45)</td>
    <td>0.5284</td>
    <td>0.6</td>
    <td>1.22</td>
    <td>(0.94, 1.59)</td>
    <td>0.1351</td>
    <td>1.5</td>
    <td>1.12</td>
    <td>(0.85, 1.48)</td>
    <td>0.4103</td>
    <td>0.8</td>
  </tr>
  <tr>
    <td>CTSD</td>
    <td>1.28</td>
    <td>(0.96, 1.70)</td>
    <td>0.0931</td>
    <td>1.7</td>
    <td>1.06</td>
    <td>(0.78, 1.43)</td>
    <td>0.7145</td>
    <td>0.4</td>
    <td>1.06</td>
    <td>(0.81, 1.38)</td>
    <td>0.6892</td>
    <td>0.4</td>
    <td>0.93</td>
    <td>(0.70, 1.24)</td>
    <td>0.6154</td>
    <td>0.5</td>
  </tr>
  <tr>
    <td>NOTCH3</td>
    <td>1.3</td>
    <td>(0.96, 1.75)</td>
    <td>0.0936</td>
    <td>1.7</td>
    <td>1.17</td>
    <td>(0.85, 1.61)</td>
    <td>0.3379</td>
    <td>1</td>
    <td>1.1</td>
    <td>(0.82, 1.49)</td>
    <td>0.5157</td>
    <td>0.7</td>
    <td>1.1</td>
    <td>(0.80, 1.51)</td>
    <td>0.5684</td>
    <td>0.6</td>
  </tr>
  <tr>
    <td>MB</td>
    <td>1.21</td>
    <td>(0.97, 1.50)</td>
    <td>0.0947</td>
    <td>1.7</td>
    <td>1.02</td>
    <td>(0.80, 1.30)</td>
    <td>0.894</td>
    <td>0.1</td>
    <td>0.98</td>
    <td>(0.78, 1.22)</td>
    <td>0.8252</td>
    <td>0.2</td>
    <td>0.85</td>
    <td>(0.66, 1.09)</td>
    <td>0.1947</td>
    <td>1.3</td>
  </tr>
  <tr>
    <td>CD5</td>
    <td>1.25</td>
    <td>(0.96, 1.63)</td>
    <td>0.0956</td>
    <td>1.7</td>
    <td>1.11</td>
    <td>(0.84, 1.48)</td>
    <td>0.4591</td>
    <td>0.7</td>
    <td>1.28</td>
    <td>(0.91, 1.79)</td>
    <td>0.1504</td>
    <td>1.4</td>
    <td>1.08</td>
    <td>(0.75, 1.55)</td>
    <td>0.6754</td>
    <td>0.4</td>
  </tr>
  <tr>
    <td>TPA</td>
    <td>1.21</td>
    <td>(0.97, 1.50)</td>
    <td>0.0975</td>
    <td>1.7</td>
    <td>1.11</td>
    <td>(0.88, 1.41)</td>
    <td>0.3743</td>
    <td>0.9</td>
    <td>0.99</td>
    <td>(0.82, 1.20)</td>
    <td>0.9333</td>
    <td>0.1</td>
    <td>0.96</td>
    <td>(0.78, 1.17)</td>
    <td>0.6772</td>
    <td>0.4</td>
  </tr>
  <tr>
    <td>PAPPA</td>
    <td>1.22</td>
    <td>(0.96, 1.55)</td>
    <td>0.0995</td>
    <td>1.6</td>
    <td>1.28</td>
    <td>(1.00, 1.65)</td>
    <td>0.0535</td>
    <td>1.9</td>
    <td>1.15</td>
    <td>(0.88, 1.50)</td>
    <td>0.2964</td>
    <td>1</td>
    <td>1.32</td>
    <td>(0.99, 1.75)</td>
    <td>0.0579</td>
    <td>1.9</td>
  </tr>
  <tr>
    <td>COL1A1</td>
    <td>1.29</td>
    <td>(0.95, 1.75)</td>
    <td>0.0996</td>
    <td>1.6</td>
    <td>1.11</td>
    <td>(0.81, 1.54)</td>
    <td>0.5109</td>
    <td>0.7</td>
    <td>1.16</td>
    <td>(0.84, 1.61)</td>
    <td>0.3769</td>
    <td>0.9</td>
    <td>1.1</td>
    <td>(0.78, 1.56)</td>
    <td>0.5765</td>
    <td>0.6</td>
  </tr>
  <tr>
    <td>IL7</td>
    <td>1.17</td>
    <td>(0.97, 1.41)</td>
    <td>0.1021</td>
    <td>1.6</td>
    <td>1.19</td>
    <td>(0.98, 1.45)</td>
    <td>0.086</td>
    <td>1.7</td>
    <td>0.96</td>
    <td>(0.78, 1.17)</td>
    <td>0.6572</td>
    <td>0.4</td>
    <td>0.96</td>
    <td>(0.78, 1.19)</td>
    <td>0.7271</td>
    <td>0.3</td>
  </tr>
  <tr>
    <td>CCL4</td>
    <td>1.16</td>
    <td>(0.96, 1.40)</td>
    <td>0.1143</td>
    <td>1.6</td>
    <td>1.14</td>
    <td>(0.94, 1.39)</td>
    <td>0.1714</td>
    <td>1.4</td>
    <td>0.98</td>
    <td>(0.81, 1.19)</td>
    <td>0.8406</td>
    <td>0.2</td>
    <td>0.96</td>
    <td>(0.78, 1.18)</td>
    <td>0.7178</td>
    <td>0.4</td>
  </tr>
  <tr>
    <td>SCF</td>
    <td>0.73</td>
    <td>(0.50, 1.08)</td>
    <td>0.115</td>
    <td>1.6</td>
    <td>0.73</td>
    <td>(0.48, 1.09)</td>
    <td>0.1228</td>
    <td>1.5</td>
    <td>1.3</td>
    <td>(0.93, 1.82)</td>
    <td>0.1216</td>
    <td>1.5</td>
    <td>1.25</td>
    <td>(0.88, 1.77)</td>
    <td>0.2118</td>
    <td>1.2</td>
  </tr>
  <tr>
    <td>CA5A</td>
    <td>1.13</td>
    <td>(0.97, 1.31)</td>
    <td>0.1184</td>
    <td>1.6</td>
    <td>0.99</td>
    <td>(0.84, 1.16)</td>
    <td>0.8755</td>
    <td>0.2</td>
    <td>1.08</td>
    <td>(0.90, 1.31)</td>
    <td>0.4065</td>
    <td>0.8</td>
    <td>0.95</td>
    <td>(0.77, 1.16)</td>
    <td>0.6048</td>
    <td>0.5</td>
  </tr>
  <tr>
    <td>PRELP</td>
    <td>1.58</td>
    <td>(0.89, 2.82)</td>
    <td>0.1185</td>
    <td>1.6</td>
    <td>1.36</td>
    <td>(0.74, 2.49)</td>
    <td>0.321</td>
    <td>1</td>
    <td>3.17</td>
    <td>(1.55, 6.49)</td>
    <td>0.0016</td>
    <td>3.2</td>
    <td>2.79</td>
    <td>(1.31, 5.94)</td>
    <td>0.008</td>
    <td>2.7</td>
  </tr>
  <tr>
    <td>FS</td>
    <td>1.29</td>
    <td>(0.93, 1.78)</td>
    <td>0.1237</td>
    <td>1.5</td>
    <td>1.24</td>
    <td>(0.88, 1.73)</td>
    <td>0.2173</td>
    <td>1.2</td>
    <td>1.4</td>
    <td>(1.02, 1.92)</td>
    <td>0.039</td>
    <td>2.1</td>
    <td>1.37</td>
    <td>(0.98, 1.91)</td>
    <td>0.0637</td>
    <td>1.9</td>
  </tr>
  <tr>
    <td>CCL17</td>
    <td>1.11</td>
    <td>(0.97, 1.28)</td>
    <td>0.1284</td>
    <td>1.5</td>
    <td>1.12</td>
    <td>(0.97, 1.29)</td>
    <td>0.1299</td>
    <td>1.5</td>
    <td>1.2</td>
    <td>(1.04, 1.38)</td>
    <td>0.0144</td>
    <td>2.4</td>
    <td>1.22</td>
    <td>(1.04, 1.42)</td>
    <td>0.0131</td>
    <td>2.5</td>
  </tr>
  <tr>
    <td>HBEGF</td>
    <td>1.27</td>
    <td>(0.92, 1.74)</td>
    <td>0.1412</td>
    <td>1.5</td>
    <td>1.25</td>
    <td>(0.90, 1.75)</td>
    <td>0.1831</td>
    <td>1.3</td>
    <td>1.29</td>
    <td>(0.99, 1.67)</td>
    <td>0.0569</td>
    <td>1.9</td>
    <td>1.34</td>
    <td>(1.01, 1.77)</td>
    <td>0.04</td>
    <td>2.1</td>
  </tr>
</table>
<table>
  <tr>
    <td>ADA</td>
    <td>1.21</td>
    <td>(0.93, 1.57)</td>
    <td>0.1589</td>
    <td>1.4</td>
    <td>1.11</td>
    <td>(0.85, 1.46)</td>
    <td>0.4453</td>
    <td>0.8</td>
    <td>0.84</td>
    <td>(0.62, 1.13)</td>
    <td>0.2553</td>
    <td>1.1</td>
    <td>0.83</td>
    <td>(0.61, 1.14)</td>
    <td>0.256</td>
    <td>1.1</td>
  </tr>
  <tr>
    <td>MMP9</td>
    <td>1.12</td>
    <td>(0.96, 1.30)</td>
    <td>0.1601</td>
    <td>1.4</td>
    <td>1.11</td>
    <td>(0.95, 1.31)</td>
    <td>0.1942</td>
    <td>1.3</td>
    <td>1.21</td>
    <td>(1.04, 1.41)</td>
    <td>0.0135</td>
    <td>2.5</td>
    <td>1.18</td>
    <td>(1.00, 1.39)</td>
    <td>0.048</td>
    <td>2</td>
  </tr>
  <tr>
    <td>PAI</td>
    <td>1.12</td>
    <td>(0.96, 1.31)</td>
    <td>0.1612</td>
    <td>1.4</td>
    <td>1.07</td>
    <td>(0.91, 1.27)</td>
    <td>0.4117</td>
    <td>0.8</td>
    <td>1.02</td>
    <td>(0.87, 1.21)</td>
    <td>0.7794</td>
    <td>0.3</td>
    <td>0.99</td>
    <td>(0.83, 1.18)</td>
    <td>0.9022</td>
    <td>0.1</td>
  </tr>
  <tr>
    <td>GIF</td>
    <td>0.92</td>
    <td>(0.81, 1.04)</td>
    <td>0.165</td>
    <td>1.4</td>
    <td>0.94</td>
    <td>(0.83, 1.07)</td>
    <td>0.3446</td>
    <td>0.9</td>
    <td>1.1</td>
    <td>(0.96, 1.27)</td>
    <td>0.1642</td>
    <td>1.4</td>
    <td>1.12</td>
    <td>(0.97, 1.30)</td>
    <td>0.1313</td>
    <td>1.5</td>
  </tr>
  <tr>
    <td>FGF5</td>
    <td>1.33</td>
    <td>(0.89, 1.97)</td>
    <td>0.1654</td>
    <td>1.4</td>
    <td>1.15</td>
    <td>(0.76, 1.75)</td>
    <td>0.5134</td>
    <td>0.7</td>
    <td>0.95</td>
    <td>(0.61, 1.50)</td>
    <td>0.8408</td>
    <td>0.2</td>
    <td>0.88</td>
    <td>(0.55, 1.43)</td>
    <td>0.6127</td>
    <td>0.5</td>
  </tr>
  <tr>
    <td>FLT3L</td>
    <td>1.23</td>
    <td>(0.92, 1.66)</td>
    <td>0.1682</td>
    <td>1.4</td>
    <td>1.18</td>
    <td>(0.86, 1.61)</td>
    <td>0.2983</td>
    <td>1</td>
    <td>1.05</td>
    <td>(0.76, 1.45)</td>
    <td>0.7568</td>
    <td>0.3</td>
    <td>0.96</td>
    <td>(0.68, 1.35)</td>
    <td>0.82</td>
    <td>0.2</td>
  </tr>
  <tr>
    <td>DCN</td>
    <td>1.28</td>
    <td>(0.90, 1.82)</td>
    <td>0.1728</td>
    <td>1.4</td>
    <td>1.15</td>
    <td>(0.79, 1.67)</td>
    <td>0.4694</td>
    <td>0.7</td>
    <td>1.43</td>
    <td>(1.02, 2.02)</td>
    <td>0.0391</td>
    <td>2.1</td>
    <td>1.33</td>
    <td>(0.93, 1.91)</td>
    <td>0.1236</td>
    <td>1.5</td>
  </tr>
  <tr>
    <td>CHIT1</td>
    <td>1.08</td>
    <td>(0.97, 1.20)</td>
    <td>0.1769</td>
    <td>1.4</td>
    <td>1.08</td>
    <td>(0.96, 1.20)</td>
    <td>0.1908</td>
    <td>1.3</td>
    <td>1.01</td>
    <td>(0.91, 1.12)</td>
    <td>0.8861</td>
    <td>0.1</td>
    <td>1.01</td>
    <td>(0.90, 1.13)</td>
    <td>0.8693</td>
    <td>0.2</td>
  </tr>
  <tr>
    <td>CPB1</td>
    <td>1.13</td>
    <td>(0.94, 1.36)</td>
    <td>0.18</td>
    <td>1.3</td>
    <td>1.1</td>
    <td>(0.90, 1.34)</td>
    <td>0.3452</td>
    <td>0.9</td>
    <td>1.15</td>
    <td>(0.95, 1.40)</td>
    <td>0.1547</td>
    <td>1.4</td>
    <td>1.1</td>
    <td>(0.89, 1.36)</td>
    <td>0.4001</td>
    <td>0.8</td>
  </tr>
  <tr>
    <td>CCL3</td>
    <td>1.1</td>
    <td>(0.95, 1.27)</td>
    <td>0.1882</td>
    <td>1.3</td>
    <td>1.05</td>
    <td>(0.90, 1.22)</td>
    <td>0.5275</td>
    <td>0.6</td>
    <td>1.13</td>
    <td>(0.91, 1.39)</td>
    <td>0.2599</td>
    <td>1.1</td>
    <td>1.05</td>
    <td>(0.84, 1.30)</td>
    <td>0.6787</td>
    <td>0.4</td>
  </tr>
  <tr>
    <td>CD84</td>
    <td>1.23</td>
    <td>(0.90, 1.67)</td>
    <td>0.1894</td>
    <td>1.3</td>
    <td>1.28</td>
    <td>(0.93, 1.77)</td>
    <td>0.1285</td>
    <td>1.5</td>
    <td>1.12</td>
    <td>(0.81, 1.55)</td>
    <td>0.5086</td>
    <td>0.7</td>
    <td>1.17</td>
    <td>(0.83, 1.66)</td>
    <td>0.3731</td>
    <td>0.9</td>
  </tr>
  <tr>
    <td>UPA_CVD3</td>
    <td>1.22</td>
    <td>(0.90, 1.65)</td>
    <td>0.1925</td>
    <td>1.3</td>
    <td>1.2</td>
    <td>(0.88, 1.63)</td>
    <td>0.251</td>
    <td>1.1</td>
    <td>1.05</td>
    <td>(0.75, 1.47)</td>
    <td>0.7792</td>
    <td>0.3</td>
    <td>1.06</td>
    <td>(0.74, 1.53)</td>
    <td>0.7324</td>
    <td>0.3</td>
  </tr>
  <tr>
    <td>AXL</td>
    <td>1.23</td>
    <td>(0.90, 1.70)</td>
    <td>0.1933</td>
    <td>1.3</td>
    <td>1.15</td>
    <td>(0.82, 1.62)</td>
    <td>0.4106</td>
    <td>0.8</td>
    <td>1.14</td>
    <td>(0.85, 1.54)</td>
    <td>0.388</td>
    <td>0.9</td>
    <td>1.08</td>
    <td>(0.79, 1.48)</td>
    <td>0.6297</td>
    <td>0.5</td>
  </tr>
  <tr>
    <td>TFPI</td>
    <td>1.26</td>
    <td>(0.87, 1.82)</td>
    <td>0.2131</td>
    <td>1.2</td>
    <td>1.25</td>
    <td>(0.85, 1.84)</td>
    <td>0.2569</td>
    <td>1.1</td>
    <td>0.98</td>
    <td>(0.71, 1.35)</td>
    <td>0.8866</td>
    <td>0.1</td>
    <td>0.96</td>
    <td>(0.68, 1.35)</td>
    <td>0.8106</td>
    <td>0.2</td>
  </tr>
  <tr>
    <td>SCGB3A2</td>
    <td>1.09</td>
    <td>(0.95, 1.26)</td>
    <td>0.216</td>
    <td>1.2</td>
    <td>1.09</td>
    <td>(0.94, 1.27)</td>
    <td>0.2515</td>
    <td>1.1</td>
    <td>1.04</td>
    <td>(0.89, 1.22)</td>
    <td>0.6438</td>
    <td>0.5</td>
    <td>0.99</td>
    <td>(0.83, 1.17)</td>
    <td>0.8647</td>
    <td>0.2</td>
  </tr>
  <tr>
    <td>ANG1</td>
    <td>1.08</td>
    <td>(0.95, 1.24)</td>
    <td>0.2223</td>
    <td>1.2</td>
    <td>1.09</td>
    <td>(0.95, 1.25)</td>
    <td>0.2388</td>
    <td>1.2</td>
    <td>1.06</td>
    <td>(0.92, 1.21)</td>
    <td>0.4174</td>
    <td>0.8</td>
    <td>1.08</td>
    <td>(0.93, 1.26)</td>
    <td>0.302</td>
    <td>1</td>
  </tr>
  <tr>
    <td>EGFR</td>
    <td>0.77</td>
    <td>(0.50, 1.18)</td>
    <td>0.2258</td>
    <td>1.2</td>
    <td>0.83</td>
    <td>(0.53, 1.31)</td>
    <td>0.4258</td>
    <td>0.8</td>
    <td>0.77</td>
    <td>(0.53, 1.10)</td>
    <td>0.1504</td>
    <td>1.4</td>
    <td>0.8</td>
    <td>(0.55, 1.18)</td>
    <td>0.2607</td>
    <td>1.1</td>
  </tr>
  <tr>
    <td>DNER</td>
    <td>0.8</td>
    <td>(0.56, 1.15)</td>
    <td>0.2294</td>
    <td>1.2</td>
    <td>0.85</td>
    <td>(0.58, 1.25)</td>
    <td>0.4125</td>
    <td>0.8</td>
    <td>0.41</td>
    <td>(0.25, 0.67)</td>
    <td>0.0003</td>
    <td>3.6</td>
    <td>0.43</td>
    <td>(0.26, 0.72)</td>
    <td>0.0012</td>
    <td>3.2</td>
  </tr>
  <tr>
    <td>HO1</td>
    <td>1.23</td>
    <td>(0.88, 1.72)</td>
    <td>0.2335</td>
    <td>1.2</td>
    <td>1.41</td>
    <td>(0.99, 2.01)</td>
    <td>0.0587</td>
    <td>1.9</td>
    <td>1.02</td>
    <td>(0.73, 1.41)</td>
    <td>0.9233</td>
    <td>0.1</td>
    <td>1.01</td>
    <td>(0.71, 1.43)</td>
    <td>0.9632</td>
    <td>0</td>
  </tr>
  <tr>
    <td>TRANCE</td>
    <td>0.88</td>
    <td>(0.70, 1.10)</td>
    <td>0.2543</td>
    <td>1.1</td>
    <td>0.89</td>
    <td>(0.70, 1.12)</td>
    <td>0.3111</td>
    <td>1</td>
    <td>0.83</td>
    <td>(0.64, 1.08)</td>
    <td>0.1626</td>
    <td>1.4</td>
    <td>0.78</td>
    <td>(0.59, 1.04)</td>
    <td>0.0863</td>
    <td>1.7</td>
  </tr>
  <tr>
    <td>PIGR</td>
    <td>1.44</td>
    <td>(0.76, 2.73)</td>
    <td>0.2581</td>
    <td>1.1</td>
    <td>1.6</td>
    <td>(0.82, 3.13)</td>
    <td>0.1693</td>
    <td>1.4</td>
    <td>1.89</td>
    <td>(1.05, 3.39)</td>
    <td>0.0333</td>
    <td>2.1</td>
    <td>1.9</td>
    <td>(1.01, 3.57)</td>
    <td>0.048</td>
    <td>2</td>
  </tr>
  <tr>
    <td>PDGFSUBUNITA</td>
    <td>1.09</td>
    <td>(0.93, 1.26)</td>
    <td>0.2869</td>
    <td>1.1</td>
    <td>1.11</td>
    <td>(0.95, 1.31)</td>
    <td>0.1923</td>
    <td>1.3</td>
    <td>1.03</td>
    <td>(0.89, 1.18)</td>
    <td>0.7228</td>
    <td>0.4</td>
    <td>1.06</td>
    <td>(0.91, 1.23)</td>
    <td>0.4793</td>
    <td>0.7</td>
  </tr>
  <tr>
    <td>THPO</td>
    <td>1.18</td>
    <td>(0.87, 1.60)</td>
    <td>0.2963</td>
    <td>1</td>
    <td>1.18</td>
    <td>(0.86, 1.63)</td>
    <td>0.2984</td>
    <td>1</td>
    <td>1.09</td>
    <td>(0.80, 1.50)</td>
    <td>0.5843</td>
    <td>0.5</td>
    <td>1.11</td>
    <td>(0.80, 1.56)</td>
    <td>0.5249</td>
    <td>0.6</td>
  </tr>
  <tr>
    <td>CTRC</td>
    <td>0.91</td>
    <td>(0.77, 1.09)</td>
    <td>0.3048</td>
    <td>1</td>
    <td>0.94</td>
    <td>(0.78, 1.13)</td>
    <td>0.496</td>
    <td>0.7</td>
    <td>0.99</td>
    <td>(0.83, 1.19)</td>
    <td>0.9303</td>
    <td>0.1</td>
    <td>1.03</td>
    <td>(0.85, 1.26)</td>
    <td>0.7581</td>
    <td>0.3</td>
  </tr>
  <tr>
    <td>CNTN1</td>
    <td>0.85</td>
    <td>(0.62, 1.16)</td>
    <td>0.3131</td>
    <td>1</td>
    <td>0.86</td>
    <td>(0.62, 1.19)</td>
    <td>0.3602</td>
    <td>0.9</td>
    <td>0.75</td>
    <td>(0.54, 1.02)</td>
    <td>0.0654</td>
    <td>1.8</td>
    <td>0.76</td>
    <td>(0.54, 1.05)</td>
    <td>0.0996</td>
    <td>1.6</td>
  </tr>
  <tr>
    <td>CXCL5</td>
    <td>1.05</td>
    <td>(0.96, 1.15)</td>
    <td>0.3253</td>
    <td>1</td>
    <td>1.03</td>
    <td>(0.94, 1.14)</td>
    <td>0.4934</td>
    <td>0.7</td>
    <td>1</td>
    <td>(0.90, 1.11)</td>
    <td>0.9813</td>
    <td>0</td>
    <td>1</td>
    <td>(0.89, 1.12)</td>
    <td>0.9958</td>
    <td>0</td>
  </tr>
  <tr>
    <td>IL17RA</td>
    <td>1.1</td>
    <td>(0.90, 1.35)</td>
    <td>0.3346</td>
    <td>1</td>
    <td>1.1</td>
    <td>(0.89, 1.36)</td>
    <td>0.3577</td>
    <td>0.9</td>
    <td>0.95</td>
    <td>(0.74, 1.23)</td>
    <td>0.7123</td>
    <td>0.4</td>
    <td>0.93</td>
    <td>(0.71, 1.22)</td>
    <td>0.6185</td>
    <td>0.5</td>
  </tr>
  <tr>
    <td>PROTEINBOC</td>
    <td>1.19</td>
    <td>(0.83, 1.71)</td>
    <td>0.3396</td>
    <td>1</td>
    <td>1.17</td>
    <td>(0.81, 1.71)</td>
    <td>0.4024</td>
    <td>0.8</td>
    <td>1.54</td>
    <td>(1.02, 2.32)</td>
    <td>0.0385</td>
    <td>2.1</td>
    <td>1.59</td>
    <td>(1.02, 2.48)</td>
    <td>0.0402</td>
    <td>2.1</td>
  </tr>
  <tr>
    <td>THBS2</td>
    <td>1.26</td>
    <td>(0.78, 2.05)</td>
    <td>0.3475</td>
    <td>0.9</td>
    <td>1.11</td>
    <td>(0.67, 1.83)</td>
    <td>0.6897</td>
    <td>0.4</td>
    <td>2.47</td>
    <td>(1.51, 4.03)</td>
    <td>0.0003</td>
    <td>3.6</td>
    <td>2.33</td>
    <td>(1.39, 3.90)</td>
    <td>0.0013</td>
    <td>3.2</td>
  </tr>
  <tr>
    <td>MCP4</td>
    <td>1.1</td>
    <td>(0.89, 1.37)</td>
    <td>0.3822</td>
    <td>0.9</td>
    <td>1.07</td>
    <td>(0.85, 1.34)</td>
    <td>0.5679</td>
    <td>0.6</td>
    <td>0.97</td>
    <td>(0.78, 1.20)</td>
    <td>0.7668</td>
    <td>0.3</td>
    <td>0.99</td>
    <td>(0.79, 1.24)</td>
    <td>0.9367</td>
    <td>0.1</td>
  </tr>
  <tr>
    <td>HAOX1</td>
    <td>1.05</td>
    <td>(0.93, 1.18)</td>
    <td>0.4242</td>
    <td>0.8</td>
    <td>1.01</td>
    <td>(0.89, 1.14)</td>
    <td>0.918</td>
    <td>0.1</td>
    <td>0.91</td>
    <td>(0.80, 1.04)</td>
    <td>0.1691</td>
    <td>1.4</td>
    <td>0.87</td>
    <td>(0.76, 1.00)</td>
    <td>0.0571</td>
    <td>1.9</td>
  </tr>
  <tr>
    <td>ADAMTS13</td>
    <td>0.79</td>
    <td>(0.43, 1.44)</td>
    <td>0.4457</td>
    <td>0.8</td>
    <td>1.08</td>
    <td>(0.57, 2.04)</td>
    <td>0.8111</td>
    <td>0.2</td>
    <td>1.32</td>
    <td>(0.76, 2.31)</td>
    <td>0.3298</td>
    <td>1</td>
    <td>1.61</td>
    <td>(0.86, 3.03)</td>
    <td>0.1348</td>
    <td>1.5</td>
  </tr>
  <tr>
    <td>GLO1</td>
    <td>1.07</td>
    <td>(0.89, 1.29)</td>
    <td>0.4772</td>
    <td>0.7</td>
    <td>1.05</td>
    <td>(0.86, 1.27)</td>
    <td>0.64</td>
    <td>0.5</td>
    <td>1.11</td>
    <td>(0.90, 1.37)</td>
    <td>0.348</td>
    <td>0.9</td>
    <td>1.07</td>
    <td>(0.85, 1.34)</td>
    <td>0.5722</td>
    <td>0.6</td>
  </tr>
  <tr>
    <td>TRAIL</td>
    <td>1.14</td>
    <td>(0.79, 1.65)</td>
    <td>0.4776</td>
    <td>0.7</td>
    <td>1.12</td>
    <td>(0.77, 1.64)</td>
    <td>0.5556</td>
    <td>0.6</td>
    <td>0.45</td>
    <td>(0.29, 0.69)</td>
    <td>0.0003</td>
    <td>3.6</td>
    <td>0.42</td>
    <td>(0.26, 0.67)</td>
    <td>0.0003</td>
    <td>3.6</td>
  </tr>
  <tr>
    <td>GH</td>
    <td>0.97</td>
    <td>(0.89, 1.06)</td>
    <td>0.4806</td>
    <td>0.7</td>
    <td>0.99</td>
    <td>(0.90, 1.09)</td>
    <td>0.8655</td>
    <td>0.2</td>
    <td>1.05</td>
    <td>(0.95, 1.16)</td>
    <td>0.3226</td>
    <td>1</td>
    <td>1.1</td>
    <td>(0.99, 1.23)</td>
    <td>0.0665</td>
    <td>1.8</td>
  </tr>
  <tr>
    <td>RAGE</td>
    <td>1.12</td>
    <td>(0.82, 1.53)</td>
    <td>0.4918</td>
    <td>0.7</td>
    <td>1.2</td>
    <td>(0.85, 1.68)</td>
    <td>0.3013</td>
    <td>1</td>
    <td>1.25</td>
    <td>(0.90, 1.74)</td>
    <td>0.1809</td>
    <td>1.3</td>
    <td>1.31</td>
    <td>(0.91, 1.88)</td>
    <td>0.1528</td>
    <td>1.4</td>
  </tr>
  <tr>
    <td>PSGL1</td>
    <td>1.09</td>
    <td>(0.84, 1.41)</td>
    <td>0.5312</td>
    <td>0.6</td>
    <td>1.12</td>
    <td>(0.84, 1.48)</td>
    <td>0.4478</td>
    <td>0.8</td>
    <td>1.39</td>
    <td>(0.92, 2.09)</td>
    <td>0.117</td>
    <td>1.6</td>
    <td>1.48</td>
    <td>(0.95, 2.30)</td>
    <td>0.0795</td>
    <td>1.8</td>
  </tr>
  <tr>
    <td>MARCO</td>
    <td>0.9</td>
    <td>(0.64, 1.27)</td>
    <td>0.5512</td>
    <td>0.6</td>
    <td>0.96</td>
    <td>(0.66, 1.38)</td>
    <td>0.8067</td>
    <td>0.2</td>
    <td>1.09</td>
    <td>(0.86, 1.38)</td>
    <td>0.467</td>
    <td>0.7</td>
    <td>1.06</td>
    <td>(0.83, 1.35)</td>
    <td>0.6562</td>
    <td>0.4</td>
  </tr>
  <tr>
    <td>IL13</td>
    <td>1.11</td>
    <td>(0.79, 1.55)</td>
    <td>0.5531</td>
    <td>0.6</td>
    <td>1.22</td>
    <td>(0.86, 1.72)</td>
    <td>0.2701</td>
    <td>1.1</td>
    <td>0.95</td>
    <td>(0.62, 1.45)</td>
    <td>0.8094</td>
    <td>0.2</td>
    <td>0.92</td>
    <td>(0.59, 1.42)</td>
    <td>0.6948</td>
    <td>0.4</td>
  </tr>
  <tr>
    <td>CCL28</td>
    <td>1.09</td>
    <td>(0.81, 1.46)</td>
    <td>0.5589</td>
    <td>0.6</td>
    <td>1.11</td>
    <td>(0.82, 1.51)</td>
    <td>0.5044</td>
    <td>0.7</td>
    <td>1</td>
    <td>(0.78, 1.30)</td>
    <td>0.9758</td>
    <td>0</td>
    <td>1.09</td>
    <td>(0.83, 1.44)</td>
    <td>0.5345</td>
    <td>0.6</td>
  </tr>
  <tr>
    <td>CXCL1</td>
    <td>1.04</td>
    <td>(0.91, 1.19)</td>
    <td>0.566</td>
    <td>0.6</td>
    <td>1.03</td>
    <td>(0.89, 1.19)</td>
    <td>0.7054</td>
    <td>0.4</td>
    <td>1.05</td>
    <td>(0.89, 1.24)</td>
    <td>0.5851</td>
    <td>0.5</td>
    <td>1.05</td>
    <td>(0.88, 1.25)</td>
    <td>0.6141</td>
    <td>0.5</td>
  </tr>
  <tr>
    <td>GDF2</td>
    <td>0.95</td>
    <td>(0.78, 1.16)</td>
    <td>0.613</td>
    <td>0.5</td>
    <td>1.03</td>
    <td>(0.83, 1.27)</td>
    <td>0.8145</td>
    <td>0.2</td>
    <td>1.01</td>
    <td>(0.81, 1.26)</td>
    <td>0.9631</td>
    <td>0</td>
    <td>1.1</td>
    <td>(0.87, 1.40)</td>
    <td>0.4238</td>
    <td>0.8</td>
  </tr>
  <tr>
    <td>AZU1</td>
    <td>1.06</td>
    <td>(0.85, 1.32)</td>
    <td>0.618</td>
    <td>0.5</td>
    <td>1.06</td>
    <td>(0.85, 1.34)</td>
    <td>0.6042</td>
    <td>0.5</td>
    <td>1.07</td>
    <td>(0.91, 1.25)</td>
    <td>0.4075</td>
    <td>0.8</td>
    <td>1.07</td>
    <td>(0.90, 1.26)</td>
    <td>0.4452</td>
    <td>0.8</td>
  </tr>
  <tr>
    <td>MEPE</td>
    <td>1.07</td>
    <td>(0.83, 1.38)</td>
    <td>0.6191</td>
    <td>0.5</td>
    <td>0.95</td>
    <td>(0.72, 1.26)</td>
    <td>0.7171</td>
    <td>0.4</td>
    <td>0.94</td>
    <td>(0.72, 1.23)</td>
    <td>0.663</td>
    <td>0.4</td>
    <td>0.8</td>
    <td>(0.60, 1.08)</td>
    <td>0.1525</td>
    <td>1.4</td>
  </tr>
  <tr>
    <td>IL20RA</td>
    <td>0.9</td>
    <td>(0.56, 1.44)</td>
    <td>0.6494</td>
    <td>0.5</td>
    <td>0.94</td>
    <td>(0.57, 1.54)</td>
    <td>0.7927</td>
    <td>0.3</td>
    <td>1.14</td>
    <td>(0.46, 2.81)</td>
    <td>0.784</td>
    <td>0.3</td>
    <td>1.39</td>
    <td>(0.54, 3.57)</td>
    <td>0.496</td>
    <td>0.7</td>
  </tr>
  <tr>
    <td>LPL</td>
    <td>0.93</td>
    <td>(0.67, 1.29)</td>
    <td>0.6713</td>
    <td>0.4</td>
    <td>0.96</td>
    <td>(0.68, 1.35)</td>
    <td>0.8206</td>
    <td>0.2</td>
    <td>0.99</td>
    <td>(0.75, 1.30)</td>
    <td>0.9345</td>
    <td>0.1</td>
    <td>1</td>
    <td>(0.75, 1.34)</td>
    <td>0.9738</td>
    <td>0</td>
  </tr>
  <tr>
    <td>LDLRECEPTOR</td>
    <td>0.96</td>
    <td>(0.78, 1.18)</td>
    <td>0.6782</td>
    <td>0.4</td>
    <td>0.97</td>
    <td>(0.78, 1.20)</td>
    <td>0.7566</td>
    <td>0.3</td>
    <td>0.89</td>
    <td>(0.70, 1.13)</td>
    <td>0.3295</td>
    <td>1</td>
    <td>0.85</td>
    <td>(0.66, 1.09)</td>
    <td>0.1969</td>
    <td>1.3</td>
  </tr>
  <tr>
    <td>KLK6</td>
    <td>1.06</td>
    <td>(0.79, 1.42)</td>
    <td>0.7023</td>
    <td>0.4</td>
    <td>0.99</td>
    <td>(0.71, 1.38)</td>
    <td>0.9555</td>
    <td>0.1</td>
    <td>0.9</td>
    <td>(0.70, 1.14)</td>
    <td>0.3731</td>
    <td>0.9</td>
    <td>0.82</td>
    <td>(0.62, 1.09)</td>
    <td>0.1705</td>
    <td>1.4</td>
  </tr>
</table>
<table><tr><td>CDH5</td><td>1.06</td><td>(0.79, 1.41)</td><td>0.7034</td><td>0.4</td><td>0.97</td><td>(0.71, 1.32)</td><td>0.8371</td><td>0.2</td><td>1.06</td><td>(0.80, 1.42)</td><td>0.6711</td><td>0.4</td><td>1.02</td><td>(0.75, 1.38)</td><td>0.9126</td><td>0.1</td></tr><tr><td>TIE2</td><td>1.07</td><td>(0.73, 1.58)</td><td>0.721</td><td>0.4</td><td>1.07</td><td>(0.72, 1.61)</td><td>0.7347</td><td>0.3</td><td>1.41</td><td>(0.90, 2.20)</td><td>0.137</td><td>1.5</td><td>1.35</td><td>(0.85, 2.14)</td><td>0.2</td><td>1.3</td></tr><tr><td>SERPINA12</td><td>1.02</td><td>(0.93, 1.12)</td><td>0.7294</td><td>0.3</td><td>0.99</td><td>(0.90, 1.09)</td><td>0.8486</td><td>0.2</td><td>1.15</td><td>(0.98, 1.36)</td><td>0.0826</td><td>1.7</td><td>1.14</td><td>(0.96, 1.35)</td><td>0.127</td><td>1.5</td></tr><tr><td>IL1RL2</td><td>0.95</td><td>(0.72, 1.26)</td><td>0.732</td><td>0.3</td><td>0.94</td><td>(0.71, 1.26)</td><td>0.7027</td><td>0.4</td><td>1.24</td><td>(0.90, 1.72)</td><td>0.1842</td><td>1.3</td><td>1.24</td><td>(0.88, 1.74)</td><td>0.2277</td><td>1.2</td></tr><tr><td>IL10RA</td><td>1.06</td><td>(0.74, 1.53)</td><td>0.7411</td><td>0.3</td><td>1.12</td><td>(0.76, 1.63)</td><td>0.5672</td><td>0.6</td><td>1.14</td><td>(0.59, 2.21)</td><td>0.7014</td><td>0.4</td><td>1.3</td><td>(0.65, 2.60)</td><td>0.4622</td><td>0.7</td></tr><tr><td>EPCAM</td><td>0.98</td><td>(0.86, 1.12)</td><td>0.7485</td><td>0.3</td><td>0.96</td><td>(0.84, 1.11)</td><td>0.6088</td><td>0.5</td><td>0.97</td><td>(0.83, 1.14)</td><td>0.7455</td><td>0.3</td><td>0.94</td><td>(0.79, 1.11)</td><td>0.4395</td><td>0.8</td></tr><tr><td>TNFB</td><td>0.96</td><td>(0.73, 1.27)</td><td>0.7851</td><td>0.3</td><td>0.98</td><td>(0.73, 1.32)</td><td>0.9046</td><td>0.1</td><td>0.83</td><td>(0.62, 1.12)</td><td>0.222</td><td>1.2</td><td>0.84</td><td>(0.61, 1.14)</td><td>0.263</td><td>1.1</td></tr><tr><td>DLK1</td><td>1.02</td><td>(0.84, 1.26)</td><td>0.812</td><td>0.2</td><td>0.88</td><td>(0.71, 1.11)</td><td>0.2825</td><td>1.1</td><td>1.1</td><td>(0.87, 1.38)</td><td>0.4338</td><td>0.8</td><td>0.96</td><td>(0.75, 1.25)</td><td>0.7821</td><td>0.3</td></tr><tr><td>TRAP</td><td>0.97</td><td>(0.71, 1.32)</td><td>0.8421</td><td>0.2</td><td>0.98</td><td>(0.71, 1.35)</td><td>0.8888</td><td>0.1</td><td>0.86</td><td>(0.65, 1.14)</td><td>0.3037</td><td>1</td><td>0.8</td><td>(0.60, 1.08)</td><td>0.1446</td><td>1.5</td></tr><tr><td>TNF</td><td>1.02</td><td>(0.75, 1.39)</td><td>0.8775</td><td>0.2</td><td>1.05</td><td>(0.76, 1.44)</td><td>0.7876</td><td>0.3</td><td>0.99</td><td>(0.69, 1.41)</td><td>0.9465</td><td>0.1</td><td>1.03</td><td>(0.71, 1.51)</td><td>0.8614</td><td>0.2</td></tr><tr><td>CCL24</td><td>0.99</td><td>(0.85, 1.15)</td><td>0.8876</td><td>0.1</td><td>1.04</td><td>(0.89, 1.21)</td><td>0.6233</td><td>0.5</td><td>0.97</td><td>(0.82, 1.14)</td><td>0.6845</td><td>0.4</td><td>0.96</td><td>(0.81, 1.15)</td><td>0.668</td><td>0.4</td></tr><tr><td>BDNF</td><td>1</td><td>(0.96, 1.05)</td><td>0.9166</td><td>0.1</td><td>1.01</td><td>(0.96, 1.05)</td><td>0.8295</td><td>0.2</td><td>1.03</td><td>(0.98, 1.09)</td><td>0.2125</td><td>1.2</td><td>1.05</td><td>(0.99, 1.11)</td><td>0.095</td><td>1.7</td></tr><tr><td>CPA1</td><td>1.01</td><td>(0.85, 1.20)</td><td>0.918</td><td>0.1</td><td>1</td><td>(0.83, 1.20)</td><td>0.9837</td><td>0</td><td>1.06</td><td>(0.88, 1.28)</td><td>0.5252</td><td>0.6</td><td>1.02</td><td>(0.84, 1.25)</td><td>0.8099</td><td>0.2</td></tr><tr><td>CD6</td><td>0.99</td><td>(0.79, 1.24)</td><td>0.9181</td><td>0.1</td><td>1.04</td><td>(0.82, 1.31)</td><td>0.7607</td><td>0.3</td><td>0.91</td><td>(0.70, 1.19)</td><td>0.5062</td><td>0.7</td><td>0.91</td><td>(0.69, 1.22)</td><td>0.5401</td><td>0.6</td></tr><tr><td>IL1RT2</td><td>1.01</td><td>(0.77, 1.34)</td><td>0.9375</td><td>0.1</td><td>0.99</td><td>(0.74, 1.32)</td><td>0.9496</td><td>0.1</td><td>0.97</td><td>(0.72, 1.30)</td><td>0.8275</td><td>0.2</td><td>0.92</td><td>(0.67, 1.26)</td><td>0.6147</td><td>0.5</td></tr><tr><td>CCL22</td><td>1</td><td>(0.89, 1.14)</td><td>0.9398</td><td>0.1</td><td>1.01</td><td>(0.89, 1.15)</td><td>0.8543</td><td>0.2</td><td>1.03</td><td>(0.88, 1.19)</td><td>0.7421</td><td>0.3</td><td>1.07</td><td>(0.91, 1.25)</td><td>0.4181</td><td>0.8</td></tr><tr><td>PRSS27</td><td>1.01</td><td>(0.77, 1.32)</td><td>0.9562</td><td>0.1</td><td>0.88</td><td>(0.66, 1.17)</td><td>0.3814</td><td>0.9</td><td>1.4</td><td>(1.01, 1.94)</td><td>0.0443</td><td>2</td><td>1.3</td><td>(0.92, 1.85)</td><td>0.1386</td><td>1.5</td></tr></table>

*FDR 1% threshold in the discovery phase
<table><caption>Supplemental Table 3. Odds ratios (OR) and 95% confidence intervals (CI) for the selected proteins (significant in both discovery and replication sets with a false discovery rate of 1%) after adjustment for the matching variables (age, sex, and follow-up time), clinical risk factors (smoking, diabetes, coronary artery disease, serum creatinine, body mass index, heart rate, anti-hypertensive medication use) and correction for multiple comparisons in both discovery and replication sets</caption><thead><tr><th rowspan="2">Protein name</th><th colspan="3">Discovery</th><th colspan="3">Replication</th></tr><tr><th>OR</th><th>(95% CI)</th><th>P-value</th><th>OR</th><th>(95% CI)</th><th>P-value</th></tr></thead><tbody><tr><td>BNP</td><td>1.59</td><td>(1.38, 1.84)</td><td>&lt;0.0001</td><td>1.78</td><td>(1.52, 2.08)</td><td>&lt;0.0001</td></tr><tr><td>NTPROBNP</td><td>1.79</td><td>(1.50, 2.14)</td><td>&lt;0.0001</td><td>2.05</td><td>(1.66, 2.53)</td><td>&lt;0.0001</td></tr><tr><td>TRAILR2</td><td>2.70</td><td>(1.86, 3.92)</td><td>&lt;0.0001</td><td>2.65</td><td>(1.72, 4.06)</td><td>&lt;0.0001</td></tr><tr><td>TNFRSF13B</td><td>1.58</td><td>(1.21, 2.07)</td><td>0.0008</td><td>2.30</td><td>(1.56, 3.39)</td><td>&lt;0.0001</td></tr><tr><td>GAL9</td><td>2.30</td><td>(1.48, 3.57)</td><td>0.0002</td><td>2.46</td><td>(1.53, 3.94)</td><td>0.0002</td></tr><tr><td>FGF23</td><td>1.48</td><td>(1.21, 1.82)</td><td>0.0002</td><td>1.71</td><td>(1.31, 2.22)</td><td>&lt;0.0001</td></tr><tr><td>TNFRSF10A</td><td>2.02</td><td>(1.41, 2.90)</td><td>0.0001</td><td>2.00</td><td>(1.32, 3.03)</td><td>0.0010</td></tr><tr><td>REN</td><td>1.17</td><td>(0.98, 1.41)</td><td>0.0798</td><td>1.36</td><td>(1.12, 1.66)</td><td>0.0019</td></tr><tr><td>TNFRSF11A</td><td>1.73</td><td>(1.29, 2.32)</td><td>0.0002</td><td>1.54</td><td>(1.12, 2.11)</td><td>0.0074</td></tr><tr><td>GDF15</td><td>2.34</td><td>(1.72, 3.19)</td><td>&lt;0.0001</td><td>1.58</td><td>(1.18, 2.12)</td><td>0.0024</td></tr><tr><td>FABP4</td><td>1.56</td><td>(1.24, 1.96)</td><td>0.0001</td><td>1.29</td><td>(1.03, 1.63)</td><td>0.0290</td></tr><tr><td>SLAMF7</td><td>1.42</td><td>(1.14, 1.77)</td><td>0.0019</td><td>2.02</td><td>(1.39, 2.93)</td><td>0.0002</td></tr><tr><td>CCL16</td><td>1.37</td><td>(1.11, 1.68)</td><td>0.0028</td><td>1.57</td><td>(1.20, 2.05)</td><td>0.0009</td></tr><tr><td>TWEAK</td><td>0.60</td><td>(0.41, 0.87)</td><td>0.0075</td><td>0.58</td><td>(0.42, 0.80)</td><td>0.0008</td></tr><tr><td>KIM1</td><td>1.30</td><td>(1.08, 1.55)</td><td>0.0050</td><td>1.33</td><td>(1.07, 1.65)</td><td>0.0093</td></tr><tr><td>CD4</td><td>1.67</td><td>(1.18, 2.35)</td><td>0.0034</td><td>1.82</td><td>(1.23, 2.70)</td><td>0.0026</td></tr><tr><td>VSIG2</td><td>1.25</td><td>(0.97, 1.60)</td><td>0.0857</td><td>1.46</td><td>(1.06, 2.00)</td><td>0.0196</td></tr><tr><td>PON3</td><td>0.83</td><td>(0.66, 1.03)</td><td>0.0962</td><td>0.72</td><td>(0.57, 0.91)</td><td>0.0070</td></tr><tr><td>PLGF</td><td>1.86</td><td>(1.28, 2.72)</td><td>0.0013</td><td>1.61</td><td>(1.11, 2.34)</td><td>0.0119</td></tr><tr><td>MMP12</td><td>1.43</td><td>(1.14, 1.80)</td><td>0.0019</td><td>1.35</td><td>(1.06, 1.72)</td><td>0.0168</td></tr><tr><td>ADM</td><td>2.10</td><td>(1.46, 3.02)</td><td>&lt;0.0001</td><td>1.40</td><td>(1.01, 1.94)</td><td>0.0408</td></tr><tr><td>RARRES2</td><td>2.42</td><td>(1.41, 4.18)</td><td>0.0015</td><td>1.69</td><td>(1.10, 2.58)</td><td>0.0158</td></tr><tr><td>CEACAM8</td><td>1.47</td><td>(1.18, 1.83)</td><td>0.0006</td><td>1.37</td><td>(1.09, 1.74)</td><td>0.0081</td></tr><tr><td>SLAMF1</td><td>1.28</td><td>(1.03, 1.59)</td><td>0.0254</td><td>1.43</td><td>(1.07, 1.90)</td><td>0.0142</td></tr><tr><td>TNFR1</td><td>1.98</td><td>(1.38, 2.84)</td><td>0.0002</td><td>1.27</td><td>(0.93, 1.74)</td><td>0.1353</td></tr><tr><td>AGRP</td><td>1.65</td><td>(1.23, 2.21)</td><td>0.0008</td><td>1.66</td><td>(1.11, 2.48)</td><td>0.0139</td></tr><tr><td>TNFR2</td><td>1.75</td><td>(1.27, 2.42)</td><td>0.0007</td><td>1.29</td><td>(0.97, 1.70)</td><td>0.0779</td></tr><tr><td>IGFBP7</td><td>1.44</td><td>(1.05, 1.96)</td><td>0.0219</td><td>1.43</td><td>(1.06, 1.92)</td><td>0.0183</td></tr><tr><td>UPAR</td><td>2.27</td><td>(1.61, 3.21)</td><td>&lt;0.0001</td><td>1.39</td><td>(1.01, 1.93)</td><td>0.0464</td></tr><tr><td>PAR1</td><td>1.65</td><td>(1.17, 2.33)</td><td>0.0040</td><td>1.53</td><td>(1.08, 2.19)</td><td>0.0176</td></tr><tr><td>PLC</td><td>1.78</td><td>(1.17, 2.70)</td><td>0.0065</td><td>1.42</td><td>(0.97, 2.08)</td><td>0.0743</td></tr><tr><td>ACE2</td><td>1.49</td><td>(1.17, 1.89)</td><td>0.0012</td><td>1.41</td><td>(1.08, 1.86)</td><td>0.0131</td></tr><tr><td>IL16</td><td>1.39</td><td>(1.07, 1.80)</td><td>0.0131</td><td>1.34</td><td>(1.04, 1.72)</td><td>0.0219</td></tr><tr><td>TFF3</td><td>1.52</td><td>(1.23, 1.87)</td><td>0.0001</td><td>1.26</td><td>(0.97, 1.63)</td><td>0.0834</td></tr><tr><td>OPN</td><td>1.81</td><td>(1.36, 2.40)</td><td>&lt;0.0001</td><td>1.36</td><td>(1.03, 1.79)</td><td>0.0304</td></tr><tr><td>SPON2</td><td>2.64</td><td>(1.35, 5.18)</td><td>0.0047</td><td>2.04</td><td>(1.14, 3.66)</td><td>0.0166</td></tr><tr><td>IL4RA</td><td>1.42</td><td>(1.07, 1.90)</td><td>0.0164</td><td>1.45</td><td>(1.04, 2.02)</td><td>0.0299</td></tr><tr><td>TNFRSF14</td><td>1.77</td><td>(1.26, 2.47)</td><td>0.0009</td><td>1.26</td><td>(0.93, 1.71)</td><td>0.1309</td></tr></tbody></table>

Legend: same as in figure 1.
<table><caption>Supplemental Table 4. Spearman correlation between the clinical risk score variables and the selected biomarkers</caption><thead><tr><th></th><th>AGE</th><th>SMK</th><th>DM</th><th>CAD</th><th>HTN</th><th>BMI</th><th>HR</th><th>CR</th></tr></thead><tbody><tr><td>BNP</td><td>0.12</td><td>0.02</td><td>-0.02</td><td>0.18</td><td>0.06</td><td>-0.03</td><td>-0.12</td><td>0.08</td></tr><tr><td>NTPROBNP</td><td>0.13</td><td>-0.02</td><td>-0.07</td><td>0.18</td><td>0.07</td><td>-0.08</td><td>-0.13</td><td>0.06</td></tr><tr><td>TRAILR2</td><td>0.12</td><td>0.10</td><td>0.08</td><td>0.09</td><td>0.07</td><td>0.08</td><td>-0.01</td><td>0.27</td></tr><tr><td>TNFRSF13B</td><td>0.00</td><td>0.10</td><td>0.07</td><td>-0.01</td><td>0.03</td><td>0.09</td><td>-0.05</td><td>0.13</td></tr><tr><td>GAL9</td><td>-0.10</td><td>0.18</td><td>0.05</td><td>-0.04</td><td>-0.03</td><td>0.14</td><td>-0.07</td><td>-0.02</td></tr><tr><td>FGF23</td><td>0.00</td><td>-0.03</td><td>0.05</td><td>0.06</td><td>0.11</td><td>0.12</td><td>-0.03</td><td>0.16</td></tr><tr><td>TNFRSF10A</td><td>0.01</td><td>0.06</td><td>0.08</td><td>0.06</td><td>0.06</td><td>0.14</td><td>-0.01</td><td>0.10</td></tr><tr><td>REN</td><td>0.04</td><td>0.06</td><td>0.19</td><td>0.08</td><td>0.18</td><td>0.12</td><td>-0.02</td><td>0.17</td></tr><tr><td>TNFRSF11A</td><td>0.08</td><td>0.04</td><td>0.10</td><td>0.06</td><td>0.09</td><td>0.16</td><td>-0.06</td><td>0.22</td></tr><tr><td>GDF15</td><td>0.15</td><td>0.04</td><td>0.13</td><td>0.09</td><td>0.15</td><td>0.03</td><td>-0.01</td><td>0.31</td></tr><tr><td>FABP4</td><td>-0.01</td><td>-0.04</td><td>0.07</td><td>-0.02</td><td>0.16</td><td>0.36</td><td>0.05</td><td>0.04</td></tr><tr><td>SLAMF7</td><td>-0.04</td><td>0.02</td><td>0.11</td><td>0.04</td><td>0.04</td><td>0.08</td><td>0.00</td><td>0.10</td></tr><tr><td>CCL16</td><td>-0.02</td><td>0.03</td><td>0.01</td><td>0.00</td><td>0.10</td><td>0.08</td><td>-0.01</td><td>0.20</td></tr><tr><td>TWEAK</td><td>-0.01</td><td>0.02</td><td>-0.11</td><td>-0.04</td><td>-0.12</td><td>-0.04</td><td>-0.10</td><td>-0.05</td></tr><tr><td>KIM1</td><td>0.02</td><td>0.03</td><td>0.16</td><td>0.02</td><td>0.09</td><td>0.08</td><td>0.00</td><td>0.12</td></tr><tr><td>CD4</td><td>-0.11</td><td>0.20</td><td>0.10</td><td>-0.01</td><td>-0.06</td><td>0.10</td><td>-0.05</td><td>0.00</td></tr><tr><td>VSIG2</td><td>0.03</td><td>0.11</td><td>0.15</td><td>0.00</td><td>0.03</td><td>0.00</td><td>-0.07</td><td>0.14</td></tr><tr><td>PON3</td><td>-0.05</td><td>0.07</td><td>-0.08</td><td>-0.13</td><td>-0.18</td><td>-0.26</td><td>-0.08</td><td>-0.11</td></tr><tr><td>PLGF</td><td>0.13</td><td>0.05</td><td>0.03</td><td>0.08</td><td>0.04</td><td>0.05</td><td>-0.05</td><td>0.34</td></tr><tr><td>MMP12</td><td>0.09</td><td>0.12</td><td>0.07</td><td>0.15</td><td>0.12</td><td>-0.01</td><td>-0.03</td><td>0.20</td></tr><tr><td>ADM</td><td>0.05</td><td>0.07</td><td>0.03</td><td>0.05</td><td>0.07</td><td>0.20</td><td>-0.04</td><td>0.16</td></tr><tr><td>RARRES2</td><td>-0.01</td><td>0.06</td><td>0.00</td><td>-0.03</td><td>0.09</td><td>0.12</td><td>0.00</td><td>0.14</td></tr><tr><td>CEACAM8</td><td>0.17</td><td>-0.07</td><td>-0.02</td><td>0.06</td><td>0.12</td><td>0.06</td><td>0.03</td><td>0.19</td></tr><tr><td>SLAMF1</td><td>-0.08</td><td>0.10</td><td>0.09</td><td>0.03</td><td>0.01</td><td>0.13</td><td>-0.04</td><td>0.15</td></tr><tr><td>TNFR1</td><td>0.10</td><td>0.06</td><td>0.06</td><td>0.00</td><td>0.10</td><td>0.10</td><td>-0.04</td><td>0.28</td></tr><tr><td>AGRP</td><td>0.10</td><td>-0.05</td><td>0.05</td><td>0.10</td><td>0.08</td><td>-0.02</td><td>-0.02</td><td>0.22</td></tr><tr><td>TNFR2</td><td>0.05</td><td>0.09</td><td>0.05</td><td>0.00</td><td>0.07</td><td>0.06</td><td>-0.05</td><td>0.20</td></tr><tr><td>IGFBP7</td><td>0.05</td><td>0.03</td><td>0.06</td><td>0.01</td><td>0.08</td><td>0.03</td><td>-0.07</td><td>0.18</td></tr><tr><td>UPAR</td><td>0.07</td><td>0.04</td><td>0.01</td><td>0.03</td><td>0.08</td><td>0.04</td><td>-0.02</td><td>0.09</td></tr><tr><td>PAR1</td><td>-0.05</td><td>0.17</td><td>0.09</td><td>-0.08</td><td>-0.08</td><td>0.07</td><td>-0.01</td><td>0.01</td></tr><tr><td>PLC</td><td>0.12</td><td>-0.03</td><td>0.00</td><td>0.03</td><td>0.11</td><td>0.13</td><td>-0.06</td><td>0.33</td></tr><tr><td>ACE2</td><td>-0.09</td><td>0.12</td><td>0.10</td><td>0.03</td><td>-0.04</td><td>0.08</td><td>-0.03</td><td>0.02</td></tr><tr><td>IL16</td><td>0.00</td><td>0.08</td><td>0.03</td><td>-0.04</td><td>0.02</td><td>0.14</td><td>-0.05</td><td>0.03</td></tr><tr><td>TFF3</td><td>0.08</td><td>0.02</td><td>0.06</td><td>0.02</td><td>0.16</td><td>-0.06</td><td>0.01</td><td>0.24</td></tr><tr><td>OPN</td><td>0.01</td><td>0.14</td><td>0.00</td><td>0.03</td><td>0.00</td><td>0.01</td><td>-0.07</td><td>0.08</td></tr><tr><td>SPON2</td><td>-0.16</td><td>0.22</td><td>0.04</td><td>-0.06</td><td>-0.14</td><td>0.04</td><td>-0.12</td><td>-0.09</td></tr><tr><td>IL4RA</td><td>-0.04</td><td>0.15</td><td>0.06</td><td>-0.01</td><td>-0.10</td><td>0.01</td><td>-0.10</td><td>0.01</td></tr><tr><td>TNFRSF14</td><td>0.11</td><td>0.05</td><td>0.06</td><td>0.00</td><td>0.09</td><td>0.03</td><td>-0.01</td><td>0.25</td></tr></tbody></table>

Legend: SMK, smoking, DM, diabetes mellitus; CAD, coronary artery disease; HTN, hypertension; BMI, body mass index; HR, heart rate; CR, creatinine.
Supplemental Table 5. Final adjusted stepwise forward model starting with the 39 proteins independently selected in both discovery and replication sets (discovery and replication sets “pooled” for this analysis)

<table><thead><tr><td>Biomarker</td><td>OR (95%CI)</td><td>P-value</td></tr></thead><tbody><tr><td>BNP</td><td>1.43 (1.25-1.64)</td><td>&lt;0.0001</td></tr><tr><td>TWEAK</td><td>0.38 (0.28-0.50)</td><td>&lt;0.0001</td></tr><tr><td>NTPROBNP</td><td>1.39 (1.17-1.66)</td><td>&lt;0.0001</td></tr><tr><td>REN</td><td>1.28 (1.10-1.49)</td><td>0.001</td></tr><tr><td>TRAILR2</td><td>1.56 (1.13-2.15)</td><td>0.007</td></tr><tr><td>PON3</td><td>0.78 (0.65-0.94)</td><td>0.008</td></tr><tr><td>CCL16</td><td>1.27 (1.06-1.53)</td><td>0.008</td></tr><tr><td>SLAMF1</td><td>1.24 (1.01-1.52)</td><td>0.036</td></tr></tbody></table>

Model adjusted for matching variables (age, sex, cohort, phase, follow-up time) and clinical variables (smoking, diabetes, history of coronary artery disease, serum creatinine, body mass index, systolic blood pressure, use of antihypertensive medication, and heart rate (the clinical model) with a p-value for inclusion set at 0.05.

AUC clinical model =0.68; AUC clinical model + final protein selection =0.78 (ΔAUC p-value <0.001).

Legend: BNP, brain natriuretic peptide; TWEAK, tumor necrosis factor (Ligand) superfamily, member 12; NTPROBNP, N-terminal prohormone brain natriuretic peptide; REN, renin; TRAILR2, TNF-related apoptosis-inducing ligand receptor 2; PON3, paraoxonase; CCL16, C-C motif chemokine 16; SLAMF1, signalling lymphocytic activation molecule.
<table><caption>Supplemental Table 6. Nodes of induced network linking the top proteins to incident heart failure.</caption><thead><tr><th>Level</th><th>Name (sorted by)</th><th>Uniprot ID</th><th>Protein / Gene</th><th>Cluster</th></tr></thead><tbody><tr><td>seed</td><td>ACE2</td><td>Q9BYF1</td><td>Angiotensin-converting enzyme 2</td><td>Blood pressure regulation</td></tr><tr><td>seed</td><td>ADM</td><td>P35318</td><td>Adrenomedullin</td><td>Blood pressure regulation</td></tr><tr><td>seed</td><td>AGRP</td><td>O00253</td><td>Agouti-related protein</td><td>Metabolism</td></tr><tr><td>seed</td><td>BNP</td><td>P16860</td><td>Natriuretic peptides B / N-terminal prohormone brain natriuretic peptide</td><td>Blood pressure regulation</td></tr><tr><td>seed</td><td>CCL16</td><td>O15467</td><td>C-C motif chemokine 16</td><td>Inflammation and apoptosis</td></tr><tr><td>seed</td><td>CD4</td><td>P01730</td><td>T-cell surface glycoprotein CD4</td><td>Inflammation and apoptosis</td></tr><tr><td>seed</td><td>CEACAM8</td><td>P31997</td><td>Carcinoembryonic antigen related cell adhesion molecule 8</td><td>Extracellular matrix remodelling, angiogenesis and growth</td></tr><tr><td>seed</td><td>FABP4</td><td>P15090</td><td>Fatty acid-binding protein, adipocyte</td><td>Metabolism</td></tr><tr><td>seed</td><td>FGF23</td><td>Q9GZV9</td><td>Fibroblast growth factor 23</td><td>Blood pressure regulation</td></tr><tr><td>seed</td><td>GAL9</td><td>O00182</td><td>Galectin-9</td><td>Extracellular matrix remodelling, angiogenesis and growth</td></tr><tr><td>seed</td><td>GDF15</td><td>Q99988</td><td>Growth/differentiation factor 15</td><td>Extracellular matrix remodelling, angiogenesis and growth</td></tr><tr><td>seed</td><td>IGFBP7</td><td>Q16270</td><td>Insulin-like growth factor-binding protein 7</td><td>Inflammation and apoptosis</td></tr><tr><td>seed</td><td>IL16</td><td>Q14005</td><td>Pro-interleukin-16</td><td>Inflammation and apoptosis</td></tr><tr><td>seed</td><td>IL4RA</td><td>P24394</td><td>Interleukin-4 receptor subunit alpha</td><td>Inflammation and apoptosis</td></tr><tr><td>seed</td><td>KIM1</td><td>Q96D42</td><td>Kidney injury molecule 1/Hepatitis A virus cellular receptor 1</td><td>Inflammation and apoptosis</td></tr><tr><td>seed</td><td>MMP12</td><td>P39900</td><td>Matrix metalloproteinase-12</td><td>Extracellular matrix remodelling, angiogenesis and growth</td></tr><tr><td>seed</td><td>OPN</td><td>P10451</td><td>Osteopontin</td><td>Extracellular matrix remodelling, angiogenesis and growth</td></tr><tr><td>seed</td><td>PAR1</td><td>P25116</td><td>Proteinase-activated receptor 1 / Coagulation Factor II Thrombin Receptor</td><td>Blood pressure regulation</td></tr><tr><td>seed</td><td>PLC</td><td>P98160</td><td>Perlecan</td><td>Extracellular matrix remodelling, angiogenesis and growth</td></tr><tr><td>seed</td><td>PLGF</td><td>P49763</td><td>Placenta growth factor</td><td>Extracellular matrix remodelling, angiogenesis and growth</td></tr><tr><td>seed</td><td>PON3</td><td>Q15166</td><td>Paraoxonase 3</td><td>Metabolism</td></tr><tr><td>seed</td><td>RARRES2</td><td>Q99969</td><td>Retinoic acid receptor responder 2</td><td>Metabolism</td></tr><tr><td>seed</td><td>REN</td><td>P00797</td><td>Renin</td><td>Blood pressure regulation</td></tr><tr><td>seed</td><td>SLAMF1</td><td>Q13291</td><td>Signaling lymphocytic activation molecule</td><td>Inflammation and apoptosis</td></tr><tr><td>seed</td><td>SLAMF7</td><td>Q9NQ25</td><td>SLAM family member 7</td><td>Inflammation and apoptosis</td></tr><tr><td>seed</td><td>SPON2</td><td>Q9BUD6</td><td>Spondin 2</td><td>Extracellular matrix remodelling, angiogenesis and growth</td></tr><tr><td>seed</td><td>TFF3</td><td>Q07654</td><td>Trefoil factor 3</td><td>Inflammation and apoptosis</td></tr><tr><td>seed</td><td>TNFR1</td><td>P19438</td><td>Tumor necrosis factor receptor 1</td><td>Inflammation and apoptosis</td></tr><tr><td>seed</td><td>TNFR2</td><td>P20333</td><td>Tumor necrosis factor receptor 2</td><td>Inflammation and apoptosis</td></tr></tbody></table>